Defining a Registry of Candidate Regulatory Elements to Interpret Disease Associated Genetic Variation by Moore, Jill E.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2017-10-10 
Defining a Registry of Candidate Regulatory Elements to Interpret 
Disease Associated Genetic Variation 
Jill E. Moore 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Biology Commons, Computational Biology Commons, and the Genomics Commons 
Repository Citation 
Moore JE. (2017). Defining a Registry of Candidate Regulatory Elements to Interpret Disease Associated 
Genetic Variation. GSBS Dissertations and Theses. https://doi.org/10.13028/M2NX0B. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/927 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
DEFINING A REGISTRY OF CANDIDATE REGULATORY 
ELEMENTS TO INTERPRET DISEASE ASSOCIATED GENETIC 
VARIATION 
 
 
A Dissertation Presented 
 
By 
 
Jill E. Moore 
 
Submitted to the Faculty of the University of Massachusetts Graduate School of 
Biomedical Sciences, Worcester in partial fulfillment of the requirements for the 
degree of 
 
DOCTOR OF PHILOSOPHY 
 
OCTOBER 10, 2017 
 
BIOINFORMATICS & COMPUTATIONAL BIOLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 ii 
DEFINING A REGISTRY OF CANDIDATE REGULATORY 
ELEMENTS TO INTERPRET DISEASE ASSOCIATED GENETIC 
VARIATION 
 
 
A Dissertation Presented  
By  
 
Jill E. Moore 
This work was undertaken in the Graduate School of Biomedical Sciences 
 
Bioinformatics and Computational Biology 
 
Under the mentorship of  
 
Zhiping Weng, Ph.D., Thesis Advisor  
Manuel Garber, Ph.D., Member of Committee  
Konstantin Zeldovich, Ph.D., Member of Committee  
Elinor Karlsson, Ph.D., Member of Committee 
Mark Gerstein, Ph.D., External Member of Committee 
Jeffrey Bailey, MD, Ph.D., Chair of Committee 
Anthony Carruthers, Ph.D., Dean of the Graduate School of Biomedical Science 
October 10, 2017  
 iii 
DEDICATION 
This thesis is dedicated to my husband Eric LaRocque, the EP300 to my RNA 
POLII, enhancing every aspect of life. 
  
 iv 
ACKNOWLEDGEMENTS 
This thesis would not have been possible without guidance from my advisor, 
the hard work and support of my peers, and the patience and love of my friends 
and family. I first would like to acknowledge fellow members of the "SCREEN 
team": Michael Purcaro and Henry Pratt. Over the last year we have worked 
tirelessly together to assemble the Registry and SCREEN. I could not have asked 
for two better partners, though I will not miss our 9pm Skype calls. All our hard 
work has paid off I know we will all celebrate when the paper eventually comes 
out. I would also like to acknowledge Zlab members as a whole for their support 
and friendship. I have thoroughly enjoyed our time spent out of lab, whether at 
Armsby or exploring after conferences.  
Third, I would like to acknowledge my "D4L" family. We started on a journey 
together in the fall of 2008 at the University of Massachusetts Amherst on a floor 
dedicated to nerds math and science. We have been inseparable ever since, which 
has enabled us to become the best architects, teachers, doctors, physician 
assistants, police officers, engineers, and computer scientists that we can be. I am 
forever thankful for the friendship that we all share. 
Fourth, I would like to acknowledge my family. To my parents Donna and 
Robert, thank you for always supporting me. Thank you, Mom, for always lending 
an ear to vent my frustrations whether about the lab or life. Thank you, Dad, for 
instilling an appreciation for math and science in me at a young age and for the 
dimple chin. To my brothers, Mike and Ricky, thank you for preparing me for a 
 v 
career in academia. Your playful (and sometimes not so playful) jabs growing up 
have readied me for the rejected grants, papers, and positions that I will 
undoubtedly face throughout my career. I am also very proud of what you have 
both accomplished at such a young age. A scientist, a lawyer, and a captain walk 
into a bar.... I am sure there is a joke somewhere in there. I also thank my husband 
Eric who has always encouraged me to be the best scientist and person that I can 
be. His unconditional patience and love throughout my PhD career have kept me 
sane and grounded, even while trying to plan a wedding. 
Finally, I would like to acknowledge and thank my advisor over the last five 
years, Zhiping Weng. After meeting Zhiping during my prospective students 
weekend I knew that I wanted to work in her lab. Not only does she have a passion 
for research, but also for learning. She has instilled in me the importance of 
continually improving yourself, to reach your highest potential. I look forward to 
continuing to work together over the next several years. 
  
 vi 
ABSTRACT 
Over the last decade there has been a great effort to annotate noncoding 
regions of the genome, particularly those that regulate gene expression. These 
regulatory elements contain binding sites for transcription factors (TF), which 
interact with one another and transcriptional machinery to initiate, enhance, or 
repress gene expression. The Encyclopedia of DNA Elements (ENCODE) 
consortium has generated thousands of epigenomic datasets, such as DNase-seq 
and ChIP-seq experiments, with the goal of defining such regions. By integrating 
these assays, we developed the Registry of candidate Regulatory Elements 
(cREs), a collection of putative regulatory regions across human and mouse. In 
total, we identified over 1.3M human and 400k mouse cREs each annotated with 
cell-type specific signatures (e.g. promoter-like, enhancer-like) in over 400 human 
and 100 mouse biosamples. We then demonstrated the biological utility of these 
regions by analyzing cell type enrichments for genetic variants reported by genome 
wide association studies (GWAS). To search and visualize these cREs, we 
developed the online database SCREEN (search candidate regulatory elements 
by ENCODE). After defining cREs, we next sought to determine their potential 
gene targets. To compare target gene prediction methods, we developed a 
comprehensive benchmark of enhancer-gene links by curating ChIA-PET, Hi-C 
and eQTL datasets. We then used this benchmark to evaluate unsupervised 
linking approaches such as the correlation of epigenomic signal. We determined 
that these methods have low overall performance and do not outperform simply 
 vii 
selecting the closest gene. We then developed a supervised Random Forest 
model which had notably better performance than unsupervised methods. We 
demonstrated that this model can be applied across cell types and can be used to 
predict target genes for GWAS associated variants. Finally, we used the registry 
of cREs to annotate variants associated with psychiatric disorders. We found that 
these "psych SNPs" are enriched in cREs active in brain tissue and likely target 
genes involved in neural development pathways. We also demonstrated that psych 
SNPs overlap binding sites for TFs involved in neural and immune pathways. 
Finally, by identifying psych SNPs with allele imbalance in chromatin accessibility, 
we highlighted specific cases of psych SNPs altering TF binding motifs resulting in 
the disruption of TF binding. Overall, we demonstrated our collection of putative 
regulatory regions, the Registry of cREs, can be used to understand the potential 
biological function of noncoding variation and develop hypotheses for future 
testing.  
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CHAPTER I: Introduction  
INTRODUCTION 
The human genome is comprised of three billion base pairs, of which less 
than 2% are protein-coding exons1. The remaining 98% of the genome contains 
introns, noncoding RNAs, pseudogenes, repeat sequences, transposons, and 
regulatory elements1. Properly annotating these regions is difficult and requires the 
integration of multiple genomic, transcriptomic, and epigenomic assays. Accurate 
characterization of these noncoding sequences has important biomedical 
applications. For example, mutations in regulatory elements are linked with 
monogenic disorders such as polydactyly2, cleft palate3, and congenital heart 
disease4,5. Additionally, 80% of common genetic variants associated with human 
disease are in noncoding regions with many overlapping potential regulatory 
elements6. Therefore, to better understand mutations linked with human disease 
and genome regulation as a whole, we aim to produce a comprehensive 
annotation of regulatory elements in the human genome. 
 
PREDICTION AND VALIDATION OF REGULATORY ELEMENTS 
Regulatory elements in the human genome 
Regulatory elements are regions of DNA where proteins known as 
transcription factors (TFs) bind and interact with one another and transcriptional 
machinery to control gene expression1,7. While the genome likely has many 
different types of regulatory elements, with varying degrees of activity, the field 
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often classifies them into four generalized categories: promoters, enhancers, 
repressors, and insulators.  Promoter elements are proximal to transcriptional start 
sites (TSSs) of genes and are responsible for recruiting TFs and polymerase 
machinery to initiate transcription7,8. The core promoter is the minimal set of DNA 
elements required for transcription to occur. In humans, this includes the TSS, 
RNA polymerase binding site and general TF binding sites such as the TATA Box8. 
In addition to the core promoter, there are also proximal promoter elements where 
additional TFs bind to further promoter transcription7.  
Enhancers are regulatory elements that increase gene expression through 
TF interactions with a gene's promoter7,9,10. Initially discovered in viral 
genomes11,12, enhancers were first characterized in a mammalian genome by 
Banerji et al., who identified a lymphocyte specific enhancer within the Ig gene13. 
Enhancers can be located close to their target gene, like the Ig enhancer, or can 
be almost 1 Mb away such as the polydactyly linked ZRS element and its target 
SHH2,14. Generally, enhancers are more cell type specific than promoters and are 
responsible for regulating cell type specific gene expression15.  
Repressors (also referred to as silencers) are elements that suppress 
transcription7,16. Though repressors are not as well characterized as their 
enhancer counterparts, several examples have been identified in the human 
genome. For example, neuron-restrictive silencer elements (NRSEs) are regions 
that repress the transcription of neuronal genes in non-neuronal cells17. These 
elements have been reported near many neuronal genes such as STMN2 
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(SCG10), which is involved in neuronal growth18 and SCN2A, which encodes a 
voltage-gated sodium channel19. NRSEs contain binding sites for the REST 
(NRSF), a repressive TF20.   
Insulators are elements that block transcriptional regulation between two 
genomic regions (often nearby genes)7. A well-studied example of insulator activity 
in the human genome is at the imprinting control region (IRC) located between the 
H19 and IGF2 genes21,22. On the paternal allele, the IRC is methylated, preventing 
TF binding, and IGF2 is expressed. However, on the maternal allele, the IRC is 
unmethylated, allowing the TF CTCF to bind and block IGF2 from interacting with 
its upstream enhancer21,22.  While the exact biochemical mechanism of insulator 
activity is not well understood, it appears that CTCF is an important component of 
insulators23. 
The aforementioned examples of regulatory elements were characterized 
over a period of years using various biochemical and validation assays. The 
majority of these methods are low throughput and attempting to apply these 
methods on a genome wide scale is not practical. With the advent of sequencing 
technology and high throughput genomic assays, we can predict regions of 
regulatory activity in the human genome. The National Human Genome Research 
Institute established The Encyclopedia of DNA Elements (ENCODE) 
Consortium24,25, a large collaborative effort, with the aim of identifying all of the 
functional elements in the human genome. Through technological development 
and collaborative analysis, the ENCODE project, along with other large consortia 
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such as the Roadmap Epigenomics Project26, has generated thousands of high 
throughput sequencing datasets which can be integrated to define an encyclopedia 
of DNA elements. 
 
Assays used to characterize regulatory elements 
The ENCODE and Roadmap Epigenomics projects have generated 
thousands of high throughput sequencing experiments that assay components of 
the genome, transcriptome, and epigenome. Using these datasets, we can identify 
genomic regions bound by TFs and interpret their chromatin context to identify 
putative regulatory elements. 
ENCODE has generated over three thousand TF chromatin 
immunoprecipitation sequencing (ChIP-seq) experiments, identifying binding sites 
for hundreds of TFs in up to hundreds of cell types. By analyzing the binding sites 
of specific TFs, we can identify regions with potential regulatory function. For 
example, POLR2A is a subunit of RNA polymerase II (POLII) and co-localizes with 
regions of transcriptional activity such as promoters27. EP300 (p300), on the other 
hand, is known to bind at enhancers28,29. Other TFs, such as the previously 
mentioned CTCF, have multiple functions and are known to bind at enhancers, 
repressors, and insulators30. In addition to assaying specific TFs, the ENCODE 
and Roadmap projects have generated chromatin accessibility data, such as 
DNase-seq31,32 and ATAC-seq (assay for transposase-accessible chromatin using 
sequencing)33. These assays identify regions of open chromatin (called DNase 
  
5 
hypersensitivity sites (DHS) and ATAC peaks) presumably due to TF binding. 
While these methods do not report the specific TFs bound at these regions, they 
produce a genome-wide list of potential regulatory sites.  
We can further annotate TF binding sites and DHSs using histone 
modification ChIP-seq data. Histone proteins are core components of 
nucleosomes, which condense and package DNA into higher order chromatin 
structures34. Chromatin structure is regulated by biochemical modifications to 
histones, particularly to their tails, causing chromatin to relax or tighten. Therefore, 
specific types of histone modifications are enriched at regulatory elements. For 
example, promoters tend to have high levels of H3K4me3 (histone 3, lysine 4, tri-
methylation) and H3K27ac (histone 3, lysine 27, acetylation) and enhancers have 
high levels of H3K4me1 (histone 3, lysine 4, mono-methylation) and H3K27ac15,28.  
Repressed regions tend to have high levels of H3K27me3 (histone 3, lysine 27, tri-
methylation) and H3K9me3 (histone 3, lysine 9, tri-methylation)35. Therefore, by 
integrating these different types of epigenomic datasets, we can begin to define 
regulatory elements in the human genome at a genome-wide scale. 
 
Computational methods for predicting enhancers 
 Because of their association with human disease and estimated abundancy 
in the genome15, labs have primarily focused on identifying enhancers. While 
EP300 binding sites have been shown to successfully predict functional 
enhancers29, ENCODE has only produced EP300 ChIP-seq data for a small set of 
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cell types. Therefore, to identify enhancers, we need to rely on computational 
methods that utilize other types of epigenomic datasets. 
Over the last several years many labs have developed computational 
methods for identifying potential enhancers – a simple literature search for 
"enhancer prediction" generates hundreds of results. Most of these methods 
integrate histone modification ChIP-seq data to predict candidate enhancers, 
sometimes incorporating additional features such as DNA methylation36 or 
conservation37. Most top performing methods use supervised machine learning 
algorithms and require a known set of enhancers for training. Because there are 
few large collections of experimentally validated enhancers, many of these 
methods use complementary epigenomic data (e.g., EP30036,38 or H3K27ac ChIP-
seq37) for their gold standard. For example, both RFECS (Random Forest based 
Enhancer identification from Chromatin States)38 and REPTILE (Regulatory 
Element Prediction Based on Tissue-specific Local Epigenetic Marks)36, two 
random forest based approaches, train on cell type specific EP300 binding sites. 
Therefore, predictions from these methods may be biased; they identify false 
positives due to spurious non-functional EP300 binding or ChIP-seq noise or fail 
to identify classes of enhancers lacking EP300 binding (false negatives). 
Additionally, while RFECS and REPTILE have high performance, they require data 
from many different experiments. For optimal performance, RFECS uses 24 
histone modification ChIP-seq datasets as input; few cell types have this many 
assayed histone modifications. While the method can be modified to use just core 
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marks H3K4me1, H3K27ac, and H3K4me3, this results in decreased performance. 
REPTILE also requires extensive types of data with cell type specific DNA 
methylation and six histone modification ChIP-seq datasets in addition to 
"comparative deviation values" for these assays calculated across multiple cell 
types. Once again, only a small percentage of cell types surveyed by the ENCODE 
and Roadmap Epigenomics projects have all of these assays. While He et al. 
demonstrated that REPTILE can be trained on H1-hESCs and validated on other 
cell types, REPTILEs performance drops dramatically. Therefore, while supervised 
methods have high performance, they do not train and test on functionally 
validated ennhancers and are not applicable to the majority of cell types. 
An alternative approach to supervised enhancer prediction are chromatin 
segmentation methods such as ChromHMM39,40 and Segway41. These methods 
integrate multiple genomic signals and assign every position in the genome to a 
chromatin state (e.g., TSS, enhancer, repressed). For example, ChromHMM takes 
a binarized matrix of histone modification signals for 200 bp bins and using a 
Hidden Markov model, assigns each bin to a state based on the combinations of 
histone modifications and emission probabilities from neighboring regions. 
Because these methods are unsupervised, the user must designate the number of 
states before running the model and then manually label each state using 
complementary data and genetic annotations. Chromatin segmentation methods 
are advantageous because they do not require a gold-standard and they annotate 
regions other than enhancers such as promoters and insulators. They can also 
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identify sub-classes of elements such as strong and weak enhancers based on 
different combinations of signals. However, like some supervised methods, both 
ChromHMM and Segway require a lot of input data (at least eight histone 
modifications) so these methods are not applicable across all cell types. 
In addition to using epigenomic datasets, enhancers can be identified by 
assaying transcriptional activity. In 2010, the Greenberg lab observed bidirectional 
transcription at cortical neuron enhancers that resulted in the production of small 
noncoding RNAs, which they called enhancer RNAs (eRNA)42. They hypothesized 
that these transcripts were the result of interactions between the enhancer and 
target promoter during the transfer of POLII. Because of these findings, groups 
have predicted enhancers by identifying regions of transcription that are distal to 
annotated TSSs. For example, the FANTOM5 consortium used cap analysis of 
gene expression (CAGE) data to identify distal regions of bidirectional transcription 
that they believed were candidate enhancers43. In total, they identified more than 
43 thousand candidate enhancers for over 800 cell and tissue types. Similarly, the 
Siepal lab developed a computation method, discriminative regulatory-element 
detections from GRO-seq (dREG), to identify transcriptional regulatory elements 
(TREs) using GRO-seq data in eight cell types44. Overall, these methods tend to 
identify fewer candidate enhancers than epigenomic based methods, suggesting 
that either we currently only have the resolution to identify a subset of enhancers 
using transcriptional activity or that not all enhancers produce eRNA.  
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Methods for experimentally validating enhancer predictions 
In order to properly validate computation methods for enhancer prediction, 
candidate regions should be experimentally tested for enhancer activity. Reporter 
assays, such as those used by Banerji et al. to identify the Ig enhancers13, test 
enhancer activity by detecting the expression of a reporter gene9. Candidate 
enhancers are cloned into a plasmid upstream of a minimal promoter and a 
reporter gene such as luciferase or GFP. Then, these plasmids are transfected 
into cells; if the candidate region has enhancer activity, the cell will test positive for 
gene expression (e.g., via luminescence). While effective, this method can only 
test one candidate enhancer per experiment, so validating the thousands of 
predictions generated by most methods would be infeasible. 
To solve this problem, researchers have modified these methods to test 
thousands of regions in one experiment45-48. In massively parallel reporter assays 
(MRPAs), each candidate enhancer is assigned a unique bar code. When these 
regions are cloned into the plasmid construct, the enhancer is positioned upstream 
of the TSS and the barcode is downstream of the reporter gene's open reading 
frame. After co-transfection, enhancer activity is quantified by sequencing the 
produced mRNAs and computing the relative abundance of each tag. These 
methods can be used to systematically investigate how genetic variation affects 
enhancer activity45,46 or to identify sequences with enhancer activity from a 
synthetic library47. Similarly, STARR-seq (self-transcribing active regulatory region 
sequencing) developed by the Stark Lab, simultaneously tests thousands of 
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genomic sequences for enhancer activity48. STARR-seq uses a gene construct 
where the candidate enhancer lies between the open reading frame and poly-A 
site of the reporter gene. Therefore, if the tested region has enhancer activity, the 
gene is transcribed and the resulting mRNA contains the enhancer sequence. 
Computationally, this sequence can be isolated and mapped directly to the 
genome. Enhancers are then identified by scanning the genome for peaks of 
mRNA signal.  
While MPRA and STARR-seq methods allow one to test thousands of 
candidate enhancers simultaneously, each experiment is limited to testing in one 
cell type. Mouse transgenic assays, on the other hand, allow researchers to 
determine the tissue specificity of an enhancer29,49,50. In these experiments, a 
candidate enhancer is cloned into a minimal promoter construct containing the lacZ 
reporter gene. This construct is microinjected into a fertilized mouse egg which is 
then implanted in a female mouse. After 11.5 days of embryonic development 
(e11.5) embryos are harvested and stained to assay enhancer activity. Tissues in 
which the enhancer is active will stain blue. With these assays, the Pennacchio 
and Visel labs have tested hundreds of candidate enhancers, the results of which 
are in the VISTA enhancer database51.  
A major pitfall for all of these methods is that they do not assay enhancer 
activity in the candidate region's native chromatin context9. For reporter assays, 
MPRA, and STARR-seq, plasmids are transiently transfected into cells and 
therefore will have no chromatin organization. For the mouse transgenic assays, 
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the constructs are stably transfected and will integrate with the genome. However, 
the location of integration differs from the enhancer's original position, and 
therefore local chromatin context and interactions may vary. 
 In order to study enhancer activity in its native environment, labs have 
utilized CRISPR-Cas9 genome editing methods. Using region specific guide 
RNAs, labs can delete candidate enhancers and perform RNA-seq to determine 
the effect of the deletion on gene expression52-54. Additionally, tiling approaches 
such as MERA (multiplexed editing regulatory assay) and CREST-seq (cis-
regulatory element scan by tiling-deletion and sequencing) allow researchers to 
investigate large stretches of DNA to observe how systematically editing these 
regions effects gene expression55,56. With these methods, enhancer activity is 
measured by the decrease in target gene expression. This may not be a direct 
measure of enhancer activity due to regulatory elements that compensate for the 
deleted enhancer. 
 
LINKING DISTAL ENHANCERS WITH TARGET GENES 
 Though labs have developed experimental and computational methods for 
identifying candidate enhancers, determining the genes they regulate (i.e., target 
genes) still remains a challenge. Some enhancers target their nearest gene, such 
as the intronic Ig enhancers. However other enhancers, such as the ZRS element, 
target genes up to 1 Mb away2. Currently, researchers utilize both experimental 
and computational approaches for predicting target genes. 
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Experimental methods for to assaying three-dimensional chromatin structure 
Capture chromosome conformation, commonly referred to as 3C, is a 
method used to investigate interacting genomic loci57. Briefly, 3C cross-links 
interacting regions of chromatin then digests and ligates the ends of the DNA 
regions. To quantify the amount of ligated product, one performs qPCR using 
region specific primers. Though this method is limited by one knowing ahead of 
time which loci to test, it has been used to successfully characterize interactions 
between regulatory elements. For example, Tolhuis et al. used 3C to characterize 
enhancer-promoter interactions at the mouse Beta Globin Locus, concluding that 
DHSs in the locus control region interact with actively expressed genes58.  
3C has been modified to identify interacting loci without knowing them a 
priori. 4C (circular chromosome conformation capture/chromosome conformation 
capture–on-chip)59,60 for example, allows one to investigate all possible 
interactions with region of interest (referred to as "one to all" approach), while 5C 
reports all interactions within a given region (up to several Mb) (referred to as a 
"many to many" approach)61. Hi-C is the most high-throughput approach reporting 
chromatin interactions on a genome wide scale62. Until recently, the resolution of 
Hi-C was not precise enough to capture the majority of enhancer-promoter 
interactions. However, in 2014, the Aiden lab generated kilobase resolution in situ 
Hi-C data and demonstrated that they could identify CTCF anchored chromatin 
loops with a resolution of up to 5 kb63. In GM12878 they identified almost ten 
  
13 
thousand loops and determined they were enriched for promoter-enhancer 
interactions. These loops have subsequently been used to predict enhancer-
promoter interactions and train computational models (such as those mentioned 
below). However, recent preprint data from the Aiden lab suggest that disrupting 
these loops by knocking out a component of the cohesion complex has little effect 
on gene expression64. A variation on the Hi-C method, promoter capture Hi-C (CHi-
C), enriches for promoter interactions by adding a hybridization step before 
sequencing, which enriches for known promoter sequences65. CHi-C results in a 
ten-fold increase for promoter reads and therefore can be used to link candidate 
enhancers with these regions. 
Another widely used method for investigating genomic interactions is 
chromatin interaction analysis by paired-end tag sequencing (ChIA-PET)66. ChIA-
PET follows a similar protocol to Hi-C except an antibody is used to select for 
interactions mediated by a specific protein such as CTCF, RAD21 or POLII.  Using 
ChIA-PET, researchers have discovered distinct biological features associated 
with the interactions mediated by these proteins. For example, the Ruan lab 
reported significant biological differences between interactions generated by 
CTCF ChIA-PET data compared to POLII ChIA-PET data67. Enhancers and 
promoters in the CTCF interactions were much farther apart (as we also report in 
Chapter III) and genes anchored at these CTCF loops were more likely to be 
house-keeping genes, ubiquitously expressed across cell types. In contrast, most 
POLII interactions occurred within CTCF loops and overlapped cell type specific 
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enhancers. From these results, the Ruan lab concluded that CTCF brings together 
distant regulatory elements to form ubiquitous large domains and within these 
domains enhancers and promoters interact to create local, context specific loops. 
 
Computational methods for linking enhancers and genes 
While three-dimensional chromatin assays have been demonstrated to 
successfully identify interacting enhancers and promoters, these experiments (Hi-
C in particular) are extremely expensive and have only been performed in a small 
number of cell types. Therefore, labs have developed computational methods for 
linking enhancers with target genes. In several publications, the members of the 
ENCODE consortium have predicted target genes by correlating epigenomic and 
transcriptomic signals. This method is based on the hypothesis that enhancers are 
active in the same cell types in which their target genes are expressed. To link 
enhancers with genes, groups correlated a range of signals such as DNase6,68,69, 
H3K4me170, POLII70, and RNA-seq69. Each of these studies reported biologically 
relevant enhancer-promoter pairs with high correlation, but these methods have 
yet to be systematically evaluated using a gold standard. These methods are 
attractive because they are unsupervised and do not require cell-type specific 
experiments, but they have several major drawbacks. One, correlation methods 
cannot identify cell type interactions. Enhancers tend to be more cell type specific 
than promoters, and their activity will not correlate with their target gene if the gene 
is regulated by other enhancers in different cell types. Second, correlation based 
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methods are dependent on the breadth of data selected for the analysis. For 
example, performance may change depending on the number and type of samples 
(e.g., tissues, primary cells, cell lines) used for correlation. To determine the 
severity these problems, we need to evaluate correlation based methods 
systematically. 
Like signal correlation, PreSTIGE (Predicting Specific Tissue Interactions of 
Gene and Enhancers), developed by the Scacheri lab, is an unsupervised 
enhancer-gene linking method71. PreSTIGE predicts enhancer-promoter 
interactions by integrating ChIP-seq and RNA-seq data. First, PreSTIGE identifies 
cell type specific enhancers and genes by calculating the Shannon entropy, using 
H3K4me1 and RNA-seq respectively, across 12 cell types. PreSTIGE then links 
these cell type specific enhancers and genes using a linear domain model that 
considers both distance and CTCF binding sites. While this method predicts many 
enhancer-gene pairs with disease relevant applications, it only can identify links 
for cell-type specific genes. Genes that are ubiquitously expressed but are 
regulated by cell-type specific enhancers are not included in this analysis.  
To address some of the problems with unsupervised prediction methods, 
labs have developed supervised learning approaches for linking enhancers with 
their target genes72-74. These methods train on enhancer-gene pairs defined using 
ChIA-PET or Hi-C datasets and use many different types of features (e.g., histone 
modification signal, conservation, distance, correlation, expression) to predict 
pairs. While each of these methods reported high performance in their original 
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results, it is almost impossible to fairly compare them because they each use a 
different gold standard for training and testing. To illustrate this fact, we will 
compare three recently published methods: PETModule73, IM-PET72, and 
TargetFinder74. First, the methods used different definitions for enhancers. 
PETModule used EP300 peaks, IM-PET used the CSI-ANN algorithm with 
H3K4me1, H3K4me3, and H3K27ac data, and TargetFinder used consensus 
enhancer states called by ChromHMM and Segway. Second, each method used 
different three-dimensional chromatin data to generate enhancer-gene pairs. 
PETModule and IM-PET both used ChIA-PET data from Li et al.66 but PETModule 
also included Hi-C data from Jin et al.75 TargetFinder exclusively used Hi-C loop 
data from Rao et al.63. Finally, each method used a different scheme for generating 
negative enhancer-gene pairs. For each enhancer, PETModule labeled all genes 
within a 2 Mb window as negatives if they did not share a ChIA-PET or Hi-C link. 
IM-PET selected negative pairs by matching a contact frequency distribution, 
selecting one non-interacting promoter per enhancer. For its negative set, 
TargetFinder generated 20 non-interacting pairs by randomly selecting gene pairs 
to match the distance distribution between enhancer and promoter. Therefore, to 
accurately compare the performance of these methods, as well as unsupervised 
methods, we need to evaluated them using a consistent benchmark dataset. 
 
NONCODING VARIATION ASSOCIATED WITH PSYCHIATRIC DISORDERS  
Genetics of Psychiatric disorders 
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Schizophrenia, bipolar disorder, and major depressive disorder are 
prevalent, debilitating psychiatry disorders and little is known about their etiologies. 
Schizophrenia (SCZ) is characterized by a series of positive symptoms (e.g. 
delusions, hallucinations, and disorganized speech and behavior) and negative 
symptoms (e.g. diminished emotional expression and avolition)76. It affects 
between 0.3-0.7% of the adult population with age an age of onset between 18 
and 30 years old. Bipolar disorder (BPD) is characterized by patterns of manic and 
depressive episodes in which an individual may experience states of inflated self-
esteem, decreased sleep, and mood changes followed by periods of deep 
depression76. BPD affects about 1.4% of the US population and usually presents 
in patients in their mid-20s. Major depressive disorder is the most common of the 
three disorders affecting 7% of the adult population76. It is marked by a depressed 
mood and loss of interest or pleasure for an extended period. 
Studying these disorders is challenging due to their imprecise diagnoses 
and treatment regimens. The fifth edition of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM 5)76 characterizes each disorder at length, but most 
patients do not present with a clear set of symptoms. Additionally, these disorders 
are part of a spectrum of psychiatric disorders, many of which have overlapping 
symptoms. For example, patients with Schizoaffective disorder experience 
delusions or hallucinations, like patients with schizophrenia, but will also suffer 
from manic or depressive episodes, similar to patients with bipolar disorder76. 
Therefore, depending on the patient's presentation of symptoms, an exact clinical 
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diagnosis is difficult. Treating these disorders is equally challenging. Treatment 
regimens may include therapy, mood stabilizers, antipsychotic drugs and 
electroshock therapy76-79. Finding a successful treatment is often a process of trial 
and error and varies greatly among patients. Therefore, learning more about 
genetic risk factors for these disorders will give the field a better understanding as 
to their etiologies and potential therapeutic targets.  
    Studies suggest that these disorders are highly heritable. With an estimated 
heritability of 60% for SCZ and BPD and 40% for MDD76,80-82. In addition to being 
highly heritable, these disorders share common genetic risk factors. By analyzing 
over 30 years of medical records from the Swedish national registry, Lichtenstein 
et al. estimated that over 50% of the genetic risk for SCZ and BPD is shared83. 
These results are concordant with findings by the Psychiatric Genomics 
Consortium (PGC) which estimated a SNP based correlation of 0.68 between SCZ 
and BPD, 0.47 between BPD and MDD, and 0.43 between SCZ and MDD84. These 
results suggest that these three psychiatric disorders share common genetic risk 
factors.  
During the mid 2000's, groups started to investigate the role of common 
genetic variation in the onset of human disease using genome wide association 
studies (GWAS). GWAS operate under the hypothesis that many common variants 
(greater that 1% frequency in the population) each contribute a small amount to 
disease risk85. These studies analyzed large cohorts of affected and healthy 
individuals to determine if common genetic variants are enriched in the affected 
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population and therefore associated with the disease. While GWAS were 
successful in identifying hundreds of variants associated with many different 
diseases, for psychiatric disorders they were only able to identify a small number 
of associations. For example, of the nine SCZ GWAS published between 2007 and 
2011, only four studies reported variants meeting a genome wide significant 
threshold resulting in only 11 significant loci86. Many regions were just under 
genome-wide significance thresholds, and comparing across studies revealed 
common risk genes between the three disorders. Variants near ANK387-91, 
CACNA1C88-90,92 and the majority histocompatibility complex93-99, were all been 
reported as associated with schizophrenia, bipolar disorder, and major depressive, 
often by multiple studies. Therefore, associations with these regions are 
replicatable across disorders and presumably by increasing sample size, more loci 
will reach genome wide significance. This was the case for the Schizophrenia 
Working Group of Psychiatric Genomics Consortium, who reported over 100 novel 
genomic regions associated with schizophrenia after analyzing over 100 thousand 
individuals. Though this study and subsequent large-scale analyses were 
successful in identifying hundreds of variants associated with psychiatric 
disorders, the majority of these variants lie in noncoding regions of the genome 
and therefore understanding how they may contribute to disease is not well 
understood. 
 
Interpreting GWAS variants with epigenomic data 
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Over the last decade, genome wide association studies (GWAS) have 
identified thousands of genetic variants associated with human disease. However, 
the majority of these variants are in noncoding regions of the genome and 
determining how they contribute to disease remains a challenge. To aid in 
interpreting genetic variants, researchers have integrated epigenomic datasets 
such as DNase-seq, TF ChIP-seq and histone modification ChIP-seq data to 
annotate surrounding noncoding regions. 
One common application is to determine disease relevant cell and tissue 
types. Using epigenomic datasets and subsequent predicted regulatory regions, 
many groups have developed methods for analyzing enriched cell types for GWAS 
variants6,26,39,100,101. Group have repeatedly reported SNPs associated with blood 
cell traits are enriched in regulatory regions active in K562 (an erythroid leukemia 
cell line)39, autoimmune SNPs are enriched in regulatory regions active in T cells 
and B cells26,100,102, and SNPs associated with cholesterol levels are enriched in 
liver regions26. While cell type enrichments from these analyses may seem 
obvious, there are important biological applications. These results can give new 
insights for disease pathology and suggest cell types to consider for therapeutic 
targets. For example, in 2012, the Stamatoyannopoulos lab reported that SNPs 
associated with multiple sclerosis were enriched in DHSs active in CD3+ T cells 
and CD19+/CD20+ B cells6. At the time, the role of T cells in multiple sclerosis was 
well established, but recent evidence also suggested B cells may also play 
important role and have therapeutic applications103. Since, clinical trials have 
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demonstrated that Ocrelizumab, an anti-CD20 antibody, can lower disease activity 
and progression compared to traditional treatments104. Therefore, analyzing cell 
type enrichments can give further insight into biological mechanisms of disease 
and highlight potential therapeutic strategies. 
In the case of schizophrenia, the schizophrenia working group of the PGC 
previously reported that variants were enriched in cell type specific H3K27ac peaks 
from brain tissues and B cells105. While the enrichment in brain was not surprising, 
the enrichment in B cells was intriguing as it remained significant even after 
removing SNPs in the major histocompatibility complex (MHC). As the authors only 
performed this analysis using data from 35 cell types, reanalyzing enrichment for 
these SNPs as well as other psychiatric associated variants using a larger panel 
of cell types is of great interest.  
Epigenomic datasets can also be used to predict the biological function of 
disease associated variants. The Kellis and Snyder labs have summarized 
intersections with epigenomic datasets in their variant annotation databases 
HaploReg106 and RegulomeDB107. For each variant, users can explore overlapping 
histone modification, DHS, and TF peaks and TF motif sites. RegulomeDB even 
supplies a score of how likely the variant is to disrupt TF based on overlapping 
peaks and TF motifs. 
Groups have also annotated the functional consequences of genetic 
variants by correlating changes in gene expression and the epigenomic landscape 
with genotypes. Now with the relatively low cost of RNA-seq, genotyping arrays, 
  
22 
and whole genome sequencing, large consortia now have the ability to detect 
expression quantitative trait loci (eQTLs) for thousands of genes in many different 
cell types. One of the largest efforts to date, The Genotype-Tissue Expression 
(GTEx) project, aims to of study the relationship between genetic variation and 
gene expression across different human tissues108. During the second phase of 
the project, the consortium identified over 1 million eQTLs in 44 tissues. eQTL 
methodology can also be applied to correlate changes in histone modification 
signal or chromatin accessibility with genotype. Groups have identified hundreds 
of histone modification QTLs109,110 and DNase QTLs111 using data lymphoblastoid 
cell lines generated by the HapMap112 and 1000 genomes projects113,114. 
While QTL based methods require hundreds of genotyped individuals to 
observe significant trends, we can gather similar types of information at a cell type 
specific level by looking for allelic imbalance at heterozygous loci. By calculating 
the ratio of alleles from high-throughput sequencing reads, one can test whether a 
variant results in an allelic imbalance. Groups have analyzed TF ChIP-seqn115,116, 
DNase-seq102 and RNA-seq data117 for sites of allelic imbalance and in doing so 
have uncovered mapping biases. It has been demonstrated that there are biases 
towards the reference allele118-121. To correct this bias, groups have suggested 
using an allele sensitive mapping tool, such as GSNAP122, or map reads to 
genomes containing the reference and alternative alleles, or masked positions121. 
Ultimately, results from both functional characterization, eQTL, and AS 
analysis can be validated experimentally to test whether the observed correlation 
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or imbalance is directly caused by variant in question. Many groups have tested 
the effect of alleles on enhancer activity using luciferase assays and Vockley et al. 
even pioneered a MPRA version123. However, as previously mentioned, these 
types of assays do not account for local genomic context. Therefore, as CRISPR-
Cas9 technology improves to edit individual nucleotides124,125, more labs will be 
effect of genomic variants using single nucleotide genomic editing.  
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CHAPTER II: Creating a Registry of Candidate 
Regulatory Elements for Human and Mouse Genomes 
 
 
PREFACE 
Results from this chapter were adapted from  
Moore*, Purcaro*, Pratt*, Epstein*, Shoresh*, Adrian*, Kawli*, Davis*, Dobin*, 
Kaul*, Halow*, Van Nostrand*, Freese*, Gorkin*, He*, Mackiewicz*, The 
ENCODE Consortium. Cherry, Myers, Bing Ren, Graveley, Stamatoyannopoulos, 
Gerstein, Pennacchio, Gingeras, Snyder, Bernstein, Wold, Hardison, and Weng. 
"ENCODE Phase III: Building an Encyclopaedia of candidate Regulatory 
Elements for Human and Mouse," 
 
which is currently under review at Nature. 
Len Pennacchio's lab tested candidate enhancers using transgenic mouse 
assays, the results of which are in Figure 2.7 Tables 2.4-6. I performed all 
analysis and generated all the figures in the chapter. Michael Purcaro and Henry 
Pratt designed, engineered and implemented the online visualization tool 
SCREEN (Search Candidate Regulatory Elements by ENCODE). 
 
ABSTRACT 
Here we described the Registry of candidate Regulatory Elements (cREs), 
which we defined using chromatin accessibility, histone modification and 
transcription factor occupancy data. The Registry currently contains 1.31 M human 
and 0.43 M mouse cREs, covering hundreds of biosample types. The cRE 
landscape recapitulates the current understanding of cellular identity, tissue 
composition, developmental progression, and disease-associated genetic 
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variants. Aided by a dedicated visualization engine called SCREEN 
(http://screen.encodeproject.org), the Registry is a resource for exploring 
noncoding DNA elements and their variants. 
 
INTRODUCTION 
 
 Over 98% of the human genome is noncoding; less than 2% composes 
protein coding exons. A portion of these noncoding bases contain regulatory 
elements where transcription factors (TF) interact to control gene expression1,7. 
There are several classes of regulatory elements including promoter, enhancers, 
repressors, and insulators each with their own regulatory roles and epigenomic 
features. Identifying regulatory elements has important biological implications for 
studying gene regulation, cell type differentiation, and human disease. 
Because of their cell-type specificity and long distance from TSSs, many 
groups have aimed to annotate enhancers. Enhancers are genomic elements that 
regulate and increase gene expression through interacting transcription factors.  
Using massively parallel report assays, STARR-seq, and mouse transgenic 
assays labs have generated collections of experimentally validated enhancers. For 
example, The VISTA enhancer browser is a collection mouse and human genomic 
regions that were tested for enhancer activity using transgenic mouse assays 
(Figure 2.2)51. These regions were selected using conservation49, EP300 ChIP-
seq data29, and/or H3K27ac ChIP-seq data50. However, this is still a relative small 
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collection of validated enhancers and it far from annotating every enhancer in the 
human and mouse genomes. 
Over the last few years many labs have developed enhancer prediction 
algorithms that integrate data from the ENCODE and Roadmap Epigenomics 
projects. Histone modifications H3K4me1 and H3K27ac and TF EP300 are 
enriched at enhancers so by integrating these datatypes, along with other 
epigenomic data, lab have generated genome wide lists of predicted enhancers. 
While some of these methods have high performance, the majority do not have 
practical biological applications. Some methods such as RFECS38 and REPTILE36, 
are supervised methods requiring a positive set of enhancers for training. These 
methods also require a large amount of input data in some cases requiring over 
20 histone modifications. Additionally, these prediction methods are designed to 
only identify potential enhancers; they do not predict other types of regulatory 
elements. Unsupervised methods of genome segmentation, such as ChromHMM, 
generate chromatin state maps genome wide40. Using a Hidden Markov Model, 
ChromHMM labels the genome with regions having promoter, enhancer, 
transcription, and repressive features. While powerful, these methods also require 
a lot of input data (up to eight histone modifications) and are only able to segment 
regions at a resolution of 200bp making comparisons across cell types difficult.  
In this chapter, we introduce the Registry of candidate Regulatory Elements 
(cREs), collection of putative regulatory regions in human in mouse. We assigned 
cREs functional annotations (i.e. promoter-like, enhancer-like) based on 
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computational methods that we experimentally validated. We compared the 
Registry with other methods element prediction finding that our method is 
concordant with other epigenomic data based methods. Finally, we demonstrated 
that these cREs have biological implications as cell types cluster based on cRE 
activity and variants reported by genome wide association studies are enriched in 
cREs active in disease relevant cell types. 
 
RESULTS 
Cell Type Specific Enhancer Prediction  
We began by developing a method for tissue-specific enhancer prediction 
that met the following criteria: One, our method needed to be unsupervised. While 
we had a collection of experimentally validated enhancers from reporter assays, 
mouse transgenic assays, and STARR-seq experiments, these data were only 
from a small number of cell types. Therefore, while we developed and tested 
models using these validated regions, our method did not require them. Two, we 
needed to use our method to predict enhancers across hundreds of cell types. 
While the ENCODE consortium generated hundreds of genomic assays in cell 
lines such as K562 and GM12878, the majority of cell types only have a handful of 
experiments such as DNase-seq and histone modification ChIP-seq. Though we 
may be able to develop a more accurate enhancer prediction model using multiple 
data types (e.g., RAMPAGE and TF ChIP-seq), this model could not be applied to 
the majority of cell types.  
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Mindful of these requirements, we decided to develop our enhancer 
prediction model using data and experimentally validated regions from embryonic 
mice. During the third phase of the ENCODE project, production labs generated a 
dense matrix of genomic data surveyed across twelve tissues in up to eight 
embryonic stages. The Ren lab assayed nine histone modifications across 72 
embryonic tissue-time points (Figure 2.1) and the Wold and Ecker labs generated 
matching RNA-seq and whole genome bisulfite sequencing data (WGBS). 
Additionally, the Stamatoyannopoulos lab produced DNase-seq data for 18 of 
these tissue-time points including limb, midbrain, hindbrain, and neural tube at 
embryonic day 11.5 (e11.5). In addition to this expansive collection of genomic 
data, we established collaborations with the Pennacchio and Visel labs who 
maintain the VISTA enhancer browser. As of November 2015, there were 1,994 
tested regions in the VISTA database; 228 were active in limb, 301 were active in 
midbrain, 271 were active in hindbrain, and 193 were active in neural tube. 
Therefore, we decided to develop our enhancer prediction method using genomic 
data and experimentally validated enhancers in mouse limb, midbrain, hindbrain, 
and neural tube tissues at e11.5. 
To develop our unsupervised enhancer prediction method, we went through 
two rounds of testing. First, we tested which data type was best for anchoring 
predictions (i.e., which peaks we should center our predictions on). Second, we 
tested methods for ranking these peaks (i.e., what type of signal or combinations 
of signals are most predictive). To begin, we tested anchoring predictions on 
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H3K27ac, H3K4me3, H3K4me1, and DNase peaks (further referred to as DNase 
hypersensitivity sites – DHSs) (Table 2.2). To fairly compare performance across 
the different data types, we selected the top 20,000 peaks from each dataset and 
then set each peak to a uniform width of 300 bp. On average, we achieved the 
highest performance anchoring on DHSs with an average AUPR of 0.36, followed 
by H3K27ac peaks with an average AUPR of 0.33 (Table 2.2). When we analyzed 
individual tissues, DHSs had the best performance for limb, hindbrain, and neural 
tube whereas H3K27ac peaks had the best performance for midbrain (Figure 2.4, 
Table 2.2). Because DHSs had the highest average AUPR and were the top 
predictor for three of the four tissues, we decided to anchor our enhancer 
predictions on DHSs.  
Our next step was to evaluate different methods of ranking DHSs. We 
tested ranking by different histone modification signals (H3K27ac, H3K4me3, 
H3K4me1, H3K9ac, H3K36me3, and H3K27me3) and DNA methylation signal. 
We also tested combining DNase with histone modification and methylation 
signals. We were unable to simple average these signals, due to differences in 
data processing. Therefore, to combine signals for region, we averaged its DNase 
signal rank and histone modification/methylation rank generating a metric we 
referred to as "average rank." In general, the best performing method was ranking 
DHSs by the average rank of DNase and H3K27ac signals (Figure 2.5, Table 2.3). 
To validate our method, the Pennacchio and Visel labs tested our enhancer 
predictions using transgenic mouse assays. For limb, midbrain, and hindbrain, we 
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curated a ranked list of predictions and selected three tiers of regions to test: ranks 
1-20, ranks 1,500-1,515 and ranks 3,000-3,015 (Tables 2.4-2.6). In general, higher 
ranking regions were more likely to show enhancer activity than lower ranking 
regions in their predicted tissue (Figure 2.6). For example, in limb, 70% of the top 
ranked regions had enhancer activity in limb compared to 40% and 20% in the 
middle and bottom tiers respectively. In addition to the predicted tissues, we also 
observed activity in biologically similar tissues for some of the tested regions. For 
example, mm154, a high-ranking midbrain prediction, was active in midbrain, 
forebrain, hindbrain, neural tube and eye (Figure 2.7a, Table 2.4) and mm1489, a 
high-ranking hindbrain prediction, was active in hindbrain, midbrain and neural 
tube (Figure 2.7b, Table 2.5). High H3K27ac signal in these tissues supported this 
additional enhancer activity (right panels Figure 2.7). In contrast, mm1485, a high-
ranking limb prediction, is only active in limb tissue (Figure 2.7c, Table 2.6) and we 
did not observe high H3K27ac signal in tissues other than limb. These results 
suggested that our unsupervised method of enhancer prediction, which combines 
DNase and H3K27ac data, was capable of successfully identifying tissue-specific 
enhancers. 
 
Developing a Registry of Candidate Regulatory Elements  
Since we developed a computational method that successfully identified 
active enhancers, our next step was to use this model to curate a collection of 
putative enhancers across human and mouse cell-types. Even though our method 
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only required DNase and H3K27ac data, only a small percentage of ENCODE and 
Roadmap cell types had both of these assays. In humans, of the 540 cell types 
surveyed by DNase and H3K27ac, only 58 had both assays while in mouse only 
23 of 131 cell types had both DNase and H3K27ac (Figure 2.8). Additionally, our 
prediction method was limited in that it only identified potential enhancers; it did 
not define other types of regulatory elements such as promoters, insulators, or 
repressors. Using DNase, H3K4me3, and gene expression data, we demonstrated 
that by using a method analogous to our enhancer prediction method, we could 
predict candidate promoters (Figure 2.9, Tables 2.7-2.8). Because of these 
concerns, we decided to adapt our method to make it applicable to more cell and 
tissues types as well as flexible enough to identify other types of regulatory 
elements. With our new method, we aimed to create a collection of putative 
regulatory regions across human and mouse that we called the registry of 
candidate regulatory elements (cREs).  
For both our enhancer and promoter prediction methods, anchoring 
predictions on DHSs consistently resulted in the best overall performance. 
Because the boundaries of DHSs are generally consistent across cell types (Figure 
2.10a), we decided to anchor cREs on a consensus set of DNase accessible 
regions, which we call representative DHSs (rDHSs). To create rDHSs in humans, 
we curated over 48 million high-quality DHSs (FDR < 0.1%) from 449 DNase 
experiments and grouped them into overlapping clusters (Figure 2.10b). For each 
cluster, we selected the DHS with the highest signal as the rDHS and discarded 
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overlapping DHSs (Figure 2.10c). Using the selected rDHSs and the remaining 
non-overlapping DHSs we iteratively repeated the clustering and selection steps 
until all DHSs overlap at least one rDHS. For humans, we defined over 2 million 
rDHSs, and for mouse, with 8.6 million high-quality DHSs from 62 datasets, we 
defined about 1 million rDHSs. 
To classify an rDHS as a cRE, we integrated DNase data with H3K4me3, 
H3K27ac, and CTCF data, adopting similar approaches to our enhancer and 
promoter prediction schemes. However, comparing these datasets and choosing 
consistent cutoffs is complicated due to differences in data processing pipelines, 
sequencing depth, and assay protocols. For example, DNase-seq, CTCF-ChIP-
seq, and histone modification ChIP-seq experiments are all processed using 
different pipelines at the ENCODE data coordination center (DCC). Signal from 
ChIP-seq experiments is normalized using input data while signal from DNase is 
dependent on sequencing depth. Additionally, even for data that has been 
processed using the same pipeline, such as H3K27ac experiments, signal files are 
not comparable across cells types (Figure 2.11a). Therefore, to normalize signal 
across assays and cell types, we took the log of the average signal across an rDHS 
and converted it to a Z-score (Figure 2.11). This resulted in an approximately 
normal distribution of signals for each cell type. For each assay and cell type, we 
assigned an rDHS a signal Z-score. We refer to a max Z-score as the maximum 
Z-score for the rDHS across all cell types for the particular assay (DNase, 
H3K4me3, H3K27ac, or CTCF). While this method may bias against cell types, 
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such as embryonic stem cells that have higher numbers of active cREs, we 
decided error on the side of being more conservative rather than over call 
elements. 
Using this signal normalization scheme, we required rDHSs to meet two 
criteria to be classified as a cRE. One, the rDHS must have a max DNase Z-score 
greater than 1.64 (95 percentile using one-tailed test). This filters out low signal 
rDHSs. Two, the rDHS must also have a max Z-score > 1.64 for either H3K4me3, 
H3K27ac, or CTCF. This step filters out rDHSs that may be due to spurious, 
nonfunctional transcription factor binding. These two requirements (DNase max Z 
> 1.64 and ChIP-seq max Z > 1.64) do not need to occur in the same cell type 
since only 3% of cell types have all four assays. However, cREs that have high 
DNase and one of the three ChIP-seq signals in the same cell-type are given a 
special designation as concordant cREs (approximately 55% of human cREs and 
52% of mouse cREs). Using the classification trees in Figures 2.12 and 2.13, we 
classified cREs into three groups (cREs with promoter-like signatures (PLS), cREs 
with enhancer-like signatures (ELS), and CTCF-only cREs) based on max Z of 
ChIP-seq signals and distance from TSS. We refer to these groups as cell-type 
agnostic classifications. In total, we curated 1.3 million cREs in human, and 432 
thousand cREs in mouse which comprise 20.8% and 8.8% of their respective 
genomes (Figure 2.14). We assigned each of these cREs a unique accession, with 
prefixes EH37E for human and EM10E for mouse. 
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After defining cREs, we next sought to determine the cell-type specific 
activity of each cRE across hundreds of human and mouse cell types. For cell 
types with DNase and all three ChIP-seq assays, there were 16 possible 
combinations of these four signals. Since we only considered a cRE as active in a 
cell type if it has a DNase Z-score > 1.64, we condense these 16 possible states 
into eight active states and one inactive state (2.15a). To simplify this classification 
scheme, we aimed to further condense these states into five groups: PLS-cREs, 
ELS-cREs, CTCF-only cREs, DNase-only cREs, and inactive cREs.  To aid in 
classification, we used GM12878 as a test case (Figures 15,16). We separated 
cREs in each of the nine states based on TSS proximity, resulting in 18 sub-states 
(Figure 15a). For cRES in each of these sub-states, we calculated the average 
POLII (Figure 2.15b), EP300 (Figure 2.15c) and RAD21 ChIP-seq signal using 
experiments in GM12878. We predicted POLII, which is present at active 
transcription start sites, should be highest at PLS elements. EP300, a TF known 
to bind at active ELS elements28, should be the highest at enhancer-like elements, 
and RAD21, part of the cohesion complex that is known to localize with CTCF, 
should be the highest at CTCF-only elements. Using the median signal values for 
each TF, we compared the 18 sub-states and observed that like sub-states formed 
clusters (Figure 16a,b). For example, distal cREs with H3K27ac z-scores > 1.64 
have EP300 high signal and low POLII and RAD21 signals (Figure 16a). Based on 
these plots, we assigned each of the 18 sub-states to one of the five groups (Figure 
16c) which in the case of GM12878 results in 36,022 PLS, 27,739 ELS, 10,913 
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CTCF-only and 16,085 DNase-only cREs (Figure 16d). As groups PLS, ELS, and 
CTCF-only cRES are enriched in POLII, EP300, and RAD21 signals respectively 
(Figure 16e).  Using this method, we classified cREs into cell-type specific groups 
for the 21 cell types with all four assays. For PLS, ELS, and CTCF-only groups, 
we plotted the saturation curve across the 21 cells types (Figure 2.17). There are 
more ELS cREs than PLS cREs, which we would expect since enhancers are more 
likely to be cell-type specific than promoters15. For the majority of cell types, we do 
not have all four genomic assays, but we are still able to combine sub-states into 
simplified groups. We listed all possible state-group classification schemes in 
Figure 2.18. In total, we assigned each human cRE to a group in 620 cell types 
and each mouse cRE to a group in 138 cell types. 
After generating cREs for human and mouse and determining their cell-type 
specificity, we wanted to compare cREs between species. We mapped mouse 
cREs to the human genome using UCSC's liftover tool. 20% of human cREs 
overlapped a mouse cRE (52% of total mouse cREs), which we refer to as 
orthologous cREs. We noticed that larger percentage of orthologous cREs were 
PLS cREs compared to either human or mouse cREs as a whole.  
 
Comprehensiveness of the Registry of cREs 
First, we examined how many GENCODE-annotated TSSs (V19 for 
human and M4 for mouse) were covered by the current version of the Registry of 
cREs. For human, 67% of all annotated TSSs and 72% of protein-coding TSSs 
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overlap a cRE. When we searched +/- 2 kb around each TSS, to account for 
possible misannotation, 92% of all TSSs were proximal to at least one cRE. 
Coverage is similarly high in mouse, despite having far fewer cREs, with 61% of 
all annotated TSSs overlapping a cRE and 80% having at least one proximal 
cRE. 
Second, we analyzed how rapidly the total number of unique rDHSs 
saturated when we increase the number of covered cell types. In ENCODE 
Phase II, Steven Wilder and Ian Dunham modelled DHS saturation using a 
Weibull distribution and estimated that they had discovered around half of the 
total DHSs25. We replicated this analysis using the 460 DNase datasets that we 
used to create the rDHSs. The saturation curves of rDHSs follow Weibull 
distributions, reaching a plateau at 1.66 M rDHSs with FDR < 0.1% and Z-score 
> 1.64 (Figure 2.17). Because only a subset of such rDHSs can be cREs (those 
with a high H3K4me3, H3K27ac, or CTCF Z-score in at least one cell type) we 
estimate that we have identified at least 78.9% of total cREs in human. We 
performed the same saturation analysis for mouse but could not reach a reliable 
estimate due to the smaller number of input tissue types.  
Third, we computed the Registry's coverage of H3K27ac and H3K4me3 
peaks (FDR<0.01) in cell types with ChIP-seq data but no DNase data. The 
Registry covered 90 ± 8% of H3K4me3 peaks (74 cell types), and 87 ± 5% of 
H3K27ac peaks (54 cell types) (Figure 2.20) The coverage was equally high for 
mouse, despite a smaller number of DNase experiments for building the mouse 
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Registry: 88 ± 5% of H3K27ac peaks (69 tissue–time-points) and 96 ± 8% of 
H3K4me3 peaks (74 tissue–time-points) were accounted for (Figure 2.21) The 
coverages for H3K4me3 peaks were low for several human and mouse cell types. 
The average -log(FDR) of the H3K4me3 peaks in these datasets were low (Figure 
2.22)  When we visually inspected the two datasets with the lowest coverage (CD-
1 megakaryocyte and GR1-ER4 in mouse), we confirmed that the peaks that were 
not covered by the Registry had low signals and were likely false positives by the 
peak calling algorithm MACS2. 
Therefore, when judged against gene annotations and epigenomic 
datasets, the human Registry appears to be comprehensive. It covers almost 80% 
of all cREs and 85% of elements marked by H3K4me3 or H3K27ac. The mouse 
Registry is less comprehensive than the human Registry, but we expect that it will 
continue to grow with experiments performed on additional cell types.  
 
Comparison with Previous Defined Regulatory Regions  
To further validate our approach, we compared the cREs to previously 
defined regulatory elements. Like cREs, ChromHMM regions are defined using 
epigenomic datasets generated by the Roadmap and ENCODE projects. Using 
states from a ChromHMM model, which was implemented using eight histone 
modifications and CTCF40, we found that the overlap between the model and our 
cREs was highly concordant. Of the top 10,000 ranked PLS cREs (ranked by 
H3K4me3 Z-scores), 90% overlapped ChromHMM TSS states while 85% of the 
top 10,000 ranked ELS cREs (ranked by H3K27ac Z-scores) overlapped 
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ChromHMM high-signal enhancers states. The overlap decreased for lower 
ranking ELS cREs, but the overlap with ChromHMM low-signal enhancers 
increased; 82% of the ELS cREs ranked above 20,000 overlap with ChromHMM 
enhancers or low-signal enhancers (Figure 2.26a,b). We also compared the cREs 
for five e11.5 and six e14.5 mouse tissues (tissues with DNase data) with the 
ChromHMM states called using eight histone modifications in the corresponding 
tissues. We observed that 95 ± 2% of PLS cREs overlapped ChromHMM TSS 
states and 78 ± 3% of ELS cREs overlapped ChromHMM enhancers states in the 
corresponding tissue and time point (Figure 2.26c,d). This suggests that while our 
method was able to identify similar putative regulatory regions as the ChromHMM 
model using less input data. 
We also compared our ELS cREs with enhancers annotated by transcription 
data and STARR-seq peaks. We intersected our ELS cREs with FANTOM defined 
enhancers in GM12878, astrocyte, hepatocyte and keratinocyte cells43. While the 
overall percentage of overlapping ELS cREs was low (2%), we observed the 
largest percentage of overlap for highly ranked enhancers (Figure 2.27a). When 
we overlapped the FANTOM enhancers with all cREs we found that 74% 
overlapped, with 70% overlapping cREs active in the cell type (Figure 2.28a, Table 
2.10). Of the active cREs the majority were ELS (66%) followed by PLS (28%). We 
observed similar results transcriptional regulatory elements (TREs) defined using 
GRO-seq data44, except that these elements overlapped a higher percentage of 
PLS cREs (57% of active cREs) because they encompass all types of regulator 
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elements (Figure 2.27b, and 2.28b, Table 2.10). STARR-seq peaks in HeLa cells 
overlapped even fewer cREs (31%) (Figure 2.27c and 2.28c, Table 2.10) but even 
by their own internal annotations, they only annotated 20% of their peaks with 
chromHMM enhancer states. 
These results suggest that while the Registry had similar performance to 
other epigenomic data based methods, such as chromHMM, it did not identify all 
potentially functional regions in the human and mouse genomes. 
 
Cell and tissue type clustering using cRE activity 
 
To examine whether the Registry of cREs captured biologically relevant 
regulatory patterns, we clustered primary cells and tissues based on the number 
of overlapping active cREs defined using DNase, H3K27ac, or H3K4me3 signal.  
We first compared the clustering schemes in mouse using the 72 embryonic tissue-
time points with H3K27ac and H3K4me3 data. Using H3K27ac, we observed 
almost perfect clustering of tissues by their organs of origin (Figure 2.23). When 
we clustered by H3K4me3 activity, the tissues do not segregate as cleanly . We 
believe this is because H3K4me3 signal is enriched at promoters, which are more 
consistent across cell types (Figure 2.17). This is reflected in average Jaccard 
coefficients; the average H3K27ac coefficient for mouse is 0.36 while for H3K4me3 
it is 0.79. Higher similarity between cell types will make them more difficult to 
cluster. 
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In humans we decided to cluster primary cells and tissues by cRE DNase 
and H3K27ac activities since these assays cover different tissues (Figure 2.8). 
Using H3K27ac signal, we observed tissues from different regions of the same 
organ cluster together (Figure 2.24a). For example, brain regions form a distinct 
group. In some cases, we also observed fetal and adult tissues clustering such 
fetal and adult adrenal gland tissues. Interestingly, samples from the 
gastrointestinal tract form two clusters, one for smooth muscle tissues (the purple 
and maroon samples at the top) and the other for mucosa tissue (the maroon 
samples at the center). This suggests that while these tissues are located in 
proximity to one another in the human body, they have different regulatory 
landscapes. When we analyzed primary cells, we observed three perfectly 
segregated groups colored by their embryonic origins: blood, non-blood 
mesoderm, and ectoderm (Figure 2.24b). Even the endothelial cells of the 
umbilical vein, which are derived from the extraembryonic mesoderm, clustered 
with the cell types derived from the embryonic mesoderm such as fibroblasts, 
myoblasts, osteoblasts, and astrocytes. 
When we clustered using DNase signal, we observed similar results. For 
DNase, we have multiple donors for the same types of tissues and in the majority 
of cases these donor samples clustered together (e.g., kidney, stomach, lung, and 
muscle tissues) (Figure 2.25a). We did observe some noticeable outliers such as 
one fetal thoracic segment muscle sample clustering with lung fetal lung tissue. 
This could be due to a possible sample swamp (i.e. samples were submitted to the 
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ENCODE DCC with incorrect labels) and therefore should be further analyzed. 
When we clustered primary cells, we observed two large clusters, with the one 
cluster composed entirely of blood cells, subdivided into to the myeloid and 
lymphoid lineages (Figure 2.25b). The second cluster, was comprised of several 
smaller "subclusters". The bottom subcluster contained of four trophoblast 
samples (in black), thus reflecting their extraembryonic fate. The topmost 
subcluster contained mostly fibroblasts, and the middle subcluster contained 
endothelial cells, epithelial cells, keratinocytes, and melanocytes. The fibroblasts 
aggregated together regardless of their anatomical locations, as did most of the 
endothelial cells, in agreement with their common mesodermal origin. Most of the 
epithelial cells also clustered together, despite their different embryonic germ 
layers. Overall, these results demonstrated that like tissues and cell types 
clustered together when we compared their cRE activity, suggesting that the 
registry of cREs is able to capture biologically relevant regulatory patterns. 
 
Applications to Genome Wide Association Studies (GWAS)  
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Previous studies have repeatedly demonstrated that most GWAS variants 
reside in noncoding regions of the genome. Annotation of these noncoding regions 
can be used to guide the interpretation of GWAS variants by predicting disease-
relevant cell types and regulatory factors6,26,39,100,101. With the broad coverage of 
cell types and rich epigenetic and transcription factor binding data associated with 
the cREs, the Registry can be particularly useful for annotating GWAS SNPs. 
We curated variants from over 50 studies in the NHGRI-EBI GWAS. For 
each phenotype-cell type comparison, we tested whether active cREs (H3K27ac 
or DNase z-score > 1.64) were significantly enriched in the GWAS SNPs. Overall, 
we observed enrichment in disease related cell types. Like previous 
studies6,26,39,100,101, we observed enrichments in immune cells such T and B cells for 
autoimmune disorders multiple sclerosis, type 1 diabetes, inflammatory bowel 
disease and Crohn's disease (Figure 26). Additionally, in blood cells we observed 
an enrichment for platelet count, platelet volume and red blood cell traits. We also 
observed enrichment for variants linked with cholesterols, metabolite, and 
fibrinogen levels in liver cREs. Finally, thyroid hormone level variants were 
enriched in thyroid tissue cREs, schizophrenia variants were enriched in brain 
cREs, and breast cancer variants were enriched in cREs active in MCF-7, a breast 
cancer cell line. 
 
SCREEN: A Web Based Visualization Tool for the Registry of cRES 
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To search and visualize the Registry of cREs, we built a web-based tool 
called SCREEN (Search Candidate Regulatory Elements by ENCODE). SCREEN 
hosts the 1.3 million human and 430 thousand mouse cREs and connects them 
with underlying ENCODE data and annotations. The first version of SCREEN is 
divided into three “apps”, each of which provide a different perspective on the 
cREs. The core app is a cRE-centric search, where users can retrieve a subset of 
cREs using genomic coordinates, a gene name, or SNP accession (Figure 2.27a). 
SCREEN returns a list cREs, annotated with their location, nearest genes, and 
max Z-scores for H3K4me3, H3K27ac, and CTCF signals (Figure 2.27b). Users 
can filter this list by selecting a cell type interest; SCREEN will then filter out cREs 
that are not active in that cell type. Users can also filter results using Z-score cutoffs 
by choosing stricter or more permissive thresholds compared to the default (Z-
scores > 1.64). If a user selects a cRE, SCREEN brings him to a cREs details 
page. Here the user can browse the cRE's H3K4me3, H3K27ac, CTCF, and 
DNase Z-scores in every cell type (Figure 2.30c), search for overlapping genomic 
datasets and genetic features such as topologically associated domains and 
SNPs.  
The gene-centric app, which opens when a user searches for a gene 
name, plots RNA-seq and RAMPAGE TSS expression data. Within this app, we 
developed a differential gene expression tool to analyze the relationship between 
changes in cRE activity and gene expression across mouse embryonic 
development. Users can selected two tissue-time point combinations and a 
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region of interest. SCREEN will display differentially expressed genes in this 
region and ELS and PLS cREs in this region. For example, we observed that 
Ogn, a protein involved in bone formation, dramatically increases in expression 
between e11.5 and e15.5 in limb tissue. This increase in gene expression 
corresponds to bone development which occurs around e12.041. SCREEN's 
differential gene expression tool displays the expression fold change of Ogn and 
nearby differentially expressed genes as bars (Figure 2.31a). PLS and ELS cREs 
are shown as red and yellow dots with the y-axis indicated difference in 
H3K4me3 and H3K27ac Z-scores between the time points. This large-scale view 
helps users identify cREs that might account for the increase in Ogn expression 
by looking for corresponding changes in cRE activity and gene expression. Using 
this approach, we identified an ELS cRE (EM10E0113220) that increases in 
activity between e11.5 and e15.5. When we analyzed EM10E0113220's 
H3K27ac activity across limb development (Figure 2.31b,c), we found that it is 
highly correlated with PLS cRE H3K4me3 activity and Ogn expression. Therefore 
we hypothesize that increase in EM10E0113220 activity leads to increased Ogn 
expression during limb development. 
Finally, the SNP-centric GWAS app intersects cREs with SNPs we 
curated from the aforementioned GWAS studies. Users can selected a study of 
interest and SCREEN will return a list of cell types and cREs that are enriched for 
GWAS SNPs. All three apps show links to the UCSC genome browser, thus 
facilitating visualization of the epigenetic signals at a cRE’s or a gene’s locus, 
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such as the Ogn example describe above. We have also set up a trackhub for 
visualizing all available signal tracks at the UCSC browser, organized by cell 
type. 
 
DISCUSSION 
By integrating DNase-seq and ChIP-seq datasets, we generated a 
collection of putative regulatory regions in human and mouse, which we referred 
to as the Registry of cREs. Adapting our unsupervised approach for enhancer 
prediction, which we used to successfully predict enhancers active in embryonic 
mouse tissues, we developed a cRE identification and classification scheme. We 
classified cREs into groups (PLS, ELS, CTCF-only, DNase-only, inactive) across 
600 human and 100 mouse cell types, generating the most comprehensive 
collection of cell-type specific regulatory elements. We demonstrated that the 
registry covers the majority of H3K4me3 and H3K27ac peaks in cell types without 
DNase data and that its classifications were concordant with ChromHMM genome 
segmentations.  
We also determined that our registry is biologically consistent with our 
current biological understanding of cell type relationships. With our clustering 
analysis, we determined that these cREs have biologically relevant activity 
patterns. While human tissues and primary cells generally clustered by their organ 
and embryonic tissues of origin, the clustering was not nearly as clean as it was in 
mouse. This could be due to a number of reasons. The human samples were 
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collected from a number of individuals who had different genetic backgrounds and 
had experienced different environmental effects. These samples also may have 
been collected using different collection methods depending the on if the samples 
were biopsies or postmortem tissues. Finally, in some cases the ChIP-seq 
experiments were run by different production labs during different phases of the 
ENCODE and Roadmap projects. The means that this experiments were run with 
different quality control standards, on different sequencing machines, and 
analyzing using different analysis pipeline. For, mouse, the embryonic tissues were 
collected from mice with identical genetic backgrounds using identical tissue 
collection procedures. The assays were all conducted during the third phase of the 
ENCODE project by the same production labs. While experimental biases may still 
exist, the nature of these datasets controls for many common sources of bias. This 
also presents one of the advantageous of using mouse data such as the 
application of mouse cREs to (see Chapter IV). 
While we have identified over 1 million cREs in human and 400 thousand in 
mouse, we are aware that our registry is far from complete. Currently, in order for 
an rDHS to be classified as a cRE, it must have high DNase signal and high 
H3K4me3, H3K27ac or CTCF signal. Therefore, we are filtering our elements such 
as poised/weak enhancers, which have high H3K4me1 and H3K27me3 signals 
and low H3K27ac signal39. Additionally, our current classification scheme only 
identifies three types of elements.  Realistically, the human genome is composed 
of many types of cREs with a spectrum of activity patterns. For example, recent 
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studies have reported promoters having enhancer-like activity and regulating the 
activity of distal genes56,126. By analyzing additional histone modifications, we may 
be able to identify PLS cREs with these long-range activities. Additionally, CTCF 
has many roles in the genome: It is associated with the cohesion complex, 
insulators, and repressors30. Therefore, we maybe be able to further separate 
CTCF-only cREs into different sub-classifications. During phase IV of the 
ENCODE project, we hope to not only increase the number of cell types for these 
assays, but continue to analyze different combinations of signal patterns, binding 
of transcription factors and transcription data play a role, particularly in cell types 
such as K562 and GM12878 that have a large number of datasets. We also hope 
to integrate in publicly available datasets, from databases such as CISTROME127 
to cover a wider range of cell types and further annotate cREs. 
Finally, while the registry of cREs had high coverage across the epigenomic 
landscape, its overlap with regulatory elements defined by other methods such as 
GRO-seq, CAGE and STARR-seq was far less. One possibility for the poor overlap 
is that our method is filtering out low signal enhancer that test positive in these 
assays or have strong transcriptional activity. For transcription based methods, 
such as CAGE and GRO-seq, this poor overlap could also be due to random 
transcription events in the genome. These regions, despite not having hallmark 
histone modifications, may have sequences with transcription initiation potential. 
These regions may have no biological function, so transcription is a result of the 
noise of genomic regulation, or they could be a different class of regulatory 
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elements. In the future, it will be worth investigating the transcriptionally active loci 
to see what features are predictive of these regions. 
For methods that test specific genomic regions for enhancer activity, such 
as STARR-seq, MPRA, and transgenic mouse assays, this poor overlap could be 
due to differences in genomic context. For example, the Stark lab reported in their 
original STARR-seq paper that 31% of STARR-seq peaks did not overlap DHSs in 
the same cell type128. They hypothesized that this is due genomic context of the 
region. For example, a sequence may innately have enhancer-like activity causing 
it to test positive in STARR-seq, luciferase, or transgenic mouse assays. However, 
in the genome, the region may be silenced and inaccessible to transcription factors 
and therefore will not overlap a DHS. Moving forward, we can isolate these cases 
to learn more about how sequence features contribute to enhancer activity. We 
can apply the same analysis to analyze human regulatory elements and use these 
features to further refine our enhancer prediction models. 
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Figure 2.1 | Protocol used to validate enhancers included in the VISTA database. 
Regions were selected based on conservation, EP300 ChIP-seq, or H3K27ac ChIP-seq 
signals. These regions were then cloned and then injected into mouse embryos. Embryos 
were harvested and enhancer activity was measured using lacZ staining (blue regions). 
This figure was adapted from the home page figure on https://enhancer.lbl.gov/. 
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Figure 2.2 | ENCODE3 mouse embryonic time series data. During phase III of the 
ENCODE project the Ren lab generated histone modification ChIP-seq data for twelve 
tissues across eight embryonic time points (orange and green boxes, 72 unique tissue-
time point combinations). The Stamatoyannopoulos lab generated DNase-seq data for 
18 of these tissue-time points (green boxes). 
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Figure 2.3 | Unsupervised enhancer prediction methods. a, Testing which peaks to 
anchor predictions. To control for genome coverage, all peaks are set to a uniform 
300bp in width. For DHSs, we use signal across the 300bp region. For histone peaks we 
use +/- 1kb from the summit of each peak. b, After we determined anchoring on DHSs 
result in the best performance, we tested ranking schemes using signal. For DHSs, we 
use signal across the 300bp region. For histone peaks we use +/- 1kb from the summit 
of each DHS. 
  
52 
 
Figure 2.4 | Precision-Recall (PR) curves for VISTA Enhancer prediction. PR curves 
for a, limb, b, midbrain, c, hindbrain, c, midbrain, and d, neural tube enhancers at e11.5. 
Colors indicate peaks and signals used for anchoring and ranking the enhancer 
predictions. All peaks were set to 300 bp centered on their summits and the 20k top-
ranked peaks were used for each tissue to ensure consistent genome coverage. 
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Figure 2.5 | PR curves for VISTA Enhancer prediction anchored on DHSs. PR 
curves for a, limb, b, hindbrain, c, midbrain, and d, neural tube enhancers at e11.5. All 
predictions were anchored on DHSs in the respective tissue. Colors indicate signals 
used for ranking predictions; black indicates the average of DNase and H3K27ac 
signals. 
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Figure 2.6 | Validation rates of predicted enhancer-like regions using transgenic 
mouse assays. Bars indicated the percent of tested regions that were positive in the 
transgenic mouse enhancer assay. Dark colors indicate the region is active in the 
predicted tissue (blue for midbrain, green for hindbrain, and orange for limb). The lighter 
color indicates a lack of activity in the predicted tissue with activity in other tissues. 
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Figure 2.7 | Examples of predicted enhancer-like regions which tested positive in 
the transgenic mouse assays. Enhancer-like regions predicted using DNase signal 
(green) and H3K27ac signal (orange) in a, midbrain, b, hindbrain and c, limb. H3K27ac 
signal on accurately predicts additional observe activity in midbrain (MB), hindbrain (HB), 
neural tube (NT), limb (LM), heart (HT), and/or liver (LV)  
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Figure 2.8 | Overlap of cell types with epigenomic datasets. Venn diagrams indicate 
the number of cell types that have either DNase-seq, H3K4me3 ChIP-seq, and/or 
H3K27ac ChIP-seq data in a, human and b, mouse. 
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Figure 2.9 | Correlation of gene expression with epigenomic signals to predict 
promoter-like regions in mouse hindbrain e11.5. Scatterplots demonstrating 
correlation of expression with a) DHSs ranked by DNase signal (r = 0.34), b) DHSs 
ranked by H3K4me3 signal (r = 0.73), c) H3K4me3 peaks ranked by DNase signal (r = 
0.24), and d) H3K4me3 peaks ranked by H3K4me3 signal (r = 0.56). 
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Figure 2.10 | Method for creating representative DNase hypersensitivity sites 
(rDHSs). a, DHSs across cell types tend to have similar boundaries. b, Method for 
generating rDHSs. We cluster DHSs if they overlap and then for each cluster select the 
DHS with the highest signal Z-score. This DHS serves as the representative DHS 
(rDHS) for the cluster. We iteratively repeat this process until all DHS overlap at least 
one rDHS. 
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Figure 2.11 | Method for normalizing genomic signals. a, Distribution of the H3K27ac 
signals at rDHSs from five cell types (B cell, Liver, K562, T cell, and GM12878; shown in 
different colors). b, Distributions of the log of the H3K27ac signals in a. Individually, 
log(signal) values of the rDHSs in each cell type roughly follow a normal distribution. c, 
Distribution of the Z-scores corresponding to the log(signal) values in b. Signal values of 
zero are assigned a Z-score of –10.  
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Figure 2.12 | Classification scheme for human cRES (hg19). We begin by clustering 
high-quality DHSs (FDR > 0.1%) to create representative DHSs (rDHSs). For each 
assay (DNase, H3K4me3, H3K27ac or CTCF), we calculate a Z-score for every rDHS in 
a particular cell or tissue type. We then obtain the maximum Z-score across all cell types 
which we denote the Max-Z. We use the decision tree to classify cREs into three cell-
type-agnostic groups according to their Max-Z and proximity to the nearest TSS, 
including cREs with promoter-like signatures (cREs-PLS, n = 254,880), cREs with 
enhancer-like signatures (cREs-ELS, n = 991,173), and cREs bound by CTCF only (n = 
64,099). The three groups comprise 1,310,152 cREs 
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Figure 2.13 | Classification scheme for mouse cRES (mm10). We begin by clustering 
high quality DHSs (FDR > 0.1%) to create representative DHSs (rDHSs). For each 
assay (DNase, H3K4me3, H3K27ac or CTCF), we calculate a Z-score for every rDHS in 
a particular cell or tissue type. We then obtain the maximum Z-score across all cell 
types, known as the Max-Z. Using the Max-Z as well as the distance to the nearest TSS, 
we classify cREs into three cell-type agnostic groups using the decision tree: cREs with 
promoter-like signatures (n = 87,119), cREs with enhancer-like signatures (n = 310,472), 
and cREs bound by CTCF only (n = 33,611). The total number of cREs is the sum of the 
three groups: 431,202. 
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Figure 2.14 | Coverage of the registry of cREs. Percent of the DNase-mappable (36 
nt, single-end reads) genome covered by each group of cREs in a, human and b, 
mouse. 
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Figure 2.15 | Nine states of cell-type specific cREs in GM12878 a, Number of 
GM12878 cREs in each group b, Violin plots show the average POLII signal for cREs 
belonging to each of the nine cRE states. cREs proximal and distal to the nearest TSSs 
are displayed separately. Median values are displayed along with the number of cREs in 
each state. c, Violin plots show the average EP300 signal for cREs belonging to each of 
the nine cRE states. cREs proximal and distal to the nearest TSSs are displayed 
separately. Median values are displayed along with the number of cREs in each state. 
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Figure 2.16 | Overview of 5 group classification method. Scatterplots of a, median 
EP300 signal or b, median RAD21 signal vs. median POLII signal for each cRE state in 
GM12878. The size of an icon is proportional to the number of cREs in that state except 
for the inactive state. Proximal cREs are represented by square icons. Distal cREs are 
represented by circular icons. c, Assignment of cRE states to the five following groups: 
with promoter-like signatures, with enhancer-like signatures, CTCF-only, DNase-only, 
and inactive. d, Number of GM12878 cREs in each group. e, Median ChIP-seq signal for 
POLII, EP300 and RAD21 in GM12878 for the cREs in each group. 
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Figure 2.17 | Saturation of cREs across 21 cell types with all four datatypes. Total 
numbers of cREs with Promoter-like, Enhancer-like, or CTCF-only signatures grow when 
more cell types are considered. Enhancer-like cREs are more cell-type-restrictive than 
promotor-like cREs or CTCF-only cREs.  
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Figure 2.18 | Cell-type specific annotations of the Registry of cREs. Scheme for 
translating cell type specific state classifications into group classifications for cell types 
with different combinations of datasets.  
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Figure 2.19 | Groups of orthologous cREs. Percentage of cREs with promoter-like 
(red), enhancer-like (yellow), or CTCF-only (blue) signatures for human and mouse 
cREs as well as orthologous human and mouse cREs. 
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Figure 2.20 | Coverage of histone modification peaks by the current human 
Registry of cREs. Overlap of cREs with a, H3K4me3 peaks and b, H3K27ac peaks and 
c, CTCF peaks from cell types without DNase data. On average 89.7% and 86.8%, 
H3K4me3 and H3K27ac peaks overlap a cRE, respectively. 
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Figure 2.21 | Coverage of histone modification peaks by the current mouse 
Registry of cREs. Overlap of cREs with a, H3K4me3 peaks and b, H3K27ac peaks 
from cell types without DNase data. On average 95.8% and 87.6% of H3K4me3 and 
H3K27ac peaks overlap a cRE, respectively. 
  
  
71 
 
 
Figure 2.22 | Coverage of the H3K4me3 peaks by the current Registry of cREs is 
plotted against the average -log(FDR) of the H3K4me3 peaks. In a, human and b, 
mouse, cell-types with peaks that have a lower average -log(FDR) across all peaks tend 
to have a lower percentage of peaks covered. Manual inspection reveals that this lower 
coverage is due to lower-signal, false-positive peaks called by the algorithm for these 
datasets. 
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Figure 2.23 | Clustering of mouse cell types on the basis of cRE histone 
modification activity. Mouse embryonic tissues were hierarchically clustered according 
to the Jaccard similarity coefficient of cREs with high a, H3K27ac and b, H3K4me3 Z-
scores. Colors indicate the organs of origin of the tissues. When clustered according to 
H3K27ac signals at cREs (panel a), the tissues segregate completely according to their 
organs of origin.  
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Figure 2.24 | Clustering of human cell and tissue types on the basis of cRE 
H3K27ac signal. Human a, primary cells and b, tissues were hierarchically clustered 
according to the Jaccard similarity coefficient of cREs with a high H3K27ac signal (Z-
score > 1.64). The tissue samples in a are colored by their organ of origin and the 
primary cells in b are colored according to their lineages. 
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Figure 2.25 | Clustering of human cell and tissue types on the basis of cRE DNase 
signal. Human a, tissues and b, primary cells hierarchically clustered according to the 
Jaccard similarity coefficient of cREs with a high DNase signal (Z-score > 1.64). The 
tissue samples in a are colored by their organ of origin and the primary cells in b are 
colored according to their lineages.   
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Figure 2.26 | Overlap of cREs with chromHMM states. In GM12878, we ranked cREs 
with a, promoter-like signatures and b, enhancer-signatures on the basis of H3K4me3 
and H3K27ac Z-scores respectively. For each bin of 1 k cREs, we calculated the 
percentage of cREs overlapping each chromHMM state. In mouse, we selected all cREs 
with c, promoter-like and d, enhancer-like signatures from tissue–time-point 
combinations with both DNase and histone data. We then calculated the percent of 
cREs that overlapped each chromHMM state. In all panels, high- and low-signal 
enhancers denote chromHMM enhancer states with high or low H3K27ac signals. 
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Figure 2.27 | Overlap of ELS cREs with previously predicted enhancers. The 
percentage of ELS cREs that overlap enhancers predicted by a, the FANTOM5 
consortium, b, GRO-seq data, c, and STARR-seq. ELS cREs are ranked based on cell 
type specific H3K27ac Z-scores. 
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Figure 2.28 | Overlap of previously predicted enhancers with cREs. The percentage 
of enhancers predicted by a, the FANTOM5 consortium, b, GRO-seq data, c, and 
STARR-seq that overlap with cREs. Colors indicate groups of cREs active in each cell 
type: red for PLS, yellow of ELS, blue for CTCF-only, green for DNase-only and gray for 
inactive. Predicted enhancers that do not overlap any cREs are shown in white. 
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Figure 2.29 | Top cell type enrichments for variants reported by genome wide 
association studies (GWAS). For each GWAS we report the cell or tissue type of which 
active cREs are significantly enriched in the disease variants. Cell types that do not meet 
the FDR threshold of 0.05 are in grey. Most studies have multiple significantly enriched 
cell types but only the top hit is reported here. Traits listed multiple times are from 
different studies. 
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Figure 2.30 | Overview of SCREEN. a, Landing page of SCREEN where user can enter 
a gene, SNP, or locus of interest to investigate cREs. Alternatively, users can select the 
GWAS app to analyze cREs overlapping disease associated genetic variants. b, 
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Example results page from searching in the main query box. SCREEN lists cREs with 
accession, location, nearby genes, and overview of activity. c, cRE details page 
displaying additional information about each cRE such as its activity across cell types 
and overlapping TF peaks 
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Figure 2.31 | Analyzing differential gene expression and cRE activity across 
developmental time-points. a, Comparison between limb e11.5 and e15.5 gene 
expression and cRE activity. Blue bars indicate differentially expressed genes, and red 
and yellow dots indicate cREs with promoter-like and enhancer-like signatures. The 
heights of bars or dots indicate changes (Log2 FC or difference in Z-score) between 
time-points. b, Genome browser view of the Ogn locus with H3K27ac, H3K4me4, 
DNase, and RNA-seq signals for the limb across all surveyed time-points. Promoter-like 
cREs are designated by red bars and enhancer-like cREs are designated by orange 
bars. c, Ogn gene expression and nearby cRE activity increase coordinately across 
time-points. The increase in gene expression lags behind the increases in cRE-PLS and 
cRE-ELS activities.  
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Table 2.1 | ENCODE mouse experiments used for enhancer prediction  
 Midbrain Hindbrain Neural Tube Limb 
DNase ENCSR292QBA ENCSR358ESL ENCSR312QVY ENCSR661HDP 
H3K27ac ENCSR088UKA ENCSR129LAP ENCSR531RZS ENCSR897WBY 
H3K4me3 ENCSR283RFW ENCSR928CYU ENCSR427OZM ENCSR654VMK 
H3K4me1 ENCSR450ITF ENCSR695FPP ENCSR448TTC ENCSR548BCO 
H3K9ac ENCSR502WUI ENCSR734IEL ENCSR547PLI ENCSR286IGS 
H3K36me3 ENCSR535NVF ENCSR175QZX ENCSR445UYH ENCSR871YCT 
H3K27me3 ENCSR545BRW ENCSR375GSG ENCSR240OUM ENCSR085EYQ 
WGBS ENCSR091VFX ENCSR398UCM ENCSR613BMI ENCSR916GKL 
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Table 2.2 | Area under PR curves for VISTA Enhancer prediction 
Peak Space Signal Limb Midbrain Hindbrain Neural Tube Average 
DNase DNase 0.4108 0.3725 0.3862 0.2958 0.3562 
H3K27ac H3K27ac 0.3375 0.4320 0.3311 0.2712 0.3310 
H3K4me3 H3K4me3 0.1228 0.2397 0.1994 0.1334 0.1749 
H3K4me1 H3K4me1 0.2589 0.3227 0.2124 0.1601 0.2280 
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Table 2.3 | AUPR for VISTA Enhancer prediction anchored on DHSs 
Peak Space Signal Hindbrain Limb Midbrain Neural Tube Average 
DNase Peak DNase Signal 0.3788 0.4159 0.3797 0.2951 0.3673 
DNase Peak H3K27ac Signal 0.3113 0.3265 0.3959 0.2526 0.3216 
DNase Peak Average Rank DNase-H3K27ac Signal 0.3764 0.3948 0.4148 0.3050 0.3727 
DNase Peak H3K4me3 Signal 0.2276 0.1828 0.2602 0.1615 0.2080 
DNase Peak Average Rank DNase-H3K4me3 Signal 0.2584 0.2392 0.2933 0.1751 0.2415 
DNase Peak H3K4me1 Signal 0.2442 0.2799 0.3122 0.1762 0.2531 
DNase Peak Average Rank DNase-H3K4me1 Signal 0.2527 0.2647 0.2901 0.1740 0.2454 
DNase Peak H3K9ac 0.2367 0.1977 0.2756 0.1721 0.2205 
DNase Peaks Average Rank DNase-H3K9ac Signal 0.2831 0.2574 0.3250 0.2147 0.2700 
DNase Peak H3K36me3 Signal 0.1910 0.1776 0.1911 0.1265 0.1715 
DNase Peak Average Rank DNase-H3K36me3 Signal 0.2280 0.2262 0.2212 0.1548 0.2075 
DNase Peak WGBS methylation 0.2470 0.2151 0.2663 0.1550 0.2208 
DNase Peak Average Rank DNase-WGBS Signal 0.3127 0.3031 0.3278 0.1981 0.2854 
DNase Peak H3K27me3 Signal 0.2187 0.1964 0.1853 0.1285 0.1822 
DNase Peak Average Rank DNase-H3K27me3 Signal 0.2700 0.2750 0.2325 0.1664 0.2360 
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Table 2.4 | Tested enhancer-like regions for midbrain e11.5 
 VISTA ID mm10 Coordinates 
Result Summary: 
predicted tissue (Hb, 
Mb, Lb pos or neg) 
Additional Tissue Activity 
Observed 
Top 
Tier 
mm1502 chr14:76253890-76257212 Mb positive (3/3)  
mm1471 chr16:35584523-35589773 Mb positive (3/3) 
Fb (3/3), Hb (3/3), neural tube 
(3/3) 
mm1461 chr2:154425426-154428462 Mb positive (3/3) 
Fb (3/3), Hb (3/3), neural tube 
(3/3), nose (3/3), facial 
mesenchyme (3/3) 
mm1454 chr2:25124845-25128090 Mb positive (3/4) 
Fb (3/4), Hb (3/4), neural 
tube (4/4), eye (3/4) 
mm1480 chr6:112808528-112813000 Mb positive (4/5) Fb (5/5) 
mm1504 chr16:44528746-44534514 Mb positive (4/5) 
Hb (4/5), Fb (4/5), neural tube 
(4/5) 
mm1503 chr14:40955282-40959325 Mb positive (4/8) 
Hb (5/8), cranial nerve (5/8), 
trigeminal V (8/8), DRG (8/8), 
Lb (6/8) 
mm1469 chr12:80059965-80065110 Mb positive (5/5) 
Fb (4/5), Hb (5/5), neural tube 
(5/5), Ht (5/5), branchial arch 
(3/5) 
mm1460 chr1:133185980-133189493 Mb positive (5/5) 
Fb (5/5), Hb (5/5), neural tube 
(4/5), eye (5/5) 
mm1458 chr8:93916782-93919741 Mb positive (5/7) 
Fb (5/7), Hb (5/7), neural tube 
(5/7) 
mm1456 chr12:109946504-109950294 Mb positive (6/6) 
Fb (6/6), Hb (6/6), neural tube 
(5/6) 
mm1462 chr11:113783367-113787793 Mb positive (8/12) 
Fb (7/12), Hb (9/12), neural 
tube (9/12), trigeminal V 
(7/12), DRG (7/12), Lb (7/12) 
mm1479 chr17:29354850-29357878 neg  
mm1472 chr11:20654380-20657594 neg  
mm1459 chr3:65973873-65976364 neg  
mm1482 chr17:37028041-37029979 neg  
mm1470 chr6:90780495-90784241 other positive 
Hb (6/8), neural tube (5/8), 
trigeminal V (6/8), DRG (7/8) 
mm1481 chr11:120314873-120317426 other positive DRG (3/4), other (3/4) 
mm1457 chr18:38378941-38381638 other positive 
Fb (6/6), Lb (6/6), cranial 
nerve (4/6), DRG (4/6) 
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mm1463 chr5:21731579-21734432 other positive Fb (4/4) 
Middle 
Tier 
mm1553 chr9:86186309-86188376 Mb positive (3/5) 
Hb (3/5) , Fb (3/5), neural 
tube (3/5) 
mm1557 chr6:65309702-65311689 Mb positive (3/6) Fb (4/6), neural tube (4/6) 
mm1552 chr19:41715402-41718238 Mb positive (5/6) Fb (6/6), Hb (6/6), DRG (4/6) 
mm1555 chr11:26772020-26774013 Mb positive (5/6) Hb (3/6) 
mm1558 chr7:117685707-117687616 Mb positive (6/12) 
Hb (8/12), Lb (9/12), Fb 
(9/12), neural tube (6/12) 
mm1546 chr1:9648223-9650965 Mb positive (6/8) 
Hb (7/8), trigeminal V (6/8), 
neural tube (5/8), DRG (4/8), 
cranial nerve (5/8) 
mm1544 chr16:94723154-94725386 neg  
mm1545 chr18:54759740-54761758 neg  
mm1547 chr9:50451431-50453445 neg  
mm1550 chr5:140767048-140769052 neg  
mm1551 chr6:144165683-144167703 neg  
mm1554 chr9:121359503-121361504 neg  
mm1549 chr3:127705248-127707248 other positive Fb (7/7), neural tube (6/7) 
mm1556 chr13:76809879-76811879 other positive Fb (3/3), Hb (3/3) 
mm1548 chr6:145855046-145857046 other positive Fb (4/4) 
Bottom 
Tier 
mm1524 chr6:52365164-52368224 Mb positive (4/4)  
mm1583 chr11:85857229-85860254 Mb positive (4/7)  
mm1526 chr11:113307639-113310548 Mb positive (4/7) Hb (4/7), neural tube (4/7) 
mm1522 chr5:114298723-114301210 Mb positive (6/7)  
mm1520 chr8:124313443-124316007 neg  
mm1580 chr13:113913477-113916032 neg  
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mm1521 chr12:111161954-111163777 neg  
mm1582 chr9:107644011-107645376 neg  
mm1523 chr14:100374296-100376562 neg  
mm1585 chr6:83434774-83436371 neg  
mm1587 chr15:84259559-84261268 neg  
mm1581 chr18:55784854-55787217 other positive Hb (4/4) 
mm1584 chr15:74155467-74158454 other positive 
Lb (4/4), other (4/4), eye 
(4/4), neural tube (4/4), 
branchial arch (4/4) 
mm1525 chr17:28105717-28108643 other positive Fb (3/4), Hb (3/4) 
mm1586 chr7:48749001-48750980 other positive trigeminal V (9/12), Hb (6/12) 
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Table 2.5 | Tested enhancer-like regions for hindbrain e11.5 
 VISTA ID mm10 Coordinates 
Result Summary: 
predicted tissue (Hb, 
Mb, Lb pos or neg) 
Additional Tissue Activity 
Observed 
Top 
Tier 
mm1444 chr12:86822930-86827112 Hb positive (7/8) Mb (3/8) 
mm1496 chr11:94158655-94162177 Hb positive (3/4) Fb (3/4) 
mm1494 chr4:136754322-136758801 other positive Mb (3/3), nose (3/3) 
mm1445 chr1:134060554-134066172 Hb positive (4/4) 
Fb (4/4), Mb (4/4), DRG (4/4), 
cranial nerve (4/4), neural tube (4/4), 
other (4/4), trigeminal V (4/4) 
mm1446 chr14:25107155-25110736 Hb positive (3/3) 
Fb (3/3), Mb (3/3), neural tube (3/3), 
eye (3/3) 
mm1488 chr17:10333563-10337174 Hb positive (4/4) Mb (4/4) neural tube (4/4) 
mm1447 chr2:21008806-21012242 Hb positive (6/6) Mb (5/6) 
mm1448 chr7:111121648-111123424 neg  
mm1449 chr15:98967479-98972541 Hb positive (5/7) Fb (6/7), Mb (6/7), neural tube (4/7) 
mm1450 chr19:45057481-45059842 neg  
mm1497 chr7:145204877-145207696 Hb positive (5/6) 
Mb (6/6), Fb (6/6), neural tube (5/6), 
Ht (4/6), Lb (4/6) 
mm1498 chr14:19984462-19988065 Hb positive (3/4) Mb (4/4) 
mm1499 chr17:66478396-66482145 Hb positive (6/6) Fb (4/6), Mb (6/6), neural tube (6/6) 
mm1451 chr5:112236129-112240520 Hb positive (10/10) 
Fb (9/10), Mb (10/10), neural tube 
(10/10), cranial nerve (5/10) 
mm1489 chr7:140056813-140059080 Hb positive (5/5) Mb (5/5), neural tube (5/5) 
mm1452 chr3:51787852-51791869 Hb positive (4/6) Mb (3/6), neural tube (5/6) 
mm1453 chr5:125140066-125142757 neg  
mm1500 chr14:66492741-66497119 Hb positive (3/4) Fb (3/4), Mb (3/4), neural tube (3/4) 
mm1501 chr13:84344551-84350110 neg  
mm1478 chr15:91016522-91020048 Hb positive (3/4) Fb (3/4), Mb (3/4), neural tube (3/4) 
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Middle 
Tier 
mm1540 chr8:108243823-108246831 Hb positive (3/5)  
mm1534 chr7:93060869-93063626 Hb positive (4/5) Fb (5/5), neural tube (5/5), Lb (4/5) 
mm1532 chr4:148859471-148860956 Hb positive (5/5) cranial nerve (3/5) 
mm1542 chr14:63585329-63587537 Hb positive (8/9) 
neural tube (9/9), Mb (8/9), Fb (7/9), 
cranial nerve (6/9) 
mm1535 chr18:54610385-54613247 neg  
mm1536 chr12:86798248-86799852 neg  
mm1560 chr4:154593394-154596395 neg  
mm1539 chr7:70329472-70332465 neg  
mm1543 chr15:77335353-77337280 neg  
mm1537 chr3:104540534-104542671 other positive neural tube (5/6) 
mm1538 chr17:62851927-62854939 other positive Mb (5/6) 
mm1603 chr2:93277888-93280895 other positive Lb (3/4) 
mm1561 chr2:163188663-163191536 other positive Fb (3/6), eye (3/6), Lb (4/6) 
mm1541 chr3:5386841-5389926 other positive Fb (6/7), neural tube (6/7) 
mm1562 chr19:21164417-21167450 other positive tail (5/6) 
mm1533 chr5:125214963-125216753 other positive Fb (3/4) 
Bottom 
Tier 
mm1515 chr2:166215189-166217391 Hb positive (4/5) neural tube (6/5) 
mm1604 chr12:105972686-105975121 Hb positive (7/9) other/abdomen (6/9) 
mm1577 chr3:5348379-5351461 Hb positive (8/10) branchial arch (4/10) 
mm1510 chr16:33593467-33596065 neg  
mm1511 chr2:70559085-70560255 neg  
mm1512 chr12:16854925-16857237 neg  
mm1578 chr16:72690693-72694735 neg  
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mm1513 chr6:95173859-95175593 neg  
mm1579 chr18:15173064-15176000 neg  
mm1517 chr1:182981864-182984314 neg  
mm1519 chr7:46452307-46455505 neg  
mm1509 chr9:63058010-63060489 other positive Mb (4/4), Fb (4/4) 
mm1516 chr6:89241345-89243919 other positive Mb (5/11), facial mesenchyme (8/11) 
mm1514 chr7:82713868-82717092 other positive Lb (6/6) 
mm1518 chr9:63958315-63961551 other positive Lb (6/8) 
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Table 2.6 | Tested enhancer-like regions for limb e11.5 
 VISTA ID mm10 Coordinates 
Result Summary: 
predicted tissue 
(Hb, Mb, Lb pos or 
neg) 
Additional Tissue Activity 
Observed 
Top 
Tier 
mm1473 chr9:72639094-72641466 Lb positive (11/11) eye (5/11) 
mm1505 chr3:101394801-101399299 Lb positive (12/12) 
somite (10/12), branchial arch 
(10/12), facial mesenchyme (9/12) 
mm1464 chr8:126825533-126828569 Lb positive (3/3)  
mm1476 chr2:128712175-128715819 Lb positive (3/4) 
facial mesenchyme (3/4), 
branchial arch (3/4), DRG (3/4) 
mm1486 chr9:41227902-41230545 Lb positive (3/5)  
mm1474 chr6:72710179-72712952 Lb positive (4/4) branchial arch (3/4) 
mm1485 chr14:24261692-24264509 Lb positive (4/4)  
mm1493 chr9:41949140-41954525 Lb positive (4/7) eye (5/7) 
mm1475 chr9:106354104-106358319 Lb positive (4/7) facial mesenchyme (6/7) 
mm1492 chr4:154707415-154711162 Lb positive (5/5) facial mesenchyme (5/5) 
mm1506 chr4:139597441-139601336 Lb positive (5/8) blood vessels (5/8) 
mm1484 chr7:123096694-123099867 Lb positive (6/6) 
Ht (6/6), eye (6/6), facial 
mesenchyme (5/6) 
mm1490 chr4:108361018-108364528 Lb positive (7/7) 
Mb (7/7), neural tube (7/7), facial 
mesenchyme (7/7), Hb (7/7), nose 
(7/7), branchial arch (6/7), somite 
(5/7), genital tubercle (7/7) 
mm1483 chr8:90860971-90863490 Lb positive (8/8) 
Fb (6/8), Hb (6/8), Mb (6/8), 
cranial nerve (6/8), trigeminal V 
(7/8), DRG (7/8) 
mm1507 chr8:11584424-11587803 neg  
mm1491 chr9:41934743-41936889 neg  
mm1477 chr13:51312386-51316734 neg  
mm1508 chr10:91179718-91183751 neg  
mm1495 chr14:65342605-65345502 neg  
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mm1487 chr10:59919229-59922102 neg  
Middle 
Tier 
mm1574 chr7:136389300-136391216 Lb positive (3/4)  
mm1567 chr8:87659116-87661534 Lb positive (4/5) tail (4/5) 
mm1564 chr2:60785660-60787563 Lb positive (5/5) branchial arch (4/5) 
mm1576 chr5:16778223-16779671 Lb positive (5/5)  
mm1571 chr15:95638744-95641449 Lb positive (5/6) Hb (6/6), neural tube (6/6) 
mm1570 chr14:49121140-49122633 Lb positive (7/8)  
mm1563 chr9:32823262-32824682 neg  
mm1559 chr6:5801484-5804011 neg  
mm1568 chr11:104288616-104290675 neg  
mm1572 chr3:81782584-81784020 neg  
mm1573 chr10:38972079-38974105 neg  
mm1565 chr13:51919913-51922132 other positive 
Fb (3/3), Mb (3/3), Hb (3/3), neural 
tube (3/3) 
mm1566 chr4:148984734-148987251 other positive nose (4/4) 
mm1575 chr1:59333923-59335433 other positive tail (4/6), somites (4/6) 
mm1569 chr5:65414975-65416572 other positive 
Unidentifiable structures in chest 
and abdomen (9/10) 
Bottom 
Tier 
mm1597 chr6:89613039-89615855 Lb positive (10/11) 
branchial arch (8/11), somites 
(7/11), Mb (6/11), facial 
mesenchyme (5/11) 
mm1598 chr8:26832486-26834858 Lb positive (3/4) 
Mb (3/4), Fb (3/4), Hb (3/4), 
somites (3/4), nose (3/4), other 
(3/4) 
mm1599 chr3:37934422-37937092 Lb positive (8/9) Hb (7/9), Fb (7/9), eye (5/9) 
mm1588 chr11:60365089-60367681 neg  
mm1589 chr12:107951151-107953994 neg  
mm1590 chr7:135888196-135890453 neg  
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mm1591 chr8:108018634-108020810 neg  
mm1592 chr12:108913631-108917155 neg  
mm1593 chr11:118083180-118085181 neg  
mm1594 chr6:85022961-85025939 neg  
mm1595 chr12:73510499-73513049 neg  
mm1596 chr7:112867931-112870363 neg  
mm1602 chr7:132203278-132205205 neg  
mm1600 chr14:21673440-21675700 other positive tail (3/3) 
mm1601 chr1:61202202-61204582 other positive facial mesenchyme (3/5) 
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Table 2.7 | Correlation of ranked peaks with ranked gene expression in mouse 
tissues 
Peak Space Signal Hindbrain Limb Midbrain Neural Tube Average 
DNase DNase 0.3454 0.3643 0.3973 0.4714 0.3946 
DNase H3K4me3 0.7332 0.7472 0.7507 0.7488 0.7450 
H3K4me3 DNase 0.2364 0.2603 0.2239 0.1055 0.2065 
H3K4me3 H3K4me3 0.5551 0.6112 0.5691 0.5555 0.5727 
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Table 2.8 | Correlation of ranked peaks with ranked gene expression in human 
cells 
Peak Space Signal GM12878 K562 HepG2 Average 
DNase DNase 0.4904 0.3848 0.4024 0.4258 
DNase H3K4me3 0.7152 0.7310 0.7084 0.7182 
H3K4me3 DNase 0.4122 0.3016 0.2469 0.3202 
H3K4me3 H3K4me3 0.5833 0.6012 0.5484 0.5777 
 
  
96 
Table 2.9 | Combined ChromHMM States 
Combined 
State State 1 State 2 State 3 State 4 
TSS 1 Active Promoter 
2 Weak 
Promoter   
TSS Bivalent 3 Poised Promoter    
High Signal 
Enhancer 
4 Strong 
Enhancer 
5 Strong 
Enhancer   
Low Signal 
Enhancer 
6 Weak 
Enhancer 
7 Weak 
Enhancer   
Insulator 8 Insulator    
Transcription 9 Txn Transition 
10 Txn 
Elongation 11 Weak Txn  
Repressed 12 Repressed 13 Heterochrom/lo 
14 
Repetitive/CNV 
15 
Repetitive/CNV 
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Table 2.10 | Overlap of previous enhancer predictions with cREs 
Assay Cell Type PLS ELS CTCF DNase Inactive No Overlap 
FANTOM5 GM12878 274 646 5 64 342 1,135 
FANTOM5 hepatocyte 36 118 2 24 127 266 
FANTOM5 keratinocyte 139 380 1 2 111 546 
FANTOM5 astrocyte 256 427 0 30 182 786 
GRO-seq GM12878 27,771 15,312 612 1,601 34,030 34,703 
GRO-seq K562 26,815 20,206 1,193 4,230 32,206 33,233 
GRO-seq IMR-90 15,993 11,020 293 1,852 25,177 26,343 
GRO-seq MCF-7 21,283 10,124 320 1,493 34,150 28,876 
GRO-seq HeLa 21,738 16,463 353 1,127 17,143 26,807 
STARR-seq HeLa 687 2,800 67 1,035 10,447 7,809 
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Table 2.11 | GWAS studies included in analysis 
First Author PMID Phenotype 
Anderson 21297633 Ulcerative colitis 
Anttila 23793025 Migraine 
Arking 24952745 QT Interval 
Barrett 19430480 Type 1 Diabetes 
Baurecht 25574825 Inflammatory skin disease 
Baurecht 25574825 Psoriasis 
Bentham 26502338 Systemic lupus erythematosus 
Berndt 23563607 Height 
Berndt 23563607 Obesity 
Cai 25130324 Heschl's gyrus morphology 
Chasman 19936222 Lipid metabolism phenotypes 
deVries 26561523 Fibrinogen levels 
Dubois 20190752 Celiac disease 
Dupuis 20081858 Fasting glucose-related traits 
Fox 22589738 Subcutaneous adipose tissue 
Fox 22589738 Visceral adipose tissue adjusted for BMI 
Fox 22589738 Visceral adipose tissue/subcutaneous adipose tissue ratio 
Fox 22589738 Visceral fat 
Franke 21102463 Crohn's disease 
Gieger 22139419 Platelet count 
Gieger 22139419 Mean platelet volume 
Gudbjartsson 18391951 Height 
Hromatka 25628336 Motion sickness 
Imboden 22424883 Pulmonary function decline 
Jostins 23128233 Inflammatory bowel disease 
Kaplan 21216879 Insulin-like growth factors 
Kapoor 24962325 Alcohol dependence (age at onset) 
Kottgen 23263486 Urate levels 
Lango 20881960 Height 
Lemaitre 21829377 Phospholipid levels (plasma) 
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Lesch 18839057 Attention deficit hyperactivity disorder 
Li 26252872 Cognitive decline rate in late mild cognitive impairment 
Li 26301688 Pediatric autoimmune diseases 
Liu 26192919 Crohn's disease 
Liu 26192919 Inflammatory bowel disease 
Liu 26192919 Ulcerative colitis 
Michailidou 23535729 Breast cancer 
Mozaffarian 25646338 Trans fatty acid levels 
Patsopoulos 22190364 Multiple sclerosis 
Perry 25231870 Menarche (age at onset) 
Porcu 23408906 Thyroid hormone levels 
Rietveld 25201988 Educational attainment 
Ripke 25056061 Schizophrenia 
Sawcer 21833088 Multiple sclerosis 
Shin 24816252 Blood metabolite levels 
Shin 24816252 Blood metabolite ratios 
Speedy 24292274 Chronic lymphocytic leukemia 
Suhre 21886157 Metabolic traits 
Surakka 25961943 Cholesterol, total 
Surakka 25961943 HDL cholesterol 
Surakka 25961943 LDL cholesterol 
Surakka 25961943 Triglycerides 
Teslovich 20686565 Cholesterol, total 
Teslovich 20686565 HDL cholesterol 
Teslovich 20686565 LDL cholesterol 
Teslovich 20686565 Triglycerides 
vanderHarst 23222517 Red blood cell traits 
Wain 21909110 Blood pressure 
Wang 20889312 Bipolar disorder and schizophrenia 
Willer 24097068 Cholesterol, total 
Willer 24097068 HDL cholesterol 
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Willer 24097068 LDL cholesterol 
Willer 24097068 Triglycerides 
Wood 25282103 Height 
Yucesoy 25918132 Diisocyanate-induced asthma 
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METHODS 
 
Mouse Transgenic Assays 
 
To test for enhancer activity, each region was cloned into a construct 
containing the Hsp68 promoter, which lacks activity in embryonic mice, and the 
LacZ reporter gene. Individually, these constructs were injected into fertilized 
mouse eggs which were then implanted into pseudopregnant female mice. At 
e11.5, the embryos were harvested and stained for LacZ reporter gene activity. If 
the tested genomic region has tissue specific enhancer activity, the tissue will 
stain blue. For a tissue to have enhancer activity, at least three embryos were 
required to test positive.  
 
 
Cell type specific enhancer prediction  
In November 2015, we downloaded regions from the VISTA database. We 
lifted these regions from the mm9 to the mm10 genome and merged overlapping 
regions, generating 1,994 unique regions. To test anchoring schemes on different 
datatypes, we selected the top 20,000 peaks ranked by p-value and shrank the 
size of the peak to 300 bp. For histone modifications, we used peaks call by 
MACS2 which were in both biological replicates. To modify the width of these 
peaks, we used +/- 150 bp around the peak summit. For DHS, we used peaks call 
by HOTSPOT2 for the first biological replicate. To modify the width of these peaks, 
we used +/- 150 bp around the peak center. To rank peaks, we used signal from 
each experiment. For histone modifications, we used "fold-change over control" 
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signal from the combined biological replicates and calculated signal over a +/- 1 
kb window around the peak summit. For DHSs, we used raw signal from replicate 
one and calculated signal over the 300 bp DHS.  
To evaluate performance, we intersected peaks with all tested VISTA 
regions. If more than one peak overlapped a region we selected the peak with the 
highest signal. VISTA regions were then ranked by the signal of their overlapping 
peak. VISTA regions that did not overlap peaks were assigned a signal of 0. We 
plotted the PR curves using the R package ROCR and calculated the area under 
the curves using custom R scripts. 
To compare ranking schemes, we ran the same pipeline except we 
anchored all predictions on the 300 bp DHSs. For histone modification and 
methylation (WGBS) signals we used a +/- 1 kb window centered at each DHS. 
For H3K27me3 and methylation signals we reversed the order of ranking when 
making our PR curves as high H3K27me3 and methylation correlate with 
repressed regions. 
 
Cell type specific promoter prediction  
To evaluate the performance of promoter prediction methods, we 
downloaded transcript expression quantifications from the ENCODE DCC 
produced from the ENCODE RNA-seq uniform processing pipeline. Using TSS-
proximal (± 2 kb) DHSs or H3K4me3 peaks, we computed the Pearson correlation 
between the ranks of these peaks and the ranks of the expression (TPM) of 
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transcripts within 2 kb. We tested four combinations of ranking schemes: DHSs 
ranked by DNase signal, H3K4me3 peaks ranked by DNase signal, DHSs ranked 
by H3K4me3 signal, and H3K4me3 peaks ranked by H3K4me3 signal. Overall, the 
method with the high correlation was anchoring predictions on DHSs and ranking 
by H3K4me3 signal. 
 
 
Creating representative DHSs (rDHSs) 
As of February 1, 2017 there were 449 hg19 DNase experiments and 62 
mm10 DNase experiments on the ENCODE data portal with HOTSPOT2 calls. As 
a preprocessing step, we normalized the signal at these DHSs so that we can 
compare relative signals across datasets. For each experiment, we calculated the 
Z-score of the log of the DNase signals across the DHSs (see below for an 
explanation of Z-score of log(signal)). We then selected for all DHSs passing an 
FDR threshold of <0.1%. Using a script adapted from the Stamatoyannopoulos 
lab, we clustered these high quality DHSs and we selected the DHS with the 
highest signal (normalized as a Z-score to enable the comparison of signal levels 
across samples) as the representative DHS for each cluster. All the DHSs that 
overlapped with this rDHS by at least one bp were removed. We iteratively 
repeated this process until we obtained a list of non-overlapping rDHSs 
representing all DHSs.  
 
Normalizing epigenomic signals 
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To normalize DNase, H3K4me3, H3K27ac, and CTCF signal for each 
rDHS, we transformed average signals into Z-scores.For each experiment, we 
used the UCSC tool bigWigAverageOverBed to compute the average signal 
across each cRE. For H3K4me3 and H3K27ac we added +/- 500 to both ends of 
the rDHS when computing the signal. Using a custom Python script, we calculated 
the log of these signals and computed a Z-score for each rDHS compared with all 
other rDHS signals within the cell type. rDHSs with a raw signal of 0 were assigned 
a Z-score of -10 due to inconsistencies with pseudocounts.  
 
Classification of cREs 
 
To classify rDHSs as cREs we used the classifications trees in Figures 
2.12 and 2.13. Based on maximum DNase, H3K4me3, H3K27ac, and CTCF Z-
scores across all cell types as well as distance from GENCODEV19 annotated 
TSS, rDHSs can be classified as PLS, ELS, or CTCF-only cREs. Because both 
promoters and enhancers can have high levels of H3K4me3 and H3K27ac, the 
classification tree first splits based on whether a rDHS is proximal (+/- 2 kb) to a 
TSS. rDHSs that are not classified as cREs are discarded. To classify cRE 
activity in a particular cell type we used the classification scheme in Figure 2.18 
relying on the Z-scores of genomic signals in the cell type of interest. 
 
  
105 
Saturation of cREs within each group with increasing numbers of cell types 
To determine the relative saturation of cREs with promoter-like, enhancer-
like or CTCF-only signatures, we used 21 cell types with all four core genomic 
marks (DNase, H3K4me3, H3K27ac, and CTCF). For X in the range of 1–21, we 
randomly selected X cell types 100 times. For each selection, we calculated the 
number of unique cREs in each of the three groups—promoter-like, enhancer-
like, and CTCF-only signatures. Then, using the R script adapted from Steven 
Wilder and Ian Dunham25, we calculated the cREs in each group to be at 95% 
saturation for each curve using a Weibull distribution. 
 
Overlap of cREs with ChromHMM states 
To compared PLS and ELS cREs with chromatin states called by 
chromHMM, we first combined similar chromHMM states to generate seven 
broad states (Table 2.9). For human, we analyzed chromHMM regions for 
GM12878 cells from the ENCODE 2012 paper (ENCODE experiment accession 
ENCFF001TDH). We selected all PLS or ELS cREs and ranked them by 
H3K4me3 and H3K27ac Z-scores, respectively. Then, we calculated the 
percentage of cREs in each 1 k bin that overlapped regions with each 
chromHMM state. Each cRE was assigned to only one chromHMM state—the 
state that overlapped the largest number of basepairs. For mouse, we analyzed 
11 tissue–time-point combinations (from e11.5 and e14.5) for which we had 
DNase, H3K4me3, and H3K27ac data. We overlapped cREs with promoter-like 
  
106 
or enhancer-like signatures with chromHMM states derived from eight histone 
modifications in the same tissue–time-point. 
 
Clustering cell types on the basis of their cRE activities 
We performed hierarchical clustering on all primary cells and tissues with 
DNase-seq data by classifying the DNase Z-score at each cRE as either high (Z-
score > 1.64) or low within each cell type. We also performed the same analysis 
using the Z-scores of H3K27ac and H3K4me3. We clustered tissues and primary 
cells separately because each tissue comprises multiple types of primary cells 
with different embryonic origins. For each cell or tissue type, we selected all 
cREs with a Z-score > 1.64 for each epigenomic mark and then calculated the 
Jaccard index for pairwise tissue or cell type comparisons. We clustered the 
tissues according to the pairwise Jaccard index using the hclust function in R. 
 
Enrichment of GWAS variants in cREs 
We curated studies from the NHGRI-EBI Catalog (Table 2.11) that were 
performed on European populations and used minor allele frequencies (MAF) 
and linkage disequilibrium (LD) of these populations to generate control SNPs. 
Because MAF and LD differ across populations, we limited the scope of our initial 
analysis to the populations with the most data. We used CEU-specific data of 
linkage disequilibrium (LD; correlation coefficient r2>0.7) to perform statistical 
tests. For each study, we generated a matching set of control SNPs as follows: 
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for each SNP in the study (p < 1E-6) we selected a SNP on Illumina and 
Affymetrix SNP ChIPs that fell within the same MAF quartile and the same 
distance to TSS quartile. We repeated this process 100 times, generating 100 
random control SNPs for each GWAS SNP. Then, for both GWAS and control 
SNPs, we retrieved all SNPs in high linkage disequilibrium (LD r2 > 0.7), creating 
LD groups. To assess whether the cREs in a cell type were enriched in the 
GWAS SNPs, we intersected GWAS and control LD groups with cREs with an 
H3K27ac Z-score > 1.64 in the cell type. To avoid over counting, we pruned the 
overlaps, counting each LD group once per cell type. We modified the 
Uncovering Enrichment through Simulation (UES) method101 with Fisher's exact 
tests for performing statistical testing. We calculated enrichment for overlapping 
cREs, comparing the GWAS LD groups with the 100 matched controls. Finally, 
we applied an FDR of 5% to each study. 
 
SCREEN 
SCREEN was engineered by Michael Purcaro and Henry Pratt of Zhiping Weng's 
lab. Their code is available at https://github.com/weng-lab/SCREEN. 
 
Scripts 
Scripts for this analysis can be found on GitHub: https://github.com/Jill-
Moore/Dissertation/tree/master/Chapter-II/  
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CHAPTER III: Systematic evaluation of enhancer target 
gene prediction methods  
 
PREFACE 
Results from this chapter were adapted from  
Moore*, Purcaro*, Pratt*, Epstein*, Shoresh*, Adrian*, Kawli*, Davis*, Dobin*, 
Kaul*, Halow*, Van Nostrand*, Freese*, Gorkin*, He*, Mackiewicz*, The 
ENCODE Consortium. Cherry, Myers, Bing Ren, Graveley, Stamatoyannopoulos, 
Gerstein, Pennacchio, Gingeras, Snyder, Bernstein, Wold, Hardison, and Weng. 
"ENCODE Phase III: Building an Encyclopaedia of candidate Regulatory 
Elements for Human and Mouse," 
 
which is currently under review at Nature and from  
Moore, Garnick, and Weng. "A Systematic Evaluation of Enhancer Target Gene 
Prediction Methods using the ENCODE Encyclopedia." 
 
which is currently in preparation. I performed all analysis and generated all the 
figures that were used in the chapter. 
 
ABSTRACT 
To interpret the biological function of an enhancer, we need to determine 
the genes it regulates. While many enhancers target nearby genes, there are 
examples of enhancers regulating genes up to 1 Mb away. Many groups have 
developed computational methods for linking enhancers with target genes, yet 
these methods are trained and tested on different enhancer-gene links, making 
comparisons between methods difficult. To systematically and accurately evaluate 
enhancer-gene linking methods, we developed a benchmark of chromatin and 
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genetic interaction datasets. In this benchmark, we used Hi-C, ChIA-PET and 
eQTL links to generate positive and negative ELS-gene pairs that can be used for 
training, validating and testing computational methods. Using this benchmark, we 
evaluated correlation based methods and found that they had low overall 
performance and did not outperform ranking genes by distance. We then 
developed a Random Forest model which outperformed unsupervised methods 
and was applicable across cell types. We used our Random Forest model to 
predict genes linked with a variant associated with multiple sclerosis identifying a 
novel GWAS risk gene. Our results establish a pipeline for generating a benchmark 
of ELS-gene pairs, which can be used to evaluate published target gene methods. 
 
INTRODUCTION 
Chapter II of this thesis detailed the Registry of candidate Regulatory 
elements (cREs), a collection of putative regulatory regions in human and mouse. 
The majority, 75%, of these cREs have enhancer-like signatures (i.e. high DNase 
and H3K27ac signals) and are distal from TSSs. To interpret the biological function 
of these cREs, we need to determine the genes they regulate. While many 
enhancers target nearby genes, there are examples of enhancers regulating genes 
up to 1 Mb away2 so simply assigning an enhancer to its nearest gene may not be 
an ideal method. Therefore, labs have developed experimental and computational 
methods for investigating enhancer-gene interactions. 
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Experimental assays such as Hi-C and ChIA-PET survey physical 
interactions between genomic regions62,66. By overlapping the anchors of these 
interactions with annotated enhancers and promoters, we can infer regulatory 
connections. However, these assays are expensive to perform and have only been 
conducted with high resolution in a small number of cell types. Therefore, we need 
to rely on computational methods to more broadly predict enhancer-gene 
interactions. 
Previous work by members of the ENCODE consortium demonstrated that 
they could identify the target genes of enhancers by correlating enhancer activity 
with transcriptional activity. Correlation based methods rely on the hypothesis that 
enhancers are active in the same cell types in which their target gene is expressed. 
These labs used DNase signal6  or H3K4me170 signal to estimate enhancer activity 
and DNase signal6,68, POLII70  signal or gene expression69 to estimate 
transcriptional activity. While these methods identified biologically relevant 
enhancer-gene links, they have yet to be systematically analyzed to evaluate their 
overall precision and recall. 
Other target gene prediction methods such as, IM-PET72, PETmodule73 and 
TargetFinder74, use supervised machine learning algorithms to predict enhancer-
gene links utilizing features such as epigenomic signal72-74, gene ontology terms73, 
and conservation72. While these methods have overall high performance they 
require known enhancer-gene pairs for training. These methods use Hi-C and 
ChIA-PET data as their gold standards but since each method uses data from 
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different studies, as well as different collections of enhancers, it is difficult to 
compare the performance of each model.  
In order to determine the best method for linking ELS cREs with potential 
target genes, we developed a collection of benchmark datasets using the Registry 
of cREs and experimentally derived enhancer-gene interactions. We then tested 
common methods of linking enhancers with genes such as using distance and 
signal correlation. Ultimately, we developed a high performing Random Forest 
approach that can be applied across cell types to predict target genes. Using this 
Random Forest model, we predicted targets genes for a SNP associated with 
multiple sclerosis and identified a novel GWAS risk gene. Our analysis lays the 
groundwork for future comparisons of gene-enhancer linking methods and a push 
towards standardizing the comparison of computational models. 
 
RESULTS 
Curating Benchmark Datasets 
In order to compare methods of predicting target genes, we curated a 
collection of potential enhancer-gene interactions. We focused on two types of 
data: three-dimensional chromatin interactions (e.g. ChIA-PET and Hi-C data) and 
genetic interactions (e.g. eQTLs). We chose to use both types of data because 
they complement each other's limitations. For example, ChIA-PET reports 
proximal physical interactions between two genomic regions, but does not imply 
regulation of one region by another. eQTLs, on the other hand, suggest a 
  
112 
functional relationship between a SNP and gene, but do not imply direct regulation 
by the SNP. Therefore, by testing methods on both types of data we can 
investigate what features are more indicative of physical interactions versus 
genetic interactions. 
We decided to create our initial benchmark using interaction data surveyed 
in GM12878 and lymphoblastoid cell lines due to the large amount of genomic data 
that has been generated by the ENCODE project and the biological community. 
For chromatin interaction data, we selected ChIA-PET and Hi-C datasets from the 
ENCODE DCC and the gene expression omnibus (GEO). During the second 
phase of the ENCODE project, the Snyder lab generated ChIA-PET data in 
GM12878 targeting RAD21, a component of the cohesion complex129. We 
supplemented this data with ChIA-PET datasets generated by the Ruan lab 
targeting POLII and CTCF67. For Hi-C, we included links from promoter capture Hi-
C (CHi-C) data generated by the Osborne lab65 and high resolution Hi-C loops 
generated by the Aiden lab63. For genetic interaction data, we included eQTLs 
reported by the Dermitzakis lab114 and the GTEx consortium108 in lymphoblastoid 
cell lines.  
To generate candidate ELS-gene pairs from these datasets, we required 
one end of a link to overlap an ELS cRE and the other end to fall within 2 kb of a 
GENCODE annotated TSS (Figure 3.1). To correctly identify the target gene, we 
excluded ambiguous links that connected to multiple gene TSSs. For eQTLs, we 
linked a cRE to a gene if it directly overlapped the eQTL SNP. To create our 
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negative set, for cREs with positive links, we selected all genes with TSSs within 
a window that were not a part of a positive or ambiguous pair. For each dataset, 
we determined the size of this window by calculating the 95th percentile of distance 
between positive ELS-gene pairs (Figure 3.2). This window ranged from +/- 170 
kb for POLII ChIA-PET to +/- 983 kb for Aiden Hi-C links (Table 3.1). Using this 
method, we generated thousands of GM12878 specific ELS-gene pairs. For each 
dataset, we split pairs into three groups with 50% of pairs forming the training set, 
25% forming the validation set, and the remaining 25% forming the test set. 
Therefore, this benchmark can be used to train, validate, and test any target gene 
prediction method. 
 
Comparing Benchmark Datasets 
To determine the similarity of the benchmark datasets, we calculated the 
overlap coefficient for the number of positive ELS-gene pairs between each 
dataset. When we clustered the datasets, we observed two large groups, one for 
genetic interaction data and the second for chromatin interaction data (Figure 3.3). 
Within the second cluster, we observed two sub-clusters with ChIA-pet and Hi-C 
datasets aggregating together. We also observed that POLII ChIA-PET and 
Osborne CHi-C data had a higher overlap with eQTL datasets compared to Aiden 
Hi-C, CTCF ChIA-PET or RAD21 ChIA-PET (max overlap coefficient = 0.14 vs. 
max overlap coefficient = 0.03) though the overall overlap was still very low. 
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 For each benchmark dataset, we also analyzed the activity and expression 
levels of the ELS-gene pairs. POLII ChIA-PET cREs tended to have higher levels 
of H3K27ac and H3K4me3 signals (p<4.2E-8, p<8.1E-8) compared to the other 
benchmarks, while RAD21 ChIA-PET cREs had lower levels (p<3.6E-9, p<2.9E-
3) (Figure 3.4a,b). We did not observe notable differences for these signals 
between the other datasets. For CTCF, however, there were differences in the 
distributions of signal for ELS cREs. For RAD21 ChIA-PET, CTCF ChIA-PET and 
Aiden Hi-C pairs, there were populations of ELS cREs with very high levels of 
CTCF signal (Figure 3.4c). For RAD21 ChIA-PET this was a large group of about 
79% of total cREs; for CTCF ChIA-PET and Aiden Hi-C, these groups were 
smaller, containing 35% and 20% of cREs respectively. This enrichment for CTCF 
signal is biologically consistent with these chromatin interaction experiments. 
CTCF was the target for the CTCF ChIA-PET experiment, RAD21 is known to co-
localize with CTCF and the Aiden lab reported that their links are anchored at 
CTCF binding sites. When we analyzed gene expression, we found that genes in 
the POLII ChIA-PET pairs had higher expression levels than other datasets 
(median 15.3 TPM) while genes in the Osborne CHi-C pairs had low expression 
levels (median of 0.2 TPM) (Figure 3.4d). This suggests that some of these CHi-C 
pairs may be false positives or are links for ELS cREs that have yet to regulate 
gene expression. 
Overall, these results suggest that these benchmark datasets capture 
different types of genomic interactions and that to accurately determine the 
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performance of a target gene method, we should test it using all of these 
benchmark datasets. 
 
Ranking by Distance Outperforms Correlation Based Methods  
We began by evaluating the simplest method of enhancer target gene 
prediction: selecting the closest gene by linear distance. We tested this method 
using TSSs for all annotated genes and only TSSs from protein coding genes by 
calculating the precision and recall for each benchmark dataset. For all datasets 
except RAD21 ChIA-PET, we observed higher performance using TSSs for protein 
coding genes, rather than all genes. POLII ChIA-PET links had the highest 
performance with a precision of 0.66 and recall of 0.46 for protein coding gene 
TSSs (Figure 3.5). eQTLs and other ChIA-PET links had moderate performance 
and the Hi-C datasets had the lowest performance. We then tested whether we 
could predict links simply by ranking genes by their linear distance from the ELS 
cRE. Since this method was independent of cell type and did not require any 
genomic data, we considered it our baseline method. For each benchmark dataset, 
we evaluated performance by calculating the areas under the receiver operating 
characteristic (ROC) and precision recall (PR) curves focusing primarily on the 
area under PR (AUPR) curves due to class imbalance in the benchmark datasets 
(Table 3.2). As expected POLII ChIA-pet pairs had the highest AUPR (0.41) and 
Aiden Hi-C pairs had the lowest (0.06) (Figure 3.6 and 3.7, Table 3.2b). We 
compared all subsequent methods to these baseline results. 
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Our next step was to evaluate correlation based approaches. Adapting 
methods from Thurman et al.68, we calculated the correlation coefficient for 
average signal across the ELS cRE and the TSS across hundreds of cell types 
(462 for DNase and 136 for H3K27ac). We tested this method using different 
epigenomic signals (e.g. DNase vs H3K27ac), signal normalization techniques 
(e.g. Raw vs Z-score) and correlation methods (e.g. Pearson vs Spearman). For 
all benchmark datasets, the best performing method was calculating the Spearman 
correlation of Z-score normalized DNase signals (Table 3.2). However, for all of 
the benchmark datasets except RAD21 ChIA-PET, this method did not outperform 
our baseline model (Figure 3.6 and 3.7). For RAD21 ChIA-PET links, though we 
achieved a 57% improvement using correlation over the baseline method (AUPR 
0.18 vs 0.11), the overall performance was still poor. To understand why the 
correlation methods had such low AUPR values, we analyzed specific ELS-gene 
pairs. We found that there were some pairs that did have high correlation 
coefficients. For example, the highest ranked POLII ChIA-PET ELS-gene pair was 
EH37E0572541-WNT10A, which had a Spearman correlation coefficient of 0.82 
(Figure 3.8a,b). Both WNT10A's promoter and EH37E0572541 have high DNase 
signal in over a hundred of DNase experiments suggesting that EH37E0572541 
regulates WNT10A in many types of cells. This example, however, is in the 
minority. There are many other cases where the DNase correlation for the ELS-
gene pair is low. For example, ELS cRE EH37E0853090 is paired with AKIRIN2 
by both a POLII ChIA-PET link and a GTEx eQTL. However, EH37E0438944 and 
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AKIRIN2 have low DNase correlation (ρ=0.06) (Figure 3.8c,d). AKIRIN2 is 
expressed across many cell types and has high DNase activity (PLS cRE DNase 
Z-score > 1.64) in all of the 462 surveyed cell types. EH37E0365491, on the other 
hand, only has high DNase signal (Z-score > 1.64) in six cell types, four of which 
are lymphoblastoid or lymphoma cell lines. Therefore, we predict that AKIRIN2 is 
only regulated by EH37E0853090 in B cell related cell types and that because of 
this cell type specific regulation, we are unable to identify this ELS-gene pair using 
correlation. In general, we hypothesized that the low overall performance for 
correlation based methods is because enhancers are much more likely to be cell 
type specific than promoters (Chapter II, Figure 2.17). Therefore, while correlation 
methods are simple to implement because they do not require cell-type specific 
data, they cannot identify cell-type specific ELS-gene pairs, such as 
EH37E0853090-AKIRIN2, which results in worse performance compared to our 
baseline method.  
When we compared the shape of the PR curves for correlation with our 
baseline method, we observed that correlation methods tended to have higher 
AUPR for the top ranked ELS-gene pairs whereas distance had better 
performance with the lower ranked pairs. We decided to combine the methods by 
taking the averaging rank of the two different schemes. For all benchmark datasets 
except eQTLs, this resulted in an average increased AUPR of 38% (Figures 3.6 & 
3.7, Table 3.3). Our baseline method remained the best performing method for 
both GTEx and Dermitzakis eQTL pairs. In conclusion, while correlation based 
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methods did not outperform selecting genes using distance, we observed an 
increase in performance when we combined the two features. 
 
Random Forest Models Outperform Unsupervised Methods 
Because simply combining distance and DNase correlation resulted in 
higher performance than our baseline model, we sought to develop a more 
sophisticated computational method that could combine multiple features to 
predict ELS-gene links. We decided to utilize the Random Forest algorithm130, a 
supervised machine learning approach that is able to handle class imbalanced 
datasets (i.e. different number of positive and negatives), and used two 
approaches for developing models (Figure 3.9). First, we focused on developing 
models that can be applied across many cell and tissue types. These models 
would only require cell type specific DNase and/or H3K27ac data along with cell 
type independent features such as signal correlation, sequence features (k-mers), 
and distance (see methods for full feature list). Second, we focused on developing 
the best performing model in GM12878 using all available data. For this model, we 
included gene expression, TF and histone modification ChIP-seq, and RAMPAGE 
data. This model may only be able to be applied across a few cell types (e.g. 
GM12878, K562, H1-hESC) but may indicate which types of experiments we 
should prioritize in the future. 
Starting with the DNase and H3K27ac only models, we found these 
relatively simple models had higher AUROC and AUPR compared to our average 
  
119 
rank method for all benchmarks (Figure 3.10 and 3.11, Table 3.4). Including both 
signals as features resulted in the best performance, but models using only one of 
the signals (for cell types with just one datatype) still had comparable performance. 
We analyzed feature importance for each model and found that distance was 
consistently ranked the most important feature (Table 3.4). The next most 
important features were average DNase and H3K27ac signal around the gene's 
TSS suggesting that activity at the gene's promoter is indicative of ELS-gene links. 
We then decided to expand on this basic model by adding in other features 
such as expression, TF ChIP-seq signal and other histone modifications (Table 
3.3). We found that expression universally improved performance, with AUPR for 
the eQTL benchmarks having the highest increases (13% and 9%) (Figures 3.10 
and 3.11). This is consistent with the methodology of defining eQTLs as the gene 
must be expressed in LCLs to be detected (Table 3.5). When we added CTCF 
signal to this expression model, considering both signal at the ELS cRE and TSS, 
AUPR increase 13% for CTCF ChIA-PET and 18% for RAD21 ChIA-PET. When 
we analyzed feature importance for this model, TSS CTCF signal was the top 
ranked feature for RAD21 ChIA-PET and the second ranked feature for CTCF 
ChIA-PET after distance (Table 3.6). For Aiden Hi-C, we only observed an 
increase of 2% for including CTCF and TSS CTCF was the fifth most important 
feature after distance and TSS DNase, H3K27ac, and conservation signals. For 
all three benchmarks, CTCF-signal at the enhancers was not even one of the top 
ten most important features. When we added POLII, EP300, RAMPAGE, or 
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additional histone modification signals to our expression model, we did not observe 
dramatic increases in performance (Table 3.7). Our comprehensive model, which 
includes all of these features only had an average improvement of 0.5% over the 
expression + CTCF model.  
  
Our Random Forest Model Can be Applied Across Cell Types 
As we do not have chromatin or genetic interaction data for the majority of 
cell types covered by the Registry of cREs, if we were to apply our method to 
predict cell type specific ELS-gene pairs, we would need to train our model in a 
cell type with benchmark data. In order to evaluate the versatility of our models 
across different cell types, we tested our basic RF model using POLII and CTCF 
ChIA-PET data from HeLa cells generated by the Ruan Lab67. We compared 
performance of models trained and validated with data from the cell type versus 
models trained and validated in different cell types. We also compared 
performance to our best performing unsupervised method: taking the average rank 
of distance and DNase correlation. We found that while the cross-cell type models 
had lower AUPR than the same cell type models, they outperformed the average 
rank method with an average increase in AUPR of 25% (Figure 3.12, Table 3.10). 
The POLII ChIA-PET datasets retained higher performance across cell types 
compared to the CTCF ChIA-PET datasets. We hypothesize this is because 
distance is a more important feature in the POLII ChIA-PET models and is truly 
cell type independent. DNase and H3K27ac data quality can vary between cell 
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types and though we normalized the signals, these biases can lower performance. 
Therefore, while we aim to improve the cross cell type application of our model, 
our random forest model still outperformed our best unsupervised approach. 
 
Our Random Forest Model Identifies a New GWAS Gene for Multiple 
Sclerosis 
Since our expression random forest model had high performance across all 
benchmark datasets without requiring multiple features, we used this model to 
predict ELS-gene pairs in GM12878 cells. Our previous GWAS enrichment 
analysis (Chapter II) demonstrated that variants associated with multiple sclerosis 
are enriched in cREs active in GM12878, which is in agreement with previously 
findings by the Stamatoyannopoulos lab102. Multiple sclerosis is an disease in 
which the body's immune system attacks the myelin sheaths of axons, resulting in 
in neurological deficits and deterioration131. The role for B cells in the pathology of 
multiple sclerosis has recently been recognized103 with clinical trials targeting B cell 
antigens reporting success for slowing disease progression104. Therefore, 
identifying potential target genes in GM12878 may present new therapeutic 
targets. 
One SNP of particular interest was rs1250568, which is in LD with two SNPs 
associated with multiple sclerosis132,133. Rs1250568 overlaps ELS cRE 
EH37E0182314 which has high H3K27ac and DNase signal in blood cells like 
GM12878. Rs1250568 also overlaps both a ChIP-seq peak and motif site for ELF1 
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(Figure 3.13a). ELF1 is primarily expressed in lymphoid cells and is involved in the 
IL-2 and IL-23 immune response pathways, both of which have previously been 
implicated in multiple sclerosis134,135. Additionally deltaSVM, a computational 
method that predicts the functional impact of variants using DNA sequence k-mers, 
predicted that rs1250568 is likely a casual SNP136. Because rs1250568 may 
disrupt ELF1 binding, thus affecting gene regulation, we aimed to identify genes 
that interact with  EH37E0182314. 
Using our expression Random Forest model trained on POLII ChIA-PET 
pairs, we predicted genes links using a probability cutoff of 0.5 (precision=0.80, 
recall=0.59). Our model reported two linked genes: ZMIZ1 and PPIF (Figure 
3.13b). These predictions are also supported by POLII ChIA-PET links that were 
not a part of our training set (Figure 3.13c). ZMIZ1 is involved with androgen 
receptor signaling pathway and is expressed at lower levels in patients with 
multiple sclerosis137. Due to its proximity to the GWAS lead SNPs, ZMIZ1 was 
reported as the risk gene in both GWAS132,133. The other linked gene, PPIF 
(Cyclophilin D), is located downstream of EH37E0182314 and encodes a 
mitochondrial permeability transition pore protein. While PPIF was not previously 
reported as a MS susceptibility gene by GWAS, evidence demonstrates that its 
dysregulation likely plays a role in the onset of multiple sclerosis. For example 
Forte et al. demonstrated that knocking out Ppif in mice with experimental 
autoimmune encephalomyelitis (EAE, a mouse disease model for multiple 
sclerosis) protected spinal cord axons, enabling the knock out mice to partially 
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recover from EAE138. These findings are supported by recent work from Warne et 
al. who demonstrated that treating EAE mice with a Ppif inhibitor protects axons 
and improves motor ability139. Therefore, our comprehensive Random Forest 
model is able to predict biologically significant enhancer-gene links which can be 
used to better understand disease etiology and identify potential therapeutic 
targets. 
 
DISCUSSION 
 In this chapter, we evaluated methods for linking enhancers with putative 
target genes. We curated a benchmark of ELS-gene pairs using chromatin and 
genetic interaction datasets and then used this benchmark to test common 
methods of target gene prediction. We found that overall, correlation of epigenomic 
signal across cell types is not an ideal method for predicting ELS-gene pairs. 
Though we observed that some ELS-gene pairs such as EH37E0572541-
WNT10A have high correlation, the overall performance of these methods are low. 
We demonstrated that one reason for low performance is that with correlation 
methods we are unable to detect cell type specific regulation, which is the case for 
EH37E0853090-AKIRIN2. Another possible reason for poor performance is we 
survey signal across a biased set of cell and tissues types. For example, we have 
many more types of blood cells than lung or heart tissue samples. This imbalance 
could dramatically alter the results depending on the gene's expression patterns. 
In the future, we could curate a set of recommended cell types to use for correlation 
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based methods (e.g., equal representation from different tissues of origin) but this 
still does address the problem of cell type specificity. Our results, however, do not 
discredit all correlation based methods. For example, correlation may be a much 
more powerful tool when analyzing activity and expression across differentiation 
or development. For example, in Chapter IV we link cREs with target genes using 
correlation of signal activity and gene expression within the same tissues across 
embryonic development. Our results simply suggest that using correlation across 
a wide range of different cell and tissue types is less than ideal. 
We also demonstrated that even basic Random Forest Models, with few cell 
type specific features had a considerable improvement in performance over 
unsupervised methods. Adding other features such as expression and CTCF 
signal improved performance for specific benchmarks, but a comprehensive model 
including all features did not result in a much higher AUPR. Since simply adding 
more types of epigenomic signal did not drastically improve performance, moving 
forward we will integrate different types of features. For example, the Aiden lab 
reported enrichment for CTCF motifs at the anchors of their Hi-C loops63 so we 
plan to include distance to nearest CTCF motif site in our model. While our 
Random Forest model had high performance when trained and validated on the 
same cell type, we were surprised of its lower performance when validated across 
cell types. With models dependent on cell type specific signals, we need to be 
aware of differences in data quality and biases in signal. For our analysis used Z-
score normalized signals to try and alleviate this problem but we may need to 
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investigate alternative methods of normalization. It is also possible fundamental 
differences between cell types may causing this lower performance. For example, 
GM12878 and HeLa cells are histologically very different from one another and 
may have different numbers of ubiquitous or cell type specific cREs. We plan on 
continuing to modify our models so that they are applicable across cell types 
perhaps implementing new normalization methods or using a ranking metric. Our 
next step will be to compare our Random Forest model with other target gene 
prediction methods such as PET-Module, IM-PET and Target Finder. These 
models have all been trained and evaluated using different enhancer-gene links 
so our benchmark will allow for an unbiased comparison between the methods. 
Finally, our analysis also revealed key differences between the benchmark 
interaction datasets. In general, there is little overlap between these datasets and 
the ELS-genes pairs have different features. For example, CTCF ChIA-PET, 
RAD21-ChIA-PET and Aiden Hi-C ELS cREs have higher CTCF signal and their 
links are better predicted when CTCF is included in the Random Forest model. 
Additionally, the Osborne CHi-C data link ELS cREs with genes with low 
expression. This suggests that either many of these interactions are random noise 
or CHi-C captures new interactions that have yet to result in gene expression. Both 
cases warrant further investigation. In the future, we can also investigate features 
that differentiate between types of links. For example, the Ruan lab reported 
differences between the gene expression patterns of genes at the anchors of their 
CTCF and POLII ChIA-PET with the CTCF genes having ubiquitous expression 
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and POLII genes having cell type specific expression. We can incorporate these 
features into our model to predict what types of interactions link the ELS-gene pair. 
 During the next phase of the ENCODE project, the Ruan labs and Aiden 
labs plan on generating new ChIA-PET and Hi-C datasets in cell types relevant to 
the Registry of cREs. Therefore, establishing these methods for creating 
benchmarks will aid in the future evaluation of target gene methods. 
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Figure 3.1 | Method for curating ELS-Gene pairs. To include a link in one of our 
benchmark datasets, it must overlap a ELS cRE active GM12878 (yellow) and the 
proximal region surrounding a TSS (+/- 2 kb). Links that overlap multiple TSSs are not 
included in either the positive or negative set of links (black listed). For the negative set 
we included all genes with a TSS within a +/- distance based on the 95th percentile.  
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Figure 3.2 | Distance distributions for benchmark datasets. a, Distribution of 
distances between ELS cREs and gene TSSs in benchmark links. b, Lines indicating 
95th percentile of distance for each benchmark dataset.  
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Figure 3.3 | Overlap of benchmark datasets. Heatmap displaying overlap coefficients 
for each pairwise comparison of benchmark datasets. Benchmark datasets cluster by 
type of dataset (i.e. ChIA-pET, Hi-C, and eQTLs). 
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Figure 3.4 | Activity of ELS cREs and expression of genes in benchmark datasets. 
a, H3K27ac b, H3K4me3 and c, CTCF Z-scores in GM12878 for ELS cREs in 
benchmark datasets. d, Gene expression in TPM for genes in benchmark datasets 
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Figure 3.5 | Performance for closest gene method. Precision (X-axis) and recall (Y-
axis) for each benchmark dataset using the closest gen method. Results from using all 
genes are indicated by circles. Results from using protein coding genes are indicated by 
triangles. 
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Figure 3.6 | PR curves for unsupervised target gene prediction methods: ChIA-
PET datasets. Precision recall curves for enhancer gene pairs ranked by distance, 
DNase and H3K27ac Z-score Spearman correlation, and the average rank of DNase 
correlation and distance for a, POLII, b, CTCF, and c, RAD21 ChIA-PET datasets 
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Figure 3.7 | PR curves for unsupervised target gene prediction methods: eQTL 
and Hi-C datasets. Precision recall curves for enhancer gene pairs ranked by distance, 
DNase and H3K27ac Z-score Spearman correlation, and the average rank of DNase 
correlation and distance for a) GTEx eQTLs, b) Dermitazkis lab eQTL, c) Aiden lab Hi-C 
and d, Osborne lab CHi-C datasets 
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Figure 3.8 | Correlation of DNase signal between of ELS-gene pairs. a, ELS cRE 
EH37E0572541 WNT10A are paired by a POLII ChIA-PET link. EH37E0572541and the 
promoter of WNT10A DNase signal correlation coefficient of 0.82. b, ELS cRE 
EH37E0853090 and AKIRIN2 are paired by a POLII ChIA-PET link and GTEx eQTL. 
EH37E0853090 and the promoter of AKIRIN2 DNase signal correlation coefficient of 
0.06. 
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Figure 3.9 | Proposed random forest models for predicting ELS-gene pairs. We 
propose developing two models. The minimal model will only cell type specific DNase 
and H3K27ac as well as cell type agnostic features such as conservation and distance. 
With the comprehensive model, we will integrate as many data types as possible to 
generate the best performing model. 
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Figure 3.10 | PR curves for Random Forest model predicting ELS-Gene links: 
ChIA-PET datasets. Precision recall curves for the average rank of DNase correlation 
and distance, and basic, expression, CTCF, and comprehensive Random Forest models 
for a, POLII, b, CTCF, and c, RAD21 ChIA-PET datasets 
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Figure 3.11 | PR curves for Random Forest model predicting ELS-Gene links: 
eQTL and Hi-C datasets. Precision recall curves for the average rank of DNase 
correlation and distance, and basic, expression, CTCF, and comprehensive Random 
Forest models for a) GTEx eQTLs, b) Dermitazkis lab eQTL, c) Aiden lab Hi-C and d, 
Osborne lab CHi-C datasets 
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Figure 3.12 | PR curves for Random Forest models trained and validated in 
different cell types. Precision recall curves for the average rank of DNase correlation 
and distance, and Random Forest models trained using GM12878 data or HeLa data for 
ELS-gene pairs from a, POLII ChIA-PET from GM12878, b, POLII ChIA-PET from HeLa, 
c, CTCF ChIA-PET from GM12878, and d, CTCF ChIA-PET from HeLa 
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Figure 3.13 | Predicting genes linked with MS variant rs1250568. a, MS variant 
rs1250568 overlaps ELS cRE EH37E0182314 which has high DNase (green) and 
H3K27ac (yellow) signal in GM12878. Rs1250568 overlaps a ELF1 ChIP-seq peak 
(blue) and ELF motif site. b, Results from comprehensive Random Forest model where 
bars indicated the probability of each gene being linked with EH37E0182314. c, 
Genome browser view of the locus showing POLII ChIA-PET links validating the 
predicting links between rs1250568 and ZMIZ1 and PPIF 
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Table 3.1 | Benchmark Datasets 
 Number of Enhancer-Gene Pairs  
Dataset Positive Set Negative Set % Positive 95th Percentile Distance 
POLII ChIA-PET67 12,118 75,380 13.85% 170,163 
CTCF ChIA-PET67 4,354 72,070 5.70% 426,155 
RAD21 ChIA-PET 198 3,979 4.74% 365,097 
Promoter Capture Hi-C65 48,638 328,724 12.89% 667,267 
High Resolution Hi-C63 1,132 43,472 2.54% 983,020 
GTEX eQTLs 1,162 24,082 4.60% 493,764 
Dermitazakis (2013) 
eQTLs114 2,145 30,223 6.63% 298,777 
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Table 3.2a | AUROC for unsupervised methods 
 H3K27ac DNase   
 Pearson Spearman Pearson Spearman   
 Raw Z-score Raw Z-score Raw Z-score Raw Z-score Distance Average Rank 
POLII 
ChIA-PET 0.5837 0.6234 0.6159 0.6220 0.6225 0.6969 0.6424 0.7070 0.8339 0.8327 
CTCF 
ChIA-PET 0.6082 0.6149 0.6202 0.6197 0.6520 0.6859 0.6835 0.6904 0.8044 0.8065 
RAD21 
ChIA-PET 0.5897 0.6328 0.6358 0.6044 0.6486 0.7220 0.7143 0.7253 0.7466 0.7954 
GTEx 
eQTLs 0.5511 0.5919 0.6159 0.6010 0.5945 0.6223 0.6053 0.6346 0.8764 0.8170 
Dermitzakis 
eQTL 0.5920 0.6346 0.6363 0.6487 0.5829 0.6388 0.5960 0.6442 0.7436 0.7594 
Osborne 
CHi-C 0.5799 0.5838 0.5832 0.5898 0.5704 0.5868 0.5732 0.6003 0.7633 0.7257 
Aiden  
HiC 0.5706 0.5994 0.5956 0.6008 0.6265 0.6795 0.6188 0.6855 0.7767 0.7823 
Average 0.5849 0.6195 0.6248 0.6192 0.6294 0.6818 0.6614 0.6893 0.8153 0.8129 
 
 
Table 3.2b | AUPR for unsupervised methods 
 H3K27ac DNase   
 Pearson Spearman Pearson Spearman   
 Raw Z-score Raw Z-score Raw Z-score Raw Z-score Distance Average Rank 
POLII 
ChIA-PET 0.1761 0.1891 0.1894 0.1898 0.2152 0.2700 0.2285 0.2911 0.4119 0.4553 
CTCF 
ChIA-PET 0.0833 0.0806 0.0847 0.0846 0.1012 0.1234 0.1097 0.1300 0.2066 0.2399 
RAD21 
ChIA-PET 0.0641 0.0657 0.0683 0.0819 0.0853 0.1544 0.0995 0.1800 0.1145 0.2507 
GTEx 
eQTLs 0.0597 0.0630 0.0710 0.0674 0.0802 0.0822 0.0810 0.0939 0.2667 0.2049 
Dermitzakis 
eQTL 0.0969 0.1053 0.0999 0.1044 0.0928 0.1142 0.0944 0.1256 0.2252 0.2158 
Osborne 
CHi-C 0.1579 0.1590 0.1588 0.1614 0.1643 0.1662 0.1635 0.1740 0.2481 0.2595 
Aiden  
HiC 0.0321 0.0342 0.0345 0.0345 0.0393 0.0517 0.0396 0.0564 0.0624 0.0875 
Average 0.0960 0.1007 0.1027 0.1056 0.1149 0.1488 0.1226 0.1641 0.2450 0.2877 
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Table 3.3a | AUROC for Random Forest models 
    Gene Expression  
 DNase H3K27ac Basic Basic CTCF POLII p300 RAMPAGE His Mods All 
POLII 
 ChIA-PET 0.9285 0.9327 0.9348 0.9396 0.9409 0.9415 0.9417 0.9411 0.9464 0.9487 
CTCF  
ChIA-PET 0.8930 0.8934 0.8967 0.9022 0.9158 0.9064 0.9046 0.9039 0.9111 0.9227 
RAD21  
ChIA-PET 0.7798 0.7847 0.7841 0.7762 0.8184 0.7777 0.7748 0.7797 0.7676 0.8037 
GTEx  
eQTLs 0.9289 0.9292 0.9297 0.9401 0.9416 0.9419 0.9401 0.9405 0.9432 0.9447 
Dermitzakis 
eQTL 0.8970 0.8984 0.9043 0.9221 0.9232 0.9241 0.9251 0.9238 0.9312 0.9337 
Osborne  
CHiC  0.8263 0.8330 0.8488 0.8521 0.8536 0.8522 0.8507 0.8731 0.8736 
Aiden  
HiC 0.9216 0.9218 0.9220 0.9270 0.9285 0.9263 0.9247 0.9256 0.9310 0.9302 
Average 0.8915 0.8838 0.8864 0.8937 0.9029 0.8959 0.8948 0.8950 0.9005 0.9082 
 
Table 3.3b | AUPR for Random Forest models 
    Gene Expression  
 DNase H3K27ac Basic Basic CTCF POLII p300 RAMPAGE His Mods All 
POLII 
 ChIA-PET 0.7353 0.7466 0.7557 0.7718 0.7761 0.7778 0.7803 0.7773 0.7985 0.8065 
CTCF  
ChIA-PET 0.4342 0.4387 0.4488 0.4712 0.5342 0.4861 0.4819 0.4826 0.5306 0.5857 
RAD21  
ChIA-PET 0.2594 0.2546 0.2532 0.2651 0.3137 0.3026 0.2812 0.2874 0.3041 0.3569 
GTEx  
eQTLs 0.5301 0.5392 0.5484 0.5982 0.6040 0.6051 0.6030 0.6041 0.6260 0.6320 
Dermitzakis 
eQTL 0.4950 0.4917 0.5184 0.5872 0.5938 0.6008 0.6017 0.5991 0.6465 0.6617 
Osborne  
CHiC  0.4753 0.4930 0.5329 0.5453 0.5446 0.5408 0.5408 0.6071 0.6074 
Aiden  
HiC 0.4949 0.5405 0.5583 0.5963 0.6139 0.6104 0.6350 0.6082 0.6823 0.6825 
Average 0.4915 0.4981 0.5108 0.5461 0.5687 0.5610 0.5606 0.5571 0.5993 0.6190 
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Table 3.4 | Feature importance for basic Random Forest Model 
 POLII ChIA-PET 
CTCF 
ChIA-PET 
RAD21 
ChIA-PET 
GTEx 
eQTLs 
Dermitzakis 
eQTL 
Osborne 
CHi-C 
Aiden 
Hi-C Average 
Distance 0.2578 0.1667 0.1074 0.1777 0.1486 0.1532 0.1030 0.1592 
Promoter 
DNase 0.0706 0.0611 0.0723 0.0602 0.0611 0.0636 0.0674 0.0652 
Enhancer 
H3K27ac 
Mean 
0.0446 0.0528 0.0602 0.0553 0.0618 0.0615 0.0655 0.0574 
Promoter 
Conservation 0.0395 0.0515 0.0605 0.0601 0.0581 0.0611 0.0676 0.0569 
Promoter 
H3K27ac 0.1027 0.0578 0.0666 0.0633 0.0630 0.0597 0.0715 0.0692 
Enhancer 
H3K27ac SD 0.0418 0.0516 0.0547 0.0571 0.0578 0.0579 0.0640 0.0550 
Promoter 
H3K27ac 
Mean 
0.0339 0.0466 0.0506 0.0495 0.0486 0.0554 0.0575 0.0489 
Promoter 
H3K27ac SD 0.0352 0.0456 0.0543 0.0487 0.0487 0.0553 0.0509 0.0484 
H3K27ac 
Correlation 0.0416 0.0536 0.0656 0.0511 0.0611 0.0525 0.0557 0.0545 
DNase 
Correlation 0.0564 0.0703 0.0853 0.0536 0.0515 0.0474 0.0593 0.0605 
K-mer 
Correlation 0.0413 0.0508 0.0705 0.0542 0.0527 0.0461 0.0565 0.0532 
Enhancer 
H3K27ac 0.0376 0.0432 0.0369 0.0440 0.0415 0.0427 0.0398 0.0408 
Promoter 
DNase Mean 0.0344 0.0436 0.0373 0.0377 0.0440 0.0424 0.0406 0.0400 
Enhancer 
Conservation 0.0323 0.0417 0.0381 0.0371 0.0408 0.0421 0.0437 0.0394 
Promoter 
DNase SD 0.0331 0.0404 0.0309 0.0451 0.0454 0.0420 0.0413 0.0397 
Enhancer 
DNase 0.0357 0.0405 0.0378 0.0386 0.0385 0.0412 0.0397 0.0388 
Enhancer 
DNase SD 0.0313 0.0424 0.0392 0.0336 0.0385 0.0387 0.0380 0.0374 
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Enhancer 
DNase Mean 0.0302 0.0397 0.0320 0.0333 0.0383 0.0373 0.0380 0.0355 
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Table 3.5 | Feature importance for expression Random Forest model  
 POLII ChIA-PET 
CTCF 
ChIA-PET 
RAD21 
ChIA-PET 
GTEx 
eQTLs 
Dermitzakis 
eQTL 
Osborne 
CHi-C 
Aiden 
Hi-C Average 
Distance 0.2512 0.1633 0.1016 0.1765 0.1470 0.1521 0.0999 0.1559 
Expression 0.0759 0.0518 0.0620 0.0713 0.0828 0.0530 0.0571 0.0648 
Promoter 
H3K27ac 0.0875 0.0522 0.0580 0.0554 0.0552 0.0542 0.0655 0.0611 
Promoter 
DNase 0.0583 0.0561 0.0664 0.0535 0.0540 0.0547 0.0624 0.0579 
DNase 
Correlation 0.0507 0.0658 0.0814 0.0478 0.0453 0.0485 0.0546 0.0563 
Promoter 
Conservation 0.0365 0.0490 0.0572 0.0596 0.0549 0.0529 0.0647 0.0535 
Promoter 
DNase Mean 0.0399 0.0496 0.0556 0.0498 0.0542 0.0536 0.0600 0.0518 
Promoter 
DNase SD 0.0389 0.0492 0.0522 0.0517 0.0531 0.0506 0.0596 0.0508 
K-mer 
Correlation 0.0383 0.0477 0.0657 0.0488 0.0474 0.0474 0.0527 0.0497 
H3K27ac 
Correlation 0.0372 0.0491 0.0592 0.0444 0.0518 0.0504 0.0532 0.0494 
Promoter 
H3K27ac 
Mean 
0.0322 0.0439 0.0480 0.0472 0.0454 0.0481 0.0556 0.0458 
Promoter 
H3K27ac SD 0.0325 0.0428 0.0520 0.0450 0.0453 0.0474 0.0485 0.0448 
Enhancer 
H3K27ac 0.0353 0.0418 0.0340 0.0401 0.0382 0.0415 0.0376 0.0384 
Enhancer 
H3K27ac 
Mean 
0.0325 0.0423 0.0362 0.0350 0.0404 0.0416 0.0388 0.0381 
Enhancer 
H3K27ac SD 0.0309 0.0387 0.0299 0.0416 0.0415 0.0414 0.0386 0.0375 
Enhancer 
Conservation 0.0302 0.0394 0.0371 0.0341 0.0373 0.0428 0.0414 0.0375 
Enhancer 
DNase 0.0340 0.0386 0.0357 0.0360 0.0351 0.0415 0.0375 0.0369 
Enhancer 
DNase SD 0.0295 0.0407 0.0367 0.0312 0.0359 0.0395 0.0362 0.0357 
Enhancer 
DNase Mean 0.0286 0.0381 0.0313 0.0308 0.0352 0.0388 0.0361 0.0341 
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Table 3.6 | Feature importance for CTCF Random Forest model  
 POLII ChIA-PET 
CTCF 
ChIA-PET 
RAD21 
ChIA-PET 
GTEx 
eQTLs 
Dermitzakis 
eQTL 
Osborne 
CHi-C 
Aiden 
Hi-C Average 
Distance 0.2436 0.1559 0.0934 0.1699 0.1409 0.1460 0.0934 0.1490 
Promoter 
CTCF 0.0346 0.0745 0.1057 0.0462 0.0521 0.0481 0.0562 0.0596 
Expression 0.0709 0.0451 0.0512 0.0660 0.0765 0.0489 0.0521 0.0587 
Promoter 
H3K27ac 0.0820 0.0464 0.0499 0.0503 0.0502 0.0496 0.0603 0.0555 
Promoter 
DNase 0.0559 0.0490 0.0560 0.0501 0.0490 0.0496 0.0567 0.0523 
DNase 
Correlation 0.0477 0.0589 0.0692 0.0438 0.0418 0.0440 0.0500 0.0508 
Promoter 
Conservation 0.0333 0.0426 0.0508 0.0546 0.0493 0.0479 0.0591 0.0482 
Promoter 
DNase Mean 0.0377 0.0439 0.0460 0.0458 0.0489 0.0485 0.0542 0.0464 
K-mer 
Correlation 0.0354 0.0418 0.0583 0.0459 0.0431 0.0430 0.0484 0.0451 
Promoter 
DNase SD 0.0357 0.0429 0.0420 0.0471 0.0491 0.0457 0.0528 0.0450 
H3K27ac 
Correlation 0.0343 0.0431 0.0518 0.0410 0.0475 0.0461 0.0485 0.0446 
Promoter 
H3K27ac 
Mean 
0.0295 0.0379 0.0420 0.0431 0.0407 0.0437 0.0495 0.0409 
Promoter 
H3K27ac SD 0.0299 0.0374 0.0438 0.0414 0.0411 0.0431 0.0431 0.0400 
Enhancer 
H3K27ac 0.0328 0.0361 0.0291 0.0370 0.0350 0.0377 0.0337 0.0345 
Enhancer 
H3K27ac 
Mean 
0.0298 0.0356 0.0313 0.0318 0.0367 0.0377 0.0351 0.0340 
Enhancer 
H3K27ac SD 0.0280 0.0340 0.0261 0.0379 0.0375 0.0375 0.0349 0.0337 
Enhancer 
Conservation 0.0277 0.0344 0.0318 0.0313 0.0342 0.0387 0.0373 0.0336 
Enhancer 
CTCF 0.0272 0.0405 0.0328 0.0284 0.0317 0.0362 0.0368 0.0334 
Enhancer 
DNase 0.0313 0.0337 0.0310 0.0324 0.0320 0.0376 0.0337 0.0331 
Enhancer 
DNase SD 0.0268 0.0344 0.0306 0.0283 0.0317 0.0354 0.0325 0.0314 
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Table 3.7 | Feature importance for comprehensive Random Forest model 
 POLII ChIA-PET 
CTCF 
ChIA-PET 
RAD21 
ChIA-PET 
GTEx 
eQTLs 
Dermitzakis 
eQTL 
Osborne 
CHi-C 
Aiden 
Hi-C Average 
Distance 0.1903 0.1212 0.0597 0.1307 0.1080 0.1114 0.0600 0.1116 
Promoter 
CTCF 0.0152 0.0471 0.0714 0.0239 0.0250 0.0227 0.0272 0.0332 
Expression 0.0392 0.0233 0.0260 0.0371 0.0433 0.0281 0.0252 0.0317 
DNase 
Correlation 0.0261 0.0359 0.0426 0.0236 0.0216 0.0218 0.0255 0.0282 
Promoter 
H2AFZ 0.0284 0.0249 0.0278 0.0231 0.0275 0.0240 0.0281 0.0262 
Promoter 
H3K4me1 0.0222 0.0244 0.0297 0.0211 0.0241 0.0230 0.0331 0.0254 
Promoter 
H3K27ac 0.0393 0.0208 0.0219 0.0223 0.0214 0.0222 0.0266 0.0249 
K-mer 
Correlation 0.0191 0.0223 0.0347 0.0251 0.0217 0.0212 0.0249 0.0241 
Promoter 
Conservation 0.0154 0.0205 0.0257 0.0297 0.0233 0.0237 0.0281 0.0238 
Promoter 
DNase 0.0242 0.0221 0.0273 0.0225 0.0214 0.0224 0.0246 0.0235 
Promoter 
H3K9ac 0.0297 0.0202 0.0226 0.0221 0.0226 0.0227 0.0236 0.0234 
H3K27ac 
Correlation 0.0163 0.0221 0.0284 0.0206 0.0250 0.0228 0.0245 0.0228 
Promoter 
EP300 0.0237 0.0194 0.0220 0.0213 0.0215 0.0233 0.0282 0.0228 
Promoter 
POLII 0.0235 0.0194 0.0224 0.0248 0.0228 0.0210 0.0233 0.0224 
Promoter 
H3K27me3 0.0146 0.0199 0.0245 0.0220 0.0268 0.0224 0.0256 0.0223 
Promoter 
H3K4me2 0.0198 0.0196 0.0276 0.0203 0.0236 0.0215 0.0229 0.0222 
Promoter 
H3K4me3 0.0227 0.0198 0.0226 0.0212 0.0215 0.0227 0.0238 0.0220 
Promoter 
DNase SD 0.0165 0.0205 0.0198 0.0246 0.0247 0.0211 0.0243 0.0217 
Promoter 
H3K79me2 0.0247 0.0177 0.0196 0.0224 0.0211 0.0208 0.0244 0.0215 
Promoter 
H3K9me3 0.0155 0.0198 0.0233 0.0212 0.0191 0.0209 0.0288 0.0212 
Promoter 
H4K20me1 0.0148 0.0196 0.0214 0.0213 0.0235 0.0212 0.0257 0.0211 
Promoter 
H3K36me3 0.0164 0.0208 0.0222 0.0205 0.0217 0.0215 0.0222 0.0208 
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Promoter 
DNase Mean 0.0148 0.0195 0.0211 0.0217 0.0225 0.0215 0.0236 0.0207 
Promoter 
H3K27ac 
Mean 
0.0132 0.0181 0.0212 0.0214 0.0195 0.0209 0.0220 0.0195 
Promoter 
RAMPAGE 0.0220 0.0164 0.0204 0.0184 0.0223 0.0147 0.0203 0.0192 
Promoter 
H3K27ac SD 0.0133 0.0177 0.0223 0.0197 0.0193 0.0206 0.0195 0.0189 
Enhancer 
H3K79me2 0.0141 0.0152 0.0146 0.0158 0.0171 0.0177 0.0186 0.0162 
Enhancer 
CTCF 0.0128 0.0204 0.0157 0.0126 0.0146 0.0162 0.0177 0.0157 
Enhancer 
H3K27ac SD 0.0131 0.0156 0.0118 0.0178 0.0179 0.0169 0.0154 0.0155 
Enhancer 
H3K9me3 0.0141 0.0174 0.0138 0.0142 0.0154 0.0176 0.0156 0.0154 
Enhancer 
Conservation 0.0127 0.0161 0.0144 0.0140 0.0158 0.0175 0.0175 0.0154 
Enhancer 
H3K27ac 
Mean 
0.0134 0.0157 0.0142 0.0142 0.0171 0.0165 0.0156 0.0152 
Enhancer 
H3K36me3 0.0144 0.0159 0.0134 0.0152 0.0150 0.0173 0.0151 0.0152 
Enhancer 
H2AFZ 0.0146 0.0170 0.0131 0.0137 0.0142 0.0159 0.0168 0.0151 
Enhancer 
POLII 0.0137 0.0160 0.0127 0.0168 0.0143 0.0173 0.0140 0.0150 
Enhancer 
EP300 0.0162 0.0151 0.0142 0.0139 0.0138 0.0168 0.0144 0.0149 
Enhancer 
H4K20me1 0.0134 0.0161 0.0117 0.0154 0.0143 0.0177 0.0156 0.0149 
Enhancer 
H3K4me1 0.0138 0.0156 0.0117 0.0149 0.0155 0.0168 0.0159 0.0149 
Enhancer 
H3K27me3 0.0131 0.0158 0.0124 0.0172 0.0146 0.0173 0.0137 0.0149 
Enhancer 
DNase 0.0145 0.0148 0.0139 0.0141 0.0137 0.0165 0.0146 0.0146 
Enhancer 
H3K27ac 0.0145 0.0153 0.0120 0.0156 0.0141 0.0158 0.0145 0.0145 
Enhancer 
DNase SD 0.0126 0.0166 0.0144 0.0130 0.0150 0.0157 0.0141 0.0145 
Enhancer 
DNase Mean 0.0122 0.0151 0.0125 0.0128 0.0144 0.0153 0.0146 0.0138 
Enhancer 
H3K4me3 0.0126 0.0147 0.0128 0.0126 0.0133 0.0159 0.0135 0.0136 
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Enhancer 
H3K9ac 0.0122 0.0145 0.0117 0.0123 0.0134 0.0151 0.0145 0.0134 
Enhancer 
H3K4me2 0.0117 0.0147 0.0120 0.0130 0.0128 0.0151 0.0124 0.0131 
Enhancer 
RAMPAGE 0.0094 0.0094 0.0084 0.0083 0.0090 0.0091 0.0100 0.0091 
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Table 3.8a | AUROC for cross cell type comparisons 
Cell Type ChIA-PET Target 
Average Rank Distance & 
DNase Correlation 
GM12878 
Trained RF 
Model 
HeLa Trained 
RF Model 
GM12878 POLII  0.8327 0.9316 0.8654 
HeLa POLII 0.8072 0.8801 0.9193 
GM12878 CTCF 0.8065 0.8936 0.8055 
HeLa CTCF 0.8346 0.8611 0.9047 
 
Table 3.8.b | AUPR for cross cell type comparisons 
Cell Type ChIA-PET Target 
Average Rank Distance & 
DNase Correlation 
GM12878 
Trained RF 
Model 
HeLa Trained 
RF Model 
GM12878 POLII 0.4553 0.7458 0.5465 
HeLa POLII 0.2658 0.3845 0.5663 
GM12878 CTCF 0.2399 0.4380 0.2681 
HeLa CTCF 0.2259 0.2827 0.4074 
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METHODS 
 
 
Creating Our Benchmark of ELS-Gene Pairs 
Defining ELS cREs 
We selected all cREs as defined as having enhancer-like signatures in 
GM12878 per own registry of regulatory elements pipeline. To be classified as an 
ELS cRE in GM12878, the cRE must have a DNase and H3K27ac Z-scores > 
1.64 in GM12878 and either be 1) distal from an annotated TSS or 2) not have a 
H3K4me3 Z-score > 1.64 in GM12878. In total, there are 27,739 ELS cREs in 
GM12878. 
 
Processing ChIA-PET Data 
We downloaded Ruan lab ChIA-PET data from NCBI's Gene Expression 
Omnibus (GEO) under the accession GSE72816. We used links from 
GSM1872886_GM12878_CTCF_PET_clusters.txt for CTCF and 
GSM1872887_GM12878_RNAPII_PET_clusters.txt for POLII. We also 
downloaded ChIA-PET data produced by the Snyder from the ENCODE DCC 
(experiment ENCSR752QCX). We used links called from both replicates in 
ENCFF002EMO and ENCFF002EMQ. 
To generate ELS-Gene pairs, we intersected the ends of the ChIA-PET links 
with GM12878 ELS cREs and TSSs from GENCODE 19 genes. We selected all 
links for which one end of the link overlapped an ELS-cRE and the other end fell 
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within 2 kb of an annotated TSS. We classified links that overlapped an ELS-cRE 
but linked to more than one TSS as "ambiguous" and added them to a blacklist. 
 
Processing Hi-C Data 
We downloaded Hi-C loops generated by the Aiden lab from GEO under 
the accession GSE63525. We used the lab's called loops from 
GSE63525_GM12878_primary+replicate_HiCCUPS_looplist.txt. We also 
downloaded CHi-C links generated by the Osborne lab from ArrayExpress under 
the accession E-MTAB-2323. We used the lab's called links from 
TS5_GM12878_promoter-other_significant_interactions.txt 
To generate ELS-Gene pairs, we intersected the ends of the (C)Hi-C links 
with GM12878 ELS cREs and TSSs from GENCODE 19 genes. We selected all 
links for which one end of the link overlapped an ELS-cRE and the other end fell 
within 2 kb of an annotated TSS. We classified links that overlapped an ELS-cRE 
but linked to more than one TSS as "ambiguous" and added them to a blacklist. 
 
Processing eQTLs 
We downloaded eQTLs curated from HaploReg, a database curated by the 
Kellis lab. To generate the GTEx eQTL pairs, we intersected ELS-cREs with 
eQTLs from lymphoblastoid cell lines. To generate the Derm eQTL pairs we 
intersected ELS-cREs with eQTLs from lymphoblastoic cell liens. For each overlap 
generated an ELS-cRE pair using the overlapping ELS and the gene reported by 
the eQTL. 
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Generating negative pairs 
For each of the seven datasets, we calculated the 95th percentile of distance 
between the ELS-gene pairs. We defined distance and the minimum linear 
distance between a ELS-cRE and any TSS of the linked gene. We then selected 
all ELS-gene pairs that fell within this distance. For each ELS cRE in this pool, we 
generated a list of all genes within the 95th percentile distance. For datasets with 
blacklisted links (ChIA-PET and (C)Hi-C) we removed all genes that appeared on 
the black list connected to the ELS cRE. We considered all remaining genes 
negatives. 
 
Generating training, validation, and test sets 
After generating positive and negative ELS-gene pairs, we assigned them 
to training, validation and test sets. For training sets, we randomly selected half of 
the ELS-cREs and assigned all of their positive and negative paris to the training 
sets. For the validation and test sets we split the remaining cREs in half and assign 
the pairs of each to validation and test sets respectively. This results in training, 
validation and test sets containing roughly 50%, 25%, and 25% of the total number 
of ELS-gene pairs respectively. All of our analysis was currently evaluated using 
the validation datasets. We plan on using the test dataset for final comparisons of 
models. 
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Predicting Target Genes Using Distance 
To identify the closest gene to each ELS cRE, we used the Bedtools 
command closest with ELS cREs as file a and GENCODE V19 TSSs as file b. We 
repeated this process using a filtered set of TSSs to identify the closest protein 
coding genes. We calculated the overall precision (TP/(TP+FP)) and recall 
(TP/(TP+FN)) for each dataset using both sets of TSSs. 
To test using distance as a ranking scheme, for each ELS-gene pair we 
calculated the minimum linear distance between the ELS cRE and every annotated 
TSS for the gene. We used a custom python script. We calculated the AUROC 
and AUPR using custom the ROCR package and custom R scripts. Because 
prediction with larger values are considered a higher rank by the ROCR package, 
we used the inverse of distance to generated the ROC and PR curves 
 
Correlation Methods 
For correlation based methods we tested DNase vs. H3K27ac signal, using 
raw signal (reported directly from ENCODE bigwig files) vs. Z-score normalized 
signal (see Chapter II for explanation), and Pearson vs Spearman correlation 
coefficients. To determine signal at each cRE, we used Z-score and raw signals 
generated during the creation of the Registry of cREs. For these cREs, Z-score 
signals were calculated across all rDHSs. For TSSs, we used 
bigwigaverageoverbed to calculate the average signal in a +/- 500bp window 
around each TSS. We converted this signal to a Z-score relative to all other TSSs. 
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Note – these Z-scores are different from PLS-cRE Z-scores. Then using custom 
python scripts we calculated the correlation between each ELS-gene pair. If a gene 
had multiple TSSs, we selected the highest correlation coefficient for the pair. We 
calculated the AUROC and AUPR using custom the ROCR package and custom 
R scripts.  
 
Random Forest Model 
We implemented the Random Forest algorithm using the python package 
scikit learn. For each test, we ran the algorithm 25 times, generating 100 trees 
each run. For each ELS-gene pair we reported the average class probability across 
the 25 runs.  
 We included the following features in our Random Forest model: 
1. Distance = the minimum linear distance between ELS cRE and any of 
the genes TSSs 
2. Expression = expression of gene in GM12878 measured in transcripts 
per million 
3. DNase correlation = Spearman correlation of DNase Z-score normalized 
signal across 460 cell types 
4. H3K27ac correlation = Spearman correlation of DNase Z-score 
normalized signal across 136 cell types 
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5. Kmer correlation = Pearson correlation of k-mer correlation (default is 3-
mer) for k-mer counts across 1 kb sequences centered at gene TSS and 
ELS cRE 
6. Enhancer DNase Mean = the average DNase Z-score for ELS cRE 
across all cell types 
7. Enhancer DNase SD = the standard deviation of ELS DNase Z-scores 
across all cell types 
8. Enhancer H3K27ac Mean = the average H3K27ac Z-score for ELS cRE 
across all cell types 
9. Enhancer H3K27ac SD = the standard deviation of ELS H3K27ac Z-
scores across all cell type Enhancer DNase Mean = the average DNase 
Z-score for ELS cRE across all cell types 
10.  Promoter DNase Mean = the average DNase Z-score for +/- 500 bp 
around surrounding the TSS across all cell types 
11.  Promoter DNase SD = the standard deviation of ELS DNase Z-score 
for +/- 500 bp around surrounding the TSS across all cell types 
12.  Promoter H3K27ac Mean = the average H3K27ac Z-score for +/- 500 
bp around surrounding the TSS across all cell types 
13.  Promoter H3K27ac SD = the standard deviation of ELS H3K27ac Z-
score for +/- 500 bp around surrounding the TSS across all cell types 
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14.  Enhancer signal = Signal at ELS cREs including DNase, H3K27ac, 
POLII, CTCF, EP300, RAMPAGE, histone modifications, and 
conservation 
15.  Promoter signal = Signal at ELS cREs including DNase, H3K27ac, 
POLII, CTCF, EP300, RAMPAGE, histone modifications, and 
conservation for +/- 500 bp around surrounding the TSS across all cell 
types 
For each benchmark, we generated a model from the training data and 
validated using the benchmark validation sets. We calculated the AUROC and 
AUPR using custom the ROCR package and custom R scripts. 
 
Scripts 
Scripts for this analysis can be found on GitHub: https://github.com/Jill-
Moore/Dissertation/tree/master/Chapter-III/ 
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CHAPTER IV: Functional annotation of noncoding 
variants reveals role of neural and immune pathways in 
psychiatric disorders 
 
PREFACE 
Results from this chapter were adapted from  
Moore and Weng. "Functional annotation of noncoding variants reveals role of 
neural and immune pathways in psychiatric disorders." 
 
which is currently in preparation. I performed all analysis and generated all the 
figures that were used in the chapter. 
 
ABSTRACT 
Schizophrenia, bipolar disorder, and major depressive disorder are 
debilitating psychiatric disorders that affect a significant percentage of the 
population. While the etiologies of these psychiatric disorders are unknown, each 
have strong hereditary components and studies have demonstrated that they 
share common genetic risk factors.  Genome wide association studies (GWAS) 
have associated over one hundred single nucleotide polymorphisms (SNPs) with 
these disorders and a majority of the associated SNPs lie in noncoding regions of 
the genome. Our aim was to functionally characterize these noncoding psych 
SNPs.  We determined psych SNPs were enriched in ELS cREs in active in brain 
tissues as well as immune related tissues such as T-cells and the thymus. We also 
determined that these SNPs regulate genes expressed in brain tissue with roles in 
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neural pathways. Under the hypothesis that psych SNPs alter gene expression by 
disrupting transcription factor (TF) binding, we analyzed TF ChIP-seq data and 
observed the SNPs are enriched in SP4 motifs and binding sites for TFs with 
enriched expression in developing brain tissue. Finally, we characterized four 
cases of allele specific binding, demonstrating that specific psych SNPs disrupt TF 
binding sites. Our findings demonstrate that common genetic variants affect both 
neural and immune pathways. 
 
INTRODUCTION  
Schizophrenia (SCZ), bipolar disorder (BPD), and major depressive 
disorder (MDD) are three prevalent and debilitating psychiatric disorders that affect 
millions of people every year.  While the causes of these disorders are unknown, 
studies demonstrate both genetic and environmental factors contribute to their 
onset. SCZ and BPD are highly heritable (~60% estimated heritability)76,80,140 and 
through large scale analyses of national medical records and correlation of genetic 
risk variants studies have reported that these disorders share common genetic risk 
factors83,84. Though MDD has a lower estimated heritability (30-40%)82, studies 
demonstrated that it also shares common genetic risks with SCZ and BPD84. 
Genome wide association studies (GWAS) have successfully identified 
hundreds of single nucleotide polymorphisms (SNPs) associated with SCZ, BPD, 
and MDD. The majority of these SNPs are in noncoding regions of the genome, 
and our understanding of how these variants contribute to disease onset is limited. 
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There have been efforts to characterize noncoding variants associated with SCZ 
but their scope was limited to characterizing individual variants, resulting in only a 
handful of annotated variants141.  
During the third phase of the Encyclopedia of DNA Elements (ENCODE) 
project we generated the ENCODE Encyclopedia, a collection of high throughput 
experiments (e.g. DNase-seq, RNA-seq, histone modification and transcription 
factor ChIP-seq) and higher-level analyses aimed at annotating the human and 
mouse genomes. In addition to assembling this resource, we also integrated 
DNase-seq data with ChIP-seq data to create the Registry of candidate Regulatory 
Elements (cREs), a collection of putative regulatory regions across human and 
mouse (described in Chapter II). In total, we identified over 1.3M human and 400k 
mouse cREs each annotated with cell-type specific signatures (e.g., promoter-like, 
enhancer-like) in over 400 human and 100 mouse cell types. Our goal was to use 
the Registry of cREs and supporting data from the ENCODE Encyclopedia to 
functionally characterize noncoding SNPs associated with SCZ, BPD, and MDD. 
By analyzing enrichments in cRE activity in over 500 cell types and integrating 
RNA-seq, TF-ChIP-seq data, we hoped to learn more about the genetic 
contributions of these diseases. 
Here we report that SNPs associated with psychiatric diseases (psych 
SNPs) are enriched in candidate regulatory elements active in brain tissues and 
neural cells. We also curated lists of potential target genes for these SNPs and 
determined that these genes are enriched for expression in brain tissue. Using 
  
161 
orthologous cREs in mouse, we analyzed temporal patterns of cRE activity during 
brain development and found specific examples of psych cREs active during brain 
development. We also determined that psych SNPs are enriched in motifs for 
neural TFs, particularly SP4, as well as immune related TFs such as IRF1. 
Additionally, we discovered specific instances of psych SNPs in regulatory 
elements that alter TF binding by disrupting TF motifs. Our analysis supports a 
genetic foundation for neural pathways in psychiatric disorders and also suggests 
a role for immune pathways. 
 
RESULTS 
The majority of GWAS signal for psych SNPs is explained by cREs  
As of July 2017, there were 139 studies in the NHGRI-EBI GWAS catalog 
tagged with the terms "schizophrenia," "bipolar disorder," or "major depressive 
disorder." Due to variations in methodology and sampled populations, we selected 
one representative study for each disorder, prioritizing studies with the largest 
number of associated variants (Table 4.1). We also considered variants reported 
by the Cross-Disorder Group of the Psychiatric Genomics Consortium (PGC) who 
analyzed a mixed cohort of SCZ, BPD, MDD, autism spectrum disorder (ASD) and 
attention deficit hyperactivity disorder (ADHD) patients. In total, we curated 96 
variants for SCZ, 23 for BPD, 43 for MDD, and 73 for cross-disorders (CD). These 
235 associations, along with 6,479 SNPs in high (r2 > 0.7) linkage disequilibrium 
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(LD), amount to 6,714 SNPs associated with psychiatric disorders (psych SNPs) 
in 233 regions of high LD, which we refer to as LD blocks. 
`We began by determining the genetic context of psych SNPs using 
GENCODE V19 gene annotations. As expected, the majority of psych SNPs (99%) 
are in noncoding regions of the genome; only ~1% overlap coding exons (Table 
4.2). Of these, only two variants (rs4584886 and rs678) are predicted by 
PROVEAN and SWIFT to be deleterious and damaging to the resulting protein 
(Table 4.3). While these two SNPs are likely causal, the majority of GWAS signal 
for psych SNPs is from noncoding regions of the genome. 
To annotate these noncoding regions, we overlapped psych SNPs with 
human and mouse cREs. On average, 20% of psych SNPs overlapped a human 
cRE accounting for 79% of LD blocks (Table 4.4a,b). Of these, the majority, 76%, 
overlap cREs with enhancer-like signatures (ELS), while 20% overlap cREs with 
promoter-like signatures (PLS) and 4% overlap CTCF-only cREs (Table 4.5). An 
average of 7% of SNPs overlapped orthologous mouse cREs accounting for 46% 
of LD blocks (Table 4.4c,d). Individually, psych SNPs were slightly more enriched 
at cREs compared to controls (~1.2 and 1.4 fold enrichment for human and mouse 
cREs respectively), but there was no significant difference when we performed this 
analysis with the LD blocks. These results suggest the majority of signal (~79%) 
from these GWAS can be explained by variants in cREs and that additional 
annotation of these regions will give us further insight into the mechanisms that 
underlie these disorders. 
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Psych SNPs are enriched in cREs active in brain regions 
Previous work has demonstrated that variants associated with human 
disease are enriched in regulatory elements active in disease-relevant cell and 
tissue types. For example, SNPs associated with Crohn’s disease were enriched 
in T-helper cell DNase peaks6, and SNPs associated with cholesterol levels are 
enriched in liver H3K27ac peaks26. The Schizophrenia Working Group of the PGC 
reported their SCZ associated loci were enriched in brain-specific and B cell-
specific H3K27ac peaks when looking across 35 tissues from the Roadmap 
epigenomics project105  
We wanted to extend this work by analyzing DNase and H3K27ac signals 
at cREs overlapping psych SNPs. Using data from the Registry of cREs, we 
calculated activity enrichments using 540 cell and tissue types (462 DNase and 
136 H3K27ac). Additionally, during the third phase of the ENCODE project, 
production labs generated H3K27ac, DNase and RNA-seq data for twelve tissues 
across mouse embryonic development (eight surveyed time points). These 
experiments enabled us to analyze enrichment for specific temporal patterns of 
activity in mouse across development. To calculate enrichment, we counted the 
number of overlapping cREs with a signal (DNase or H3K27ac) Z-score greater 
than 2, indicating high signal in that cell type. To prevent over counting of SNPs in 
LD, we pruned our results by only reporting one hit per LD block for each cell type 
(see methods). We calculated enrichment using Fisher's exact test. Additionally, 
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differing number of SNPs between the studies makes using a uniform p-value 
cutoff difficult. P-values from Fisher's exact test inflate as sample size increases, 
and therefore it is ideal to use more stringent cutoffs for studies with more reported 
SNPs. We also used a more conservative method for calculating our FDR than 
previous studies26 (see methods). Therefore, for our analysis, we focused the top 
5 most enriched tissues with at least p<0.05 for each study, noting those that meet 
our FDR threshold of 5%.  
Overall, we detected significant enrichments for SCZ and CD SNPs in cREs 
active in neural cells and brain tissues (Figures 4.1 and 4.2, External Table 4.1). 
For SCZ SNPs, when we filtered cREs using H3K27ac Z-scores, the five most 
significantly enriched cell types were temporal lobe, angular gyrus, middle frontal 
area, iPS DF 19.11, and caudate nucleus (Figure 4.1a). The enrichment in neural 
tissues was so pronounced that when we expanded our search to the top ten most 
significantly enriched cell types, seven were from brain tissues or neural cells. Of 
the remaining three, two were iPSCs, and one was from fetal thymus (External 
Table 4.1). Even after removing variants on chromosome 6 to account for SNPs in 
the major histocompatibility complex (MHC), we still observed enrichment in fetal 
thymus (External Table 4.1). When we filtered cREs using DNase Z-scores, we 
also observed enrichment in brain tissues (fetal brain and superior temporal gyrus) 
and neural cells (neuronal progenitor and stem cells) (External Table 4.2). 
Interestingly, the most significant enrichment was for NCI-H226, a lung cancer cell 
line. When we clustered DNase cell types by their activity in cREs overlapping SCZ 
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SNPs, we observed that NCI-H226 did not cluster with lung tissue but rather in a 
large block consisting of various primary cells and cell lines suggesting that the 
enrichment is not due to lung-related factors but rather properties unique to the 
immortalized cell NCI-H226 (External Figure 4.1). For CD SNPs, when we filtered 
using H3K27ac, the top five most enriched tissues were brain (middle frontal area), 
neural cells, OCI-LY7 (lymphoma cell line), neural progenitor cells, and iPS-20b. 
When we excluded cREs on chromosome 6, OCI-LY7 dropped in ranked from third 
most enriched tissue to tenth and was replaced by temporal lobe tissue (External 
Table 4.1). When we filtered by DNase four of the top five most enriched tissues 
were from the brain (occipital lobe, superior temporal gyrus, middle frontal gyrus 
and the cerebellar cortex) with other being L1-S8R, an iPS cell line (External Table 
4.2). 
When we analyzed H3K27ac signal orthologous mouse cREs, we also 
observed enrichment in brain tissues for SCZ and CD SNPs. SCZ SNPs were 
enriched in midbrain, forebrain, and hindbrain regions particularly at later 
developmental time points (Figure 4.1b, External Table 4.3). CD SNPs were 
enriched primarily in forebrain. These tissues were also highly ranked when filtered 
cREs using DNase signal but none of the tissues met our FDR threshold of 5%. 
With BPD and MDD SNPs we did not observe any enrichments that met our 
FDR threshold of 0.05, however, due to the small number of SNPs reported in each 
study we still analyzed top-ranked tissues to look for general patterns of 
enrichment (External Tables 4.1-4.4). In the case of MDD, there were no 
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enrichments for human cell types (p < 0.05) thresholding by either H3K27ac or 
DNase. However, when we filtered with H3K27ac in mouse, we observed 
enrichments in hindbrain and neural tube tissue at time points e13.5 and e14.5 
(Figure 4.1b, External Table 4.3). When we used DNase for filtering, we observed 
enrichment in CD-1 mesoderm tissue (External Table 4.4). For BPD SNPs, we only 
observed enrichment for human cell types with H3K27ac data. Four of the top five 
most enriched tissues were from blood (T cell subtypes and mononuclear blood 
cells) while the fifth was iPS cell line 20b (External Table 4.1). We repeated the 
analysis filtering out variants on chromosome 6 to account for SNPs in the MHC. 
We still observed enrichments in T helper cells and iPSCs but now observed 
enrichments in SK-N-MC, a neuroblast cell line, HUES64 ESCs and fetal adrenal 
gland (External Table 4.1). In mouse, the only tissue with p<0.05 for CD SNPs was 
bone marrow (External Table 4.3). 
Overall, psych SNPs, particularly SCZ and CPD SNPs, are enriched in 
cREs that are active in brain tissue and neural cells in both human and mouse. We 
also observed enrichment of cREs in immune-related tissues such as fetal thymus 
for SCZ SNPs, T cells for BPD SNPs, and lymphoma cell line for CD SNPs. While 
these enrichments became less significant when we removed cRES on 
chromosome 6, they were still some of the top-ranked tissues.  
 
SCZ and CD SNPs regulate genes expressed in the brain involved in neural 
pathways 
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Since we determined that the majority of signals for the psych GWAS can 
be explained by SNPs in cREs, we wanted to determine the genes regulated by 
these regions. We began by analyzing expression quantitative trait loci (eQTLs) 
generated by the Genotype-Tissue Expression (GTEx) project. In their 2015 
release, the GTEx project reported over one milion eQTLs surveyed across 44 
tissues, ten of which are from the brain. We intersected our psych SNPs with a list 
of GTEx tissue specific eQTLs curated by HaploReg106. LD blocks containing SCZ 
and CD SNPs were enriched for eQTLs with about 43% of LD blocks overlapping 
at least one eQTL (p=4.5E-3, p=8.5E-3, fisher's exact test) (Table 4.6). BPD and 
MDD LD blocks were neither enriched nor depleted.  
When we analyzed the tissue specificity of these eQTLs we did not observe 
any enrichments with an FDR < 5% (External Table 4.5). Unlike cRE enrichments, 
most of the top ranked tissues for SCZ and CD genes were not from the brain. For 
SCZ only two of the top five tissues were from the brain (cerebellum and frontal 
cortex) with the others from thyroid, whole blood, and testis. For CD eQTLs, there 
were no brain regions in the top five tissues. BPD and MDD eQTLs did not have 
any tissues with p< 0.05. In order to further investigate these eQTL genes, we first 
looked for enrichment of gene ontology (GO terms) using PantherDB142. For all 
four eQTL genes sets, we did not observe any significant enrichments for GO 
terms. Using GTEx expression data we compared the expression of these eQTL 
linked genes to those linked with control SNPs. When we analyzed the top ten 
most enriched tissues, we only observed three brain regions for SCZ SNPs; the 
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other tissues were testis, female reproductive tissues and colon (Figure 4.3, 
External Tables 4.6). CD eQTL genes were enriched for expression in immune 
tissues such as EBV lymphocytes, spleen and whole blood. MDD and BPD eQTLs 
genes did not have enrichments with p < 0.05. 
These results lead us to believe that many of these eQTL links were tissue 
specific and LD may prevent us from identifying the direct target of the cRE. For 
example, rs9936474 overlaps cRE EH37E1142914 which has high H3K4me3, 
H3K27ac, and DNase signal in human brain tissues (External Table 4.13). While 
this cRE overlaps a noncoding RNA (CTD-2574D22.4), its closest protein coding 
gene (1.6 kb away) is KCTD13, a gene which encodes a potassium channel 
tetramerization domain protein. KCTD13 is highly expressed in developing brain 
and neural cells (External Table 4.9) and has previously been linked with 
psychiatric disorders and brain development pathways143,144. If we only consider 
genes linked via eQTLs as potential target genes, KCTD13 is not one of the 16 
genes on the list. This example highlights two major problems with solely using 
eQTLs to predict target genes. First, none of the eQTL links for rs9936474 are in 
brain; some of the eQTLs may be tissue specific and therefore are not relevant to 
SCZ. If we restrict ourselves to only using eQTLs from brain tissue, however, we 
cover less than 20% of GWAS LD blocks. Second, of these 16 potential gene 
targets, only five are within 100kb of EH37E1142914. The majority of these links 
are likely due to indirect regulatory effects or SNPs in LD with rs9936474 rather 
than direct regulation by EH37E1142914. Because of these two issues, we believe 
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using only eQTL genes for target gene prediction results in a gene list full of false 
positives and negatives. Therefore, we decided to curate our own lists of putative 
target genes for further 
analysis.                                                                                                                             
   In chapter III, we demonstrated that 61% of high resolution GM12878 
POLII ChIA-PET data links connected ELS cREs with the promoter of the closest 
protein coding gene; additionally, 86% of ELS-promoter links are with 100kb 
(Figure 4.4a). As we did not have POLII ChIA-PET in human or mouse brain 
tissues, we curated potential target genes based the observed ranges in 
GM12878. For each study, we generated two lists of genes: 1) all protein coding 
genes with a TSS within 100kb of the SNP, 2) the closest protein coding gene 
using linear distance from TSS for each SNP.  These gene lists have limited 
overlap with eQTL genes (Figure 4.4b); in fact, approximately 41% of eQTL genes 
are unique. 
We began by analyzing the expression of each of the genes sets comparing 
them to gene sets generated using control SNPs. For SCZ and CD, both the 
closest gene set and 100kb gene sets were enriched for expression in brain tissues 
surveyed by GTEx and ENCODE (Figure 4.3b,c, External Tables 4.7-4.8). 
Specifically, the closest genes for SCZ (N=157) had the most significant 
enrichment in the frontal cortex, cortex and anterior cingulate cortex. When we 
compared the expression of these genes using ENCODE RNA-seq data, we also 
observed enrichment in brain tissue, such as the parietal, occipital and temporal 
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lobes of fetal brain (Figure 4.3d). We also analyzed the expression of orthologous 
mouse genes using gene expression data from the developmental time series. 
SCZ genes were enriched for expression in brain tissue (forebrain, midbrain, and 
hindbrain) particularly at later time points (Figure 4.3e). CD genes also were 
enriched for expression in brain tissues for both human GTEx and ENCODE 
samples, but these enrichments did not meet our FDR threshold of 5% (External 
Tables 4.7 and 4.8). We did not observe any significant (p<0.05) tissue-specific 
enrichments in expression for the BPD and MDD gene lists (External Tables 4.7 
and 4.8). This is not surprising since we were also unable to detect strong tissue-
specific enrichments in cRE activity for these disorders. 
We also performed gene ontology analysis using these genes lists. For SCZ 
genes, we observed overwhelming enrichment in neural pathway terms (Figure 
4.4f, Table 4.7, External Table 4.10) such as neuron components, synaptic 
transmission and gated channel activity. This suggests that these SCZ genes have 
primary roles in neural pathways. For the other disorders, there were not many 
enriched terms (External Table 4.10). For CD genes, we observed significant 
enrichments in immune related terms such as T-cell activation and MHC Class II 
receptor activity. However, these terms were no longer significant after removing 
genes on chromosome 6; therefore, these enrichments were only driven by SNPs 
in the MHC. The one enrichment that did remain significant was for genes in the 
Alzheimer disease-amyloid secretase pathway. For MDD, there were two genes, 
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IL12A and IL12B, that were components of the interleukin-12 complex. Finally, 
there were three BPD genes involved with mannose metabolic processes.  
Overall, we determined that potential target genes of SCZ SNPs have 
enriched expression in brain tissues and have roles in neural pathways. We also 
determined that solely using eQTLs to predict target genes results in enrichments 
for unrelated cell and tissues types possibly due to tissue specificity and LD. 
 
Temporal activity of cREs containing psych SNPs reveals biological role  
Since psych SNPs are enriched in orthologous mouse cRES active in 
developing brain tissues and are near genes expressed during these timepoints, 
we wanted to know if there was a temporal dependence on this enrichment. Using 
K-means clustering (K=4), we grouped cREs using H3K27ac signal across 
embryonic development in mouse forebrain, midbrain, and hindbrain. The resulting 
four clusters had nearly identical temporal patterns across the three brain 
subregions: cluster 1 cREs increased in activity overtime, cluster 2 cREs 
decreased in activity over time, cluster 3 cREs increased in activity until ~e12.5 
then decrease in activity, and cluster 4 cREs increased in activity and tapered 
off/slightly decreased just before birth (Figure 4.5a). Comparing across the tissues, 
we determined that cREs tended to belong to the same clusters in all three tissues 
(Figure 4.5b). For each cRE group, we generated a list of linked genes by selecting 
the nearest protein coding gene defined using linear distance to the closest TSS. 
We observed the gene expression patterns of these linked genes followed the 
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same trends as H3K27ac signal patterns across forebrain, midbrain, and hindbrain 
demonstrating that trends we observed in cREs hold for gene expression (Figure 
4.5c). We then performed GO analysis with these gene lists and selected all 
enriched terms with a bonferroni corrected p-value > 0.05 (Figure 4.5d, External 
Table 4.11). Cluster 1 cREs were near genes involved with basic cellular 
processes such as translation, nuclear transport and metabolism. Cluster 2 cREs 
were near genes involved with embryonic development including neural crest cell 
differentiation, regulation of cell cycle arrest and embryonic pattern specification. 
Cluster 3 cREs, were enriched in terms related to CNS development such as 
neuron fate specification, cranial nerve development, and pallium development. 
Cluster 4 cREs, were enriched GTPase signaling, axon development, and neuron 
projection morphogenesis. 
Using these clusters, we tested whether psych SNPs were enriched in cREs 
with a specific temporal activity pattern. To account for LD structure for both psych 
SNPs and controls, we randomly selected one representative cRE per LD block 
and averaged the results over 500 trials. In general, psych SNPs were not enriched 
for cREs with a specific temporal pattern.  SCZ, MDD, and CD SNPs were evenly 
distributed across cREs clusters in the three brain regions (External Table 4.12). 
BPD SNPs on the other hand were enriched in cREs in cluster 2 cREs in midbrain 
and hindbrain (Chi-Square test p=2.83E-02, 5.47E-03). While only a small number 
of LD blocks overlap mouse cREs, on average 71 and 91% of the cREs are in 
cluster 2 in midbrain and hindbrain compared to 20 and 21% in controls. 
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While the majority of psych SNPs were not enriched in a particular temporal 
cluster, this type of analysis leads to new biological insights of how these SNPs 
contribute to disease. For example, CD SNP rs12424245 overlaps an ELS cRE in 
both human and mouse (EH37E0250841 and EM10E0283811). EH37E0250841 
lies within CACNA1C, a well-documented SCZ and BPD associated gene88-90,92. 
CACNA1C encodes a calcium voltage-gated channel subunit and expressed in 
many tissues such as heart, muscle, and brain (External Table 4.9). In humans, 
EH37E0250841 has high H3K27ac signal (z-score > 1.64) in 28 cell types including 
adult brain, heart, and GI tissues and high DNase activity in 168 cell types including 
fetal brain, spinal cord, and kidney (External Table 4.13). Interestingly, the 
orthologous mouse cRE, EM10E0283811, only has high H3K27ac signal in neural 
tissues: forebrain, midbrain, hindbrain and neural tube (Figure 4.6a). In these 
tissues, EM10E0283811's H3K27ac z-score increases over time, plateauing just 
before birth; therefore, the K-means algorithm classified EM10E0283811 as a 
group 4 cRE in forebrain, midbrain, and hindbrain. This pattern of H3K27ac activity 
also correlates with CACNA1C expression these brain tissues (r=0.79) (Figure 
4.6b). Though CACNA1C is also highly expressed in heart and lung tissue during 
embryonic development, EM10E0283811 is a neural specific enhancer and 
therefore would only control CACNA1C in developing brain tissue. Because of this 
temporal pattern and EH37E0250841's high H3K27ac signal in human adult brain 
tissue and high DNase signal in fetal brain tissue, we predict that this ELS cRE 
turns on during brain development and remains active throughout adulthood. 
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Therefore, we predict rs12424245 may contributes to the onset of psychiatric 
disorders by altering the regulation of CACNA1C expression. 
Additionally, this temporal analysis enables us to more preciously determine 
target genes of SNPs. For example, rs7959408, a SCZ SNP, overlaps human cRE 
EH37E1112284 and mouse cRE EM10E0066315. EH37E1112284 is classified as 
a distal PLS cRE because it only has high H3K4me3 signal in two cell types: WERI-
Rb-1 and bipolar spindle neurons. However, it does have high DNase signal in 
fetal brain tissue (External Table 4.13). In mice, EM10E0066315 has high DNase 
and H3K27ac signals across brain tissues (External Table 4.13). Because, 
EM10E0066315 H3K27ac z-score increases then decreases in forebrain and 
midbrain (Figure 4.6c), the K-means algorithm classified EM10E0066315 as a 
group 3 cRE; because of the steady decrease of H3K27ac signal in hindbrain, 
the K-means algorithm classified EM10E0066315 as a group 2 cRE. These 
temporal patterns in mouse embryonic brain and the complementary DNase data 
from human fetal brain suggests that this ELS cRE in only active during brain 
development. In humans, the closest protein coding gene (GENCODE V19 
annotations) to EH37E1112284 is RP11-552I14.1, which has no mouse ortholog 
and is only expressed in the testis and prostate gland (External Table 4.9). More 
recent annotations of GENCODE genes (on hg38 genome) reclassify RP11-
552I14.1 as a lincRNA gene. Therefore, we sought to identify the potential gene 
target of this ELS cRE. Using a +/- 300 kb window we analyzed expression levels 
of all protein coding, human-mouse orthologous genes. The two next closest 
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protein coding genes, C12orf42 and PAH are not expressed in brain tissue or 
neural cells. C12orf42 overall has very low expression except in testis and PAH is 
almost exclusively expressed in the liver tissues (Figure 4.6d, External Table 4.9). 
ASCL1, a gene involved with neuronal commitment and differentiation, is highly 
expressed in developing brain and has correlated gene expression with 
EM10E0066315 H3K27ac signal (r=0.78) (Figure 4.6e, External Table 4.9). 
Therefore, we predict the target gene of EH37E1112284 and rs7959408 is ASCL1. 
This analysis demonstrates how analyzing temporal patterns of activity during 
embryonic development can lead to new biological insights for SCZ and CD. 
 
Psych SNPs overlap putative binding sites for TFs involved in neural and 
immune pathways 
Since we determined psych SNPs are in cREs active in neural and brain 
tissues and likely regulate genes expressed in these tissues, we wanted to 
determine the mechanism by which these SNPs alter gene expression. One 
possibility is that psych SNPs disrupt transcription factor (TF) binding sites, thus 
altering the regulation of target genes. To test this hypothesis, we analyzed TF 
binding motifs and ChIP-seq peaks that overlap psych SNPs. 
We began by searching for TF sequence motifs overlapping each SNP 
using experimentally derived motifs from Cis-BP145 and FIMO, a motif search 
software146. In general, SCZ, MDD, and CD SNPs were enriched for TF motifs but 
this enrichment was only significant for individual SNPs, not LD blocks as a whole 
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(External Table 4.14). Conversely, while individual BPD SNPs were not enriched 
for TF motifs, BPD LD blocks were with 22 of 23 LD blocks (95%) containing a 
SNP that overlaps a motif instance. We then tested for enrichment for specific TFs 
using fisher's exact test. After selecting all enrichments with FDR < 5%, we 
clustered TFs with similar motifs (e.g. GC rich SP family motifs) using overlap 
coefficients and selected one representative TF per group based on the most 
significant p-value (Figure 4.7). 
For SCZ, MDD and CD SNPs, we observed enrichments in motifs 
corresponding to TFs with important roles in neural differentiation and brain 
development. For both SCZ SNPs and CD SNPs, SP4 was the most significantly 
enriched motif (Figure 4.8a). SP4 is primarily expressed in the brain (External 
Table 4.9) and is thought to play a role in central nervous system development147-
149. SP4 has also been previously reported as a disease susceptibility gene in 
schizophrenia150 and major depressive disorder151,152. In addition to SP4, SCZ 
SNPs were also enriched in motifs for FOXJ3, NR2F2, and LHX9 all of which are 
highly expressed in embryonic mouse brain tissue and human neural cells 
(External Table 4.9) and have roles in CNS (central nervous system) function 
development153-156. MDD SNPs were enriched for neural related transcription 
factors HOXA1 and TCF4. HOXA1 is involved with hindbrain and neural tube 
development and subsequently is highly expressed in these tissues during 
embryonic development (External Table 4.9). TCF4 is involved in initiating 
  
177 
neuronal differentiation and is primarily expressed in the brain (External Table 4.9). 
It is also a well-established SCZ susceptibility risk gene89,93-96,105,150,157-159. 
In addition to neural related TFs, psych SNPs were enriched for motifs 
related to immune response and blood cell development (Figure 4.8a). SCZ SNPs 
were enriched for MGA motifs. MGA is highly expressed in hematopoietic stem 
cells (External Table 4.9) and is linked with development cell proliferation and 
development160. CD SNPs were enriched for IRF1 motifs. IRF1, encodes an 
interferon regulatory factor, which is primarily expressed in blood cells and immune 
related tissues such as the thymus (External Table 4.9). BPD SNPs were 
significantly enriched for the SPI1 motif, a transcription factor known to regulate 
blood cell development161. MDD SNPs were enriched in motifs for RREB1, which 
is involved with cell differentiation and is a negative regulator of HLA complex162 
as well as MEIS1, which regulates hematopoietic development163. 
We then compared these enrichments with TF ChIP-seq data by 
intersecting psych SNPs with ChIP-seq peaks from 914 ENCODE experiments. 
We calculated enrichment for general TF peak overlap as well as for individual TFs 
(N=303) and cell types (N=85) using fisher's exact test, removing SNPs on 
chromosome 6 due to the overwhelming enrichment of RNA POLIII machinery at 
the MHC. Overall, all SNPs were enriched for overlapping TF peaks but only SCZ 
SNPs were enriched for specific TFs and cell types. SCZ SNPs were enriched for 
ChIP-seq peaks for 21 TFs and 14 cells types (Table 4.8). Six of the top ten most 
enriched cell types were lymphoblastoid cell lines (LCLs); only one, SK-N-SH, was 
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neural related. While this enrichment for TFs in LCLs may have biological 
significance, such as the enrichment Ripke et al. observed for SCZ SNPs in B cell 
H3K27ac peaks105, it is most likely due to fact that ENCODE TF ChIP-seq 
experiments were performed in a different subset of cell types. For example, 22 
(25%) of the cell types surveyed for TF ChIP-seq are LCLs, which is significantly 
higher compared to DNase (0.6%) and H3K27ac (0.7%) experiments. Additionally, 
unlike DNase and H3K27ac experiments, there are no ENCODE TF ChIP-seq 
experiments in human brain tissue. 
Therefore, in order to gain a better of understanding of the role of cell type 
specificity with TFs, we decided to compare the expression patterns of the 21 
enriched TFs against the other 282 TFs. While we did not observe an enrichment 
in human cell types, we observed significantly enriched expression in mouse 
embryonic brain tissues and blood cells (Figure 4C, Table 4.12). In mouse brain, 
we observed the most significant enrichments in hindbrain and midbrain at 
timepoints e11.5 and e13.5. In addition to brain, we observed enrichment for 
expression in mouse B cell and megakaryocytes (Table 4.10). This enrichment in 
both neural and immune cells compliments both the enrichments we observed in 
motifs for both neural and immune related TFs.  
One possibility for the connection between neural and immune enrichments 
is due to the dual role of some transcription factors in immune and neural 
pathways. For example, SCZ SNPs are enriched 2.5-fold in POU2F2 ChIP-seq 
peaks in lymphoblastoid cell lines GM12878 and GM12891. POU2F2 has well 
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documented roles in the immune system164 but has also been identified as a 
regulator of neuronal differentiation165. In humans, POU2F2 is highly expressed 
(30-40 tpm) in lymphoblastoid cells and bipolar spindle neurons (External Table 
4.9) and in mouse, Pou2f2 is highly expressed (30-50 tpm) during brain 
development. Therefore, the dual roles of POU2F2 and other enriched TFs in both 
neural and immune pathways may explain the enrichment that we observe for 
neural and immune system factors. Overall, psych SNPs are enriched in regions 
bound by TFs involved in neural and immune pathways. 
 
Psych SNPs disrupt sequence motifs resulting in the disruption of TF 
binding   
After identifying global enrichment patterns for psych SNPs, we wanted to 
identify specific psych SNPs that are likely to be causal. We decided to analyze 
SNPs that result in allele specific binding of TFs. Using mapped reads directly from 
the ENCODE processing DNase pipeline, we performed in silico genotyping using 
a method adapted from Maurano et al.102. We classified a SNP as heterozygous 
in a given cell-type if there were at least 15 non-redundant DNase reads at the 
locus and a ratio of minor allele reads to major allele reads greater than 0.05. 
Similar to Maurano et al, we evaluated our method using SNPs which were 
genotyped using Illumina Human 1M-Duo arrays during phase 2 of the ENCODE 
project. Though only 4.7% of the psych SNPs had more than 15 reads, our method 
had perfect sensitivity (100%) and specificity (100%). To test for allelic imbalance 
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of DNase reads at heterozygous SNPs, we used a binomial test with an FDR 
threshold of 5%. In total, we identified 263 allele specific SNPs: 129 for SCZ, 38 
for BPD, 24 for MDD and 78 for CD (External Table 4.15). We further annotated 
these psych SNPs filtering for those that also overlap TF motifs (21%) (External 
Table 4.15). Within these lists there were several examples of allelic imbalance 
with interesting biological implications -- four of which we describe in detail below.  
MDD SNP rs12552369 overlaps ELS cRE EH37E1025241, which lies in 
AK8, which encodes an adenylate kinase. AK8 is expressed in human adult 
hepatocytes and mouse developing lung and brain and has also been reported as 
a susceptibility genes for ADHD166. EH37E1025241 has high H3K27ac signal in 
endodermal cells and high DNase signal in fetal brain tissues. We observed allelic 
imbalance for DNase reads in fetal brain tissue (day 58) with reads favoring the 
alternative allele A over the reference allele G (Figure 4.9a). Rs12552369 overlaps 
a RFX2 motif site, and the reference allele results in lower log odds score 
compared to the alternative allele (Figure 4.9a). We hypothesize rs12552369 
disrupts RFX2 binding resulting in altered expression of AK8. 
SCZ SNP rs12895055 overlaps ELS cRE EH37E0354132, which lies within 
BCL11B (Figure 4.9b).  BCL11B is a transcriptional repressor that has been linked 
to T cell and neuronal development167. BCL11B is expressed in skin and brain 
tissue and its murine ortholog, Bcl11b, is highly expressed in embryonic thymus 
and brain tissue (External Table 4.9). EH37E0354132 has high DNase signal and 
H3K27ac across many different cell and tissue types (T-cells, neural cells, and 
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fetal brain) as does its orthologous mouse cRE EM10E0105028 (External Table 
4.13). We observed allelic imbalance at rs12895055 in both fetal arm muscle and 
eye tissues. DNase reads favored the reference allele, C (72%), over the 
alternative allele T (Figure 4.9b). Rs12895055 overlaps a SP4 motif, and the 
alternative allele results in lower log odds score compared to the reference allele 
(Figure 4.9b). We hypothesize rs12895055 disrupts SP4 binding therefore altering 
expression of BCL11B during brain development. 
BPD SNP rs2861405 overlaps PLS cRE EH37E1171401, which overlaps 
the TSSs of two genes ZNF490 and ZNF791 (Figure 4.9c). Rs2861405 overlaps 
a motif for IKZF1, a tumor suppressor TF linked with lymphocyte differentitation168. 
We observed allelic imbalance at rs2861405 in kidney, blood vessel and cerebellar 
cortex DNase reads all favoring the reference allele C. Interestingly, we also 
observed allelic imbalance favoring the alternative allele A in fetal muscle. While 
both ZNF490 and ZNF791 are highly expressed in many tissues, they genes are 
not expressed equally across all cell types suggesting differing regulation between 
the genes. Rs2861405 overlaps a motif site for a IKZF1 motif site that slightly 
favors reference allele C which is reflected in the observed allelic imbalance. We 
also observe binding of IKZF1 in five of the eight surveyed cell types. Therefore, 
we hypothesize that rs2861405 disrupts the binding of IKZF1 resulting changes in 
expression of ZNF490 and/or ZNF791. 
Finally, CD SNP rs73048919 overlaps EH37E0884523 a ELS cRE in 22 cell 
types and a CTCF-only cRE in 18 cell types. We detected significant allelic 
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imbalance across rs73048919 in 14 cell types with 80% of DNase reads favoring 
the reference allele, C, over the alternative allele, A (Figure 4.9d). Rs73048919 
overlaps CTCF ChIP-seq peaks in 81 ENCODE experiments including the brain 
cancer cell line SK-N-SH (Figure 4.9d). After confirming our in silico genotyping of 
rs73048919 in SK-N-SH using array genotyped SNPs in LD (rs12666575 and 
rs6461049), we observe almost complete imbalance of CTCF reads favoring the 
reference allele (Figure 4.9d). We believe this is because the minor allele of 
rs73048919 disrupts a CTCF motif site reducing the log odds score of matching 
the motif. Unlike the previous examples it is difficult to determine the biological 
consequence of this imbalance. CTCF-only cREs may have different biological 
functions such as insulators, repressors or anchors of three-dimensional chromatin 
loops. Since we also observed allelic imbalance of RAD21, a component of the 
cohesion complex, we propose that in SK-N-SH EH37E0884523 may be an anchor 
for chromatin loops mediate by cohesion. However, in order to truly elucidate the 
function of EH37E0884523 we need to perform additional experiments such as 
CRISPR-CAS9. 
 
DISCUSSION 
In this chapter, we used the Registry of cREs and data from the ENCODE, 
Roadmap and GTEx consortia to annotate noncoding variants associated with 
psychiatric disorders. We observed overwhelming evidence for the role of psych 
SNPs in neuronal development and function. We demonstrated that SCZ and CD 
  
183 
SNPs are enriched in cREs active in brain tissue and neuronal precursor cells and 
that these cREs likely target genes expressed in these tissues. While these results 
are not surprising, they do reaffirm the role for neural development pathways in the 
onset of psychiatric disorders. 
 
The most significantly enriched TF motif for both SCZ and CD SNPs was 
for SP4, which we demonstrated has high expression in human neural cells and 
mouse developing brain. We were also able to identify a potential SP4 binding site 
within a ELS cRE that we believe is disrupted by the alternative allele ultimately 
affecting the expression of BCL11B. This strong enrichment for SP4 is of particular 
interest due to previously established link between SP4 and psychiatric disorders. 
SP4 has previously been reported as a disease susceptibility gene for BPD152,169 
and groups have reported altered SP4 levels in the brain of patients with SCZ and 
BPD170,171 However, some of the most striking evidence for the role of SP4 in 
neural development is from Zhou et al who demonstrated hypomorphic SP4 mice 
undergo changes in behavior and memory formation analogous to symptoms of 
psychiatric disorders172,173. 
Additionally, we demonstrated that we can gain additional insight into the 
temporal dynamics of cRE activity during brain development. In order to properly 
study the developing human brain, we would need to collect fetal brain samples 
for DNase and ChIP-seq experiments at uniform time intervals. Even if we could 
accomplish this very difficult task there are many factors that may bias results such 
as gender, genetic background, and gestational conditions. During ENCODE3, 
  
184 
production groups were about to precisely harvest brain regions at specific time 
points from genetically identical mice. Because of this, we are able to clearly see 
patterns of activity over time for cREs and identity potential therapeutic targets. 
For example, EM10E0066315 and ASCL1 are only active during brain 
development and therefore would not likely be a therapeutic target for an adult 
presenting with SCZ. However, EH37E0250841 and CACNA1C are active 
throughout adulthood and may present a better potential target. Our findings also 
enable us to use mouse models in the future to understand the global response of 
these variants. Since we demonstrated that psych SNPs are enriched in cREs that 
are active in mouse brain tissues, we can further investigate the role of these cREs 
through mouse transgenic assays and CRISPR-Cas9 experiments.  
While our analysis supports a strong link between psych SNPs and neural 
development, our data also suggests that factors linked with the immune system 
have a role in the genetic risk for psychiatric disorders. We observed enrichments 
for cREs active in immune tissues, fetal thymus for SCZ, T-cells for BPD SNPs, 
and lymphoma cells for CD SNPs. We also observed enrichment of motifs for TFs 
with strong links to the immune system such as IRF1, RREB1, and MEIS1.  
There have been several studies suggesting that dysregulation in the 
immune system has a role in the onset of psychiatric disorders. Smith was one of 
the first to propose the involvement of the immune system with his macrophage 
theory of depression174 and macrophage-T-lymphocyte theory of 
schizophrenia175,176. Additionally, Schwarz and colleagues proposed the Th2-
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hypothesis of schizophrenia in which certain subgroups of schizophrenia patients 
had altered ratio of Th1 cells vs. Th2 cells resulting in differing ratios of cell specific 
cytokines177,178. There have been numerous studies looking at the levels of 
cytokines in blood samples of patients with psychiatric disorders. Results from 
some of these studies are inconsistent with one another due to complexity of 
psychiatric disorders. For example, difference in results have been attributed to 
the psychiatric state of the patient during sample collection (e.g. manic episode, 
first psychotic episode, latent period)179,180. However, there is a general pattern of 
dysregulation of many different cytokines. Imbalances in cytokines could directly 
lead to the onset of psychiatric disorders or could be the results of the 
dysregulation of immune pathways that have roles in regulating the CNS. Recently, 
Filiano et al. demonstrated that reducing the number of meningeal T cells in mice 
resulted in a decrease of social behaviors analogous to autism and 
schizophrenia181.  
One hypothesis is that genes involved with the onset of psychiatric disorders 
have duels roles in both immune and neural development pathways. For example, 
BCL11B and POU2F2, two genes we report as potential psych risk genes, have 
important roles in both the immune system and neural development. Therefore, it 
is possible that the dysregulation of these genes during embryonic development 
alters brain structure and connections leaving the patient more susceptible to 
developing a psychiatric disorder. These genes are also dysregulated in the adult 
immune system, but this is not causal towards developing a psychiatric disorder. 
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We hope to test this hypothesis by analyzing cell type specific activity patterns and 
integrating results from additional GWAS. 
Even though the signal for the majority of LD blocks can be explained by 
SNPs in cREs, we currently cannot explain the signal for 21% of the LD blocks. 
This could be for a variety of reasons. First, SNPs in these LD blocks may overlap 
cREs that we have yet to annotate. While we have surveyed over 500 biosamples, 
we have not covered every type of cell in the human body. Additionally, even if we 
have surveyed the cell type, our current method of curating cREs requires a cRE 
to have both high DNase signal (Z-score > 1.64) and high H3K4me, H3K27ac, or 
CTCF signal in at least one cell type. Some cell types such as fetal brain tissue 
only have DNase signal and therefore we are unable to curate cREs specific to 
these tissues without additional experiments. Also, psych SNPs may overlap cREs 
specific to a particular neural cell type such as neurons or glial cells; tissues 
collected from different brain regions are comprised of many different cell types so 
signals from a particular cell type may become diluted. Second, the signal for some 
of these LD blocks may be explained by SNPs that function at the level of 
transcriptomic regulation versus genomic regulation. These variants may disrupt 
RNA binding proteins sites, splicing sites or microRNA target sites, altering final 
protein production. In the future, we can consider these option by analyzing eCLIP 
and RNA-seq data to further annotate these variants. 
Overall our results suggest that genetic variants associated with psychiatric 
disorders effect the regulation of genes involved in neural development pathways 
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and that while components of the immune system may also play a role, the nature 
of their contribution remains unknown. 
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FIGURES 
 
Figure 4.1 | Top tissues with enhancer-like cREs enriched for psych SNPs. 
Enrichment for a, Human cell types with cREs enriched for psych SNPs. Pie charts 
indicated the number of LD blocks that overlap cREs. Bars indicapte Z-score of –log(p) 
for each enrichment. MDD SNPs did not have any enrichments with p<0.05. b, 
Embryonic mouse tissues with orthologous cREs enriched for psych SNPs. Pie charts 
indicated the number of LD blocks that overlap orthologous mouse cREs. Colors indicate 
Z-score of –log(p) for each enrichment. BPD SNPs did not have any enrichments with 
p<0.05. 
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Figure 4.2 | Enrichment for Psych SNPs in cREs with high H3K27ac signal. 
Enrichment for a, schizophrenia, b, bipolar disorder, c, major depressive disorder, and d, 
cross disorder SNPs in cREs with H3K27ac activity. X axis indicates –log(p). Color 
indicates tissue of origin with purple representing brain tissue and neural cells and red 
indicating immune tissue and blood cells 
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Figure 4.3 | SCZ SNP genes are enriched for brain expression and neural pathway 
terms. Enrichment for expression of a, eQTLs genes, b, closest genes, and c, genes 
within 100 kb for SCZ SNPs in GTEx tissues. Color indicates tissue of origin with purple 
representing brain tissue and neural cells. d, Enrichment for expression of SCZ closest 
genes in ENCODE d, human cell types and e, mouse embryonic tissues. f, Enriched 
gene ontology terms for SCZ closest genes. 
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Figure 4.4 | Determining genes associated with psych SNPs. a, Distribution of 
distances between ELS-genein POLII ChIA-PET dataset. 86% of pairs occur within 100 
kb.  b, Overlap of genes called by three different methods: green = eQTLs, red=closest 
gene, blue= all genes within 100 kb. 
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Figure 4.5 | Analysis of cRE activity across brain development. a, H3K27ac Kmeans 
clustering of H3K27ac signal across embryonic time points results in four clusters. b, 
Overlap of cREs in each group between brain subregions. cREs tend to be in the same 
activity group in all three brain subregions. Color indicates overlap coefficient. c, 
Expression of closest protein coding genes linked with cREs in each group. d, Enriched 
gene ontology terms for genes linked with cREs in each group. 
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Figure 4.6 | Psych SNPs overlap orthologous mouse cREs active throughout brain 
development. a, H3K27ac Z-score signal at EM10E0283811, whose orthologous cRE 
overlaps CD SNP rs12424245. Color in heatmap indicates H3K27ac Z-score. b, 
Expression of Cacna1c across embryonic development with focus on brain subregions. 
Color in heatmap indicates Log(TPM). c, H3K27ac Z-score signal at EM10E00066315, 
whose orthologous cRE overlaps SCZ SNP rs7959408. Color in heatmap indicates 
H3K27ac Z-score. d, Expression of Ascl1 across embryonic development with focus on 
brain subregions. Color in heatmap indicates Log(TPM). e, Expression of protein coding 
genes near EM10E00066315 across mouse embryonic development. Noncoding genes 
are shown in gray. Color in heatmap indicates Log(TPM). 
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Figure 4.7 | Clustering of enriched transcription factor motifs. We connected motifs 
if they overlapped the same SNP with the thickness of the line indicating the number of 
common SNPs. Size of each motif is relative to its -log(FDR). For each cluster, we 
reported the most significant motif. 
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Figure 4.8 | Psych SNPs are enriched for motifs and binding sites of TFs involved 
in neural and immune pathways. a, Enriched TF motifs at psych SNPs. b, Enriched 
expression in mouse tissues and cell types for TF peaks enriched at SCZ SNPs. Colors 
indicate tissue of origin with purple for brain tissue and red for blood. 
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Figure 4.9 | Examples of allele specific chromatin accessibility and TF binding at 
psych SNPs. Allele specific chromatin accessibility at a, MDD SNP rs12552369, b, SCZ 
SNP rs12895055, c, BPD SNP rs2861405  and d, CD SNP rs73048919. Pie charts 
indicate percentage of reads with each allele. Numbers next to motif sequences indicate 
FIMO score for the TF motif at each sequence. 
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TABLES 
 
Table 4.1 | GWAS studies included in analysis 
Disorder Authors PMID Publication Date 
# Reported 
Variants 
Schizophrenia 
(SCZ) 
Schizophrenia Working 
Group of the Psychiatric 
Genomics Consortium 
25056061 July 2014 98 
Bipolar Disorder 
(BPD) Jiang and Zhang 21254220 Feb 2011 24 
Major Depressive 
Disorder (MDD) GENDEP 23377640 Feb 2013 49 
Cross-disorders 
Cross-Disorder Group of the 
Psychiatric Genomics 
Consortium. 
23453885 April 2013 74 
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Table 4.2 | Genetic context of psych SNPs 
 
 Psychiatric Disorders 
 Schizophrenia Bipolar Disorder 
Major Depressive 
Disorder Cross-Disorder 
 # SNPs % SNPs # SNPs % SNPs # SNPs % SNPs # SNPs % SNPs 
Coding Exon 38  1.11% 3  0.41% 1 0.13% 24  1.35% 
UTR 88  2.57% 18  2.45% 7 0.90% 34  1.91% 
Intron 2,226  65.13% 450  61.22% 268 34.49% 1,274  71.41% 
Intergenic 1,066  31.19% 264  35.92% 501 64.48% 452  25.34% 
         
Proximal 505  14.77% 76  10.34% 50 6.44% 285  15.98% 
Distal 2,913  85.23% 659  89.66% 727 93.56% 1,499  84.02% 
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Table 4.3 | Deleterious predictions for psych SNPs overlapping coding exons 
Study SNP Protein Reference AA 
Alternative 
AA 
PROVEAN 
Prediction 
SIFT 
Prediction 
SCZ rs4584886 ENSP00000326870 R W Deleterious Damaging 
SCZ rs2955365 ENSP00000205890 A T Neutral Damaging 
SCZ rs2955367 ENSP00000205890 W G Neutral Damaging 
SCZ rs12596883 ENSP00000457441 E D Neutral Tolerated 
SCZ rs13107325 ENSP00000349174 A T Neutral Tolerated 
SCZ rs20551 ENSP00000263253 I V Neutral Tolerated 
SCZ rs3176443 ENSP00000354481 L V Neutral Tolerated 
SCZ rs3617 ENSP00000415769 Q K Neutral Tolerated 
SCZ rs950169 ENSP00000286744 T I Neutral Tolerated 
SCZ rs10117 ENSP00000297185 L L Neutral Tolerated 
SCZ rs10414643 ENSP00000394510 L L Neutral Tolerated 
SCZ rs1047361 ENSP00000384899 S S Neutral Tolerated 
SCZ rs1051431 ENSP00000445859 Y Y Neutral Tolerated 
SCZ rs1143702 ENSP00000353030 Y Y Neutral Tolerated 
SCZ rs13189822 ENSP00000261483 Q Q Neutral Tolerated 
SCZ rs2074090 ENSP00000262815 S S Neutral Tolerated 
SCZ rs216193 ENSP00000263073 A A Neutral Tolerated 
SCZ rs2229193 ENSP00000332549 L L Neutral Tolerated 
SCZ rs2274267 ENSP00000439065 T T Neutral Tolerated 
SCZ rs2955355 ENSP00000268719 G G Neutral Tolerated 
SCZ rs2955366 ENSP00000205890 P P Neutral Tolerated 
SCZ rs3743739 ENSP00000219345 G G Neutral Tolerated 
SCZ rs3745474 ENSP00000246794 F F Neutral Tolerated 
SCZ rs3745475 ENSP00000394510 P P Neutral Tolerated 
SCZ rs4368210 ENSP00000326870 L L Neutral Tolerated 
SCZ rs4685 ENSP00000335321 V V Neutral Tolerated 
SCZ rs5629 ENSP00000244043 R R Neutral Tolerated 
SCZ rs6163 ENSP00000358903 S S Neutral Tolerated 
SCZ rs62021888 ENSP00000260402 R R Neutral Tolerated 
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SCZ rs7148456 ENSP00000338814 P P Neutral Tolerated 
SCZ rs749240 ENSP00000263073 Q Q Neutral Tolerated 
SCZ rs769267 ENSP00000262815 P P Neutral Tolerated 
SCZ rs788018 ENSP00000335321 G G Neutral Tolerated 
SCZ rs788023 ENSP00000335321 K K Neutral Tolerated 
SCZ rs8539 ENSP00000340019 K K Neutral Tolerated 
SCZ rs9611519 ENSP00000216237 P P Neutral Tolerated 
SCZ rs9806806 ENSP00000332549 R R Neutral Tolerated 
SCZ rs4072738 record not found     
BPD rs10458896 ENSP00000263181 I V Neutral Tolerated 
BPD rs2297815 ENSP00000354623 V V Neutral Tolerated 
BPD rs4804725 record not found     
MDD rs4777035 ENSP00000403392 P L Neutral Damaging 
CD rs678 ENSP00000273283 E V Deleterious Damaging 
CD rs214967 ENSP00000341887 S L Neutral Damaging 
CD rs3132580 ENSP00000417182 E K Neutral NA 
CD rs1042779 ENSP00000273283 Q R Neutral Tolerated 
CD rs41273537 ENSP00000358064 M V Neutral Tolerated 
CD rs3094086 ENSP00000417182 S S Neutral NA 
CD rs1058766 ENSP00000338629 R R Neutral Tolerated 
CD rs11121172 ENSP00000338629 R R Neutral Tolerated 
CD rs13596 ENSP00000338629 P P Neutral Tolerated 
CD rs2071702 ENSP00000436786 N N Neutral Tolerated 
CD rs2229193 ENSP00000332549 L L Neutral Tolerated 
CD rs2230534 ENSP00000233027 P P Neutral Tolerated 
CD rs2230535 ENSP00000233027 L L Neutral Tolerated 
CD rs2275271 ENSP00000402831 S S Neutral Tolerated 
CD rs2523721 ENSP00000391879 R R Neutral Tolerated 
CD rs3740387 ENSP00000339479 D D Neutral Tolerated 
CD rs6951493 ENSP00000265854 H H Neutral Tolerated 
CD rs7107305 ENSP00000436786 L L Neutral Tolerated 
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CD rs72696841 ENSP00000358064 S S Neutral Tolerated 
CD rs748002 ENSP00000264051 A A Neutral Tolerated 
CD rs9324 ENSP00000273283 S S Neutral Tolerated 
CD rs9332801 ENSP00000436786 I I Neutral Tolerated 
CD rs943037 ENSP00000402831 A A Neutral Tolerated 
CD rs9806806 ENSP00000332549 R R Neutral Tolerated 
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Table 4.4a | Overlap of psych SNPs with cREs 
 GWAS Control   
Study Total # SNPs 
# Overlap 
cREs Percent 
Total # 
SNPs 
# Overlap 
cREs Percent Enrichment P-value 
SCZ 3418 687 20.10% 1635798 298134 18.23% 1.10 5.19E-03 
BPD 735 150 20.41% 371792 67310 18.10% 1.13 1.13E-01 
MDD 777 159 20.46% 715619 114342 15.98% 1.28 1.01E-03 
CD 1784 409 22.93% 1198932 211708 17.66% 1.30 1.76E-08 
 
Table 4.4b | Overlap of LD Blocks with cREs 
 GWAS Control   
Internal 
ID 
Total # LD 
Blocks 
# Overlap 
cREs Percent 
Total # LD 
Blocks 
# Overlap 
cREs Percent Enrichment P-value 
SCZ 96 78 81.25% 47408 37518 79.14% 1.03 7.06E-01 
BPD 23 20 86.96% 11221 8901 79.32% 1.10 4.51E-01 
MDD 43 34 79.07% 21276 16002 75.21% 1.05 7.24E-01 
CD 71 49 69.01% 36298 27849 76.72% 0.90 1.24E-01 
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Table 4.5 | Type of overlapping cREs 
 
 PLS cREs ELS cREs CTCF-only cREs 
Disorder # % # % # % 
Schizophrenia 150 26.83% 387 69.23% 22 3.94% 
Bipolar Disorder 21 19.63% 78 72.90% 8 7.48% 
Major Depressive Disorder 15 12.82% 98 83.76% 4 3.42% 
Cross-Disorder 68 20.86% 253 77.61% 5 1.53% 
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Table 4.6 | Overlap of eQTLs and psych SNPs 
 
 GWAS Control  
Disorder # eQTL SNPs % Total SNPs # eQTL SNPs % Total SNPs P-value 
SCZ 2171 63.52% 757632 46.32% 1.87E-90 
BPD 189 25.71% 142694 38.38% 5.24E-13 
MDD 217 27.93% 223867 31.28% 4.41E-02 
CD 868 48.65% 495409 41.32% 4.34E-10 
      
Disorder # eQTL LD Blocks 
% Total LD 
Blocks 
# eQTL LD 
Blocks 
% Total LD 
Blocks P-value 
SCZ 52 54.17% 18707 39.46% 4.52E-03 
BPD 10 43.48% 3641 32.45% 2.70E-01 
MDD 11 25.58% 5600 26.32% 1.00E+00 
CD 35 49.30% 12403 34.17% 8.52E-03 
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Table 4.7 | Enriched gene ontology terms for SCZ closest genes 
Category Term Fold Enrichment P-Value 
GO Cellular Component postsynapse (GO:0098794) 5.81 3.82E-06 
GO Cellular Component neuron projection (GO:0043005) 3.44 1.43E-05 
GO Cellular Component somatodendritic compartment (GO:0036477) 4.16 5.46E-05 
GO Cellular Component neuron part (GO:0097458) 3.01 7.47E-05 
GO Cellular Component dendrite (GO:0030425) 4.71 2.13E-04 
GO Cellular Component postsynaptic density of dendrite (GO:0014069) 7.45 4.79E-04 
GO Cellular Component postsynaptic specialization (GO:0099572) 7.42 5.02E-04 
GO Cellular Component asymmetric synapse (GO:0032279) 7.31 5.80E-04 
GO Cellular Component neuron to neuron synapse (GO:0098984) 7.24 6.38E-04 
GO Biological Process modulation of chemical synaptic transmission (GO:0050804) 6.14 7.96E-04 
PANTHER Pathways Nicotine pharmacodynamics pathway (P06587) 19.93 1.02E-03 
GO Cellular Component synapse part (GO:0044456) 3.73 1.29E-03 
GO Cellular Component synapse (GO:0045202) 3.42 1.30E-03 
GO Cellular Component neuronal cell body (GO:0043025) 4.63 1.47E-03 
GO Cellular Component cell projection (GO:0042995) 2.36 3.80E-03 
GO Cellular Component plasma membrane bounded cell projection (GO:0120025) 2.37 5.10E-03 
GO Cellular Component cell body (GO:0044297) 4.06 7.20E-03 
GO Cellular Component postsynaptic membrane (GO:0045211) 6.08 9.84E-03 
GO Biological Process regulation of membrane potential (GO:0042391) 4.73 1.71E-02 
PANTHER Pathways Nicotinic acetylcholine receptor signaling pathway (P00044) 8.05 1.88E-02 
GO Cellular Component synaptic membrane (GO:0097060) 5.05 1.90E-02 
GO Biological Process chemical synaptic transmission, postsynaptic (GO:0099565) 11.86 2.27E-02 
GO Molecular Function gated channel activity (GO:0022836) 4.91 2.37E-02 
GO Biological Process biological regulation (GO:0065007) 1.31 3.45E-02 
GO Biological Process regulation of neurogenesis (GO:0050767) 3.49 4.13E-02 
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Table 4.8 | Enriched TF ChIP-seq peaks overlapping SCZ SNPs 
TF Fold Enrichment P-value FDR 
BCLAF1 3.6255 2.38E-04 2.85E-02 
TAF1 2.1440 3.06E-04 2.85E-02 
TAF7 3.2253 3.53E-04 2.85E-02 
ZNF263 2.2811 3.76E-04 2.85E-02 
POU2F2 2.5088 5.81E-04 3.52E-02 
CCNT2 2.5539 7.34E-04 3.71E-02 
USF1 2.0150 9.89E-04 3.78E-02 
PHF8 2.3665 1.08E-03 3.78E-02 
SREBF1 3.0027 1.12E-03 3.78E-02 
SAP30 2.8971 1.49E-03 4.40E-02 
CEBPD 3.2675 1.83E-03 4.40E-02 
eGFP-ATF1 1.9465 2.03E-03 4.40E-02 
NBN 2.7484 2.25E-03 4.40E-02 
RFX5 2.2771 2.28E-03 4.40E-02 
ZNF207 2.8709 2.63E-03 4.40E-02 
eGFP-ZBTB11 2.1681 2.64E-03 4.40E-02 
FLAG-SSRP1 2.8535 2.74E-03 4.40E-02 
eGFP-ELF1 2.3168 2.76E-03 4.40E-02 
SIN3A 1.7325 2.85E-03 4.40E-02 
TBP 1.8900 2.90E-03 4.40E-02 
TARDBP 2.1932 3.26E-03 4.70E-02 
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Table 4.9 | Enriched cell types with TF ChIP-seq peaks overlapping SCZ SNPs 
TF Fold Enrichment P-value FDR 
GM15510 2.97 1.51E-04 9.89E-03 
GM10847 3.33 2.68E-04 9.89E-03 
HEK293 1.82 4.02E-04 9.89E-03 
GM19099 2.64 5.27E-04 9.89E-03 
GM18526 2.88 5.82E-04 9.89E-03 
SK-N-SH 1.59 1.81E-03 2.17E-02 
PFSK-1 2.14 2.23E-03 2.17E-02 
GM19193 2.28 2.28E-03 2.17E-02 
H1-hESC 1.44 2.43E-03 2.17E-02 
GM18505 2.34 2.55E-03 2.17E-02 
Panc1 2.07 3.03E-03 2.31E-02 
Raji 2.37 3.26E-03 2.31E-02 
GM18951 2.07 4.13E-03 2.69E-02 
Ishikawa 1.79 4.42E-03 2.69E-02 
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Table 4.10 | Top 10 mouse RNA-seq experiments with enriched expression for TF 
Tissue/Cell Types Enriched Expression 
Background 
Expression 
~ Fold 
Enrichment P-value FDR 
B10.H-2aH-4bp/Wts 
CH12.LX 39.86 13.87 2.87 1.18E-03 3.78E-02 
C57BL/6 hindbrain 
embryo (11.5 days) 31.75 18.65 1.70 4.60E-03 3.78E-02 
C57BL/6 midbrain 
embryo (13.5 days) 39.86 18.26 2.18 5.22E-03 3.78E-02 
C57BL/6 midbrain 
embryo (11.5 days) 35.90 19.29 1.86 5.60E-03 3.78E-02 
C57BL/6 forebrain 
embryo (13.5 days) 38.17 20.49 1.86 6.45E-03 3.78E-02 
C57BL/6 midbrain 
embryo (16.5 days) 24.05 15.55 1.55 7.40E-03 3.78E-02 
C57BL/6 forebrain 
embryo (11.5 days) 46.56 22.09 2.11 7.43E-03 3.78E-02 
C57BL/6 hindbrain 
embryo (13.5 days) 30.95 17.58 1.76 7.85E-03 3.78E-02 
C57BL/6 megakaryocyte 
male adult (5-6 weeks) 23.19 13.56 1.71 8.99E-03 3.78E-02 
C57BL/6 midbrain 
embryo (12.5 days) 41.95 25.41 1.65 9.06E-03 3.78E-02 
 
 
  
  
209 
EXTERNAL FIGURES AND TABLES  
These figures and tables are too large to include in the PDF version of this 
thesis. They are available online at 
https://drive.google.com/drive/folders/0B07orkTYRj9pRy1IdE9JUVVYTzA?usp=s
haring 
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METHODS 
 
Generating Control Datasets 
For each lead SNP from the NHGRI GWAS catalog182,183, we selected a 
random SNP from the SNP chip used in the study that fell in the same minor allele 
frequency (MAF) quartile and distance from transcription start site (TSS) quartile 
as the lead SNP. For each of the control SNPs, we extracted all SNPs in LD 
(r2>0.7) based on phasing analysis from the 1000 Genomes Project European 
population (EUR)113 using the HaploReg Database106. This constituted one control 
dataset. We generated 500 control datasets for each GWAS. This method was 
adapted from the Understanding Enrichment Through Simulation (UES) algorithm 
from the Klein lab101. 
 
Testing for Enrichment in cRE Activity 
Using Bedtools (v25.5.0) we intersected psych and control SNPs with cREs 
from the Registry of cREs. To assess whether the cREs in a cell type were 
enriched in psych SNPs, we select all cREs overlapping psych or control SNPs 
with cREs that have a H3K27ac/DNase Z-score > 2 in the cell type. To avoid over 
counting, we pruned the overlaps, counting each LD group once per cell type. We 
calculated enrichment between GWAS LD groups with the 500 matched controls 
using a one-sided Fisher's exact test. Finally, we applied an FDR of 5% to each 
study. To compare relative enrichments across studies, we calculated Z-scores of 
the -log(p-value).  
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Enrichment for Gene Expression 
For each cell type, we tested whether the psych genes group had higher 
expression than the control group using a one-sided Wilcoxon-Rank Sum test. 
We used gene expression values generated by the GTEx consortium108 and the 
ENCODE project. We also considered mouse datasets for which we compared 
the expression of genes with ortholgous mouse genes as defined by the Jackson 
laboratory (HOM_MouseHumanSequence.rpt) 
 
Gene Ontology Analysis 
We performed gene ontology analysis using the online tool Panther's  
statistical overrepresentation test (http://pantherdb.org/). For all analyses, we 
reported enrichments from five collections: GO Molecular Function, GO Biological 
Process, GO Cellular Component, Reactome Pathways, and Panther Pathways. 
We only report categories with a Bonferroni p-value < 0.05.  
 
Temporal Clustering of Brain cREs 
We selected all mouse cREs that had a DNase Z-score > 1.64 and H3K27ac 
Z-score > 1.64 for at least one brain region time point. For each of these brain 
cREs we extracted their Z-score signal for forebrain, midbrain, and hindbrain. For 
each cRE in each tissue, we normalized the range of Z-scores so that all values 
fell between 0 and 1. Using the elbow method, we determined the optimal number 
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of clusters was four. We then implemented K-means clustering for each tissue 
using the python scikit learn package.  
 
 
Determining Overlapping Motifs 
For each psych SNP, we generated major and minor allele sequences for 
41 bps window centered on the SNP. Using the FIMO algorithm, we searched for 
motifs from the CISBP transcription factor database145. We selected all motifs that 
overlapped a psych SNP with a q-value < 0.05. We tested for motif enrichment by 
comparing the fraction of psych SNPs overlapping each motif compared to the 
control SNPs using one-sided fisher's exact test and applying an FDR of 5%. 
 
Enrichment for TF Binding Sites 
We intersected psych and control SNPs with optimal IDR ChIP-seq peaks 
from 914 ENCODE experiments. To assess whether psych SNPs we enriched for 
a TF binding sites, we used a one-sided Fisher's exact test comparing the number 
psych SNPs overlapping peaks vs control SNPs after pruning for LD. We ran three 
tests: 1) analyzing TFs 2) analyzing cell types, and 3) analyzing individual 
experiments.  In all three cases we applied an FDR of 5%. 
 
Testing for Allele Specificity 
To test for allele specificity, began by first identifying heterozygous loci. 
For each psych SNP, we determined for which cell types it overlapped an active 
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cRE (DNase Z-score). For these cell types, we downloaded mapped reads 
DNase reads (bam files) and determined the allele at the SNP. We considered a 
locus heterozygous if it has at least 15 reads at the ratio of the alternative allele 
to reference allele was at least 0.05. If a SNP was heterozygous, we tested for 
allele specificity in that cell type using a two-sided Fisher's exact test. We 
evaluated our in silico genotyping method using genotyping results generated by 
the ENCODE consortium: wgEncodeHaibGenotypeBalleleSnp2015-03-04.tsv 
 
Scripts 
Scripts for this analysis can be found on GitHub: https://github.com/Jill-
Moore/Dissertation/tree/master/Chapter-IV/ 
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CHAPTER V: Conclusions and Future Directions 
 
Introduction 
In this thesis, we described the Registry of candidate Regulatory Elements, 
a collected of putative regulatory regions we curated across the human and mouse 
genomes. We demonstrated several biological applications of cREs, in particular 
their use in annotating variants reported by genome wide association studies 
(GWAS). In Chapter III, we evaluated methods for linking cREs with potential target 
genes. We developed a benchmark of ELS-gene links which we used to test 
correlation methods and Random Forest models. In Chapter IV, we demonstrated 
the usefulness of the Registry by annotating genetic variants associated with 
psychiatric disorders. Our results suggest that in GWAS variants disrupt neural 
pathways and may also play a role in the immune system.  
 
The Registry of cREs and Future Plans for Expansion 
Chapter II of this thesis detailed the creation and implementation of the 
Registry of cREs. We curated this registry by integrating hundreds of DNase-seq 
and ChIP-seq datasets, generating over 1.3 million cREs in human and 400 
thousand cREs in mouse. We classified these cREs into groups using H3K4me3, 
H3K27ac, and CTCF ChIP-seq signals and extended these classification schemes 
to generate cell type specific annotations for every cRE. We based these 
classification schemes on unsupervised enhancer prediction methods that we 
developed using embryonic mouse data. In this analysis, we determined that 
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combining DNase and H3K27ac data was the best performing method and we 
used this method to predict enhancers which were validated using transgenic 
mouse assays. Subsequent analyses of our classification schemes demonstrated 
they are concordant with other enhancer prediction methods, particularly those that 
also integrate epigenomic datasets. We further demonstrated the utility of the 
registry of cREs by annotating variants reported by GWAS, particularly in Chapter 
IV where we focused on SNPs associated with psychiatric disorders. 
Unlike other collections of regulatory elements, The Registry of cREs has 
several unique features which make it useful for biological research. First, we 
accessioned all cREs so they can be accurately referenced in presentations and 
publications. Other tools generate run-specific identifiers for their called regions, 
but these are not maintained during subsequent uses of the programs. 
Additionally, the Roadmap Epigenomics Consortium generated genome 
segmentations for 3 different ChromHMM models (15 state, 18 state and 25 state 
models). Determining the exact elements a paper used may be difficult if the 
authors do not specifically mention which set of segmentations they used. Second, 
boundaries of cREs are fixed across cell types, which allows us to evaluate the 
cell type specificity of a cRE. While not all elements retain the same boundaries 
between cell types, we have observed that the vast majority do within 50 bp. In the 
future, we can further annotate cREs with estimated boundaries in each cell type 
using overlapping DHSs. Third, to annotate and investigate cREs, users can 
download the Registry from the ENCODE portal or use our web based tool 
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SCREEN. Unlike other web-based catalogs of regulatory elements, SCREEN is 
user friendly, especially for biologists without a computational background. 
Additionally, by integrating other data from the ENCODE Encyclopedia and the 
NHGRI-EBI GWAS catalog, users can easily characterize regions of interest. The 
Registry of cREs also bridges the gap between mouse and human for comparing 
gene regulation. Users can investigate cREs that are ortholgous between the 
species, which ultimately allows them to survey different types of data across new 
cell types. 
Moving forward, we plan on expanding the Registry of cREs. During Phase 
IV of the ENCODE project, production labs will generate new DNase-seq and 
histone modification ChIP-seq datasets which we will incorporate into the registry. 
We are collaborating with data production labs to expand the Registry in two ways. 
One to generate datasets that will increase the number of cell types with four core 
epigenomic marks (DNase, H3K4me3, H3K27ac, and CTCF). We currently have 
21 cell types with all four marks and by increasing this number we can further 
analyze cREs for tissue specificity and different regulatory roles across cell types. 
Two, generate datasets from underrepresented cell types that are not currently 
covered by the Registry. Using publicly available data processed by CISTROME, 
we plan on identifying cell types with a low numbers of overlapping histone 
modification peaks or DHSs and will prioritize these cell type for data generation.  
We also aim to identify new classes of regulatory elements such as 
repressors. While labs have experimentally characterized repressive elements, 
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there are currently no methods for computationally predicting them. One possible 
direction is to study REST ChIP-seq binding sites. As mentioned in Chapter I, 
REST is a repressive transcription factor that binds at RE-1 elements and prevents 
the transcription of neuronal genes in non-neuronal cell types20 . The ENCODE 
consortium has generated REST ChIP-seq data for over 25 cell types. Using the 
Registry of cRE we can determine if REST binding sites overlap 1) our current set 
of cREs, or 2) rDHSs that are not currently classified as cREs. If the former, this 
suggests that: a) repressors are also enriched for H3K27ac signal, b) repressors 
act as enhancers in other cell types, or c) the majority of REST binds to enhancers. 
If the latter, we can determine which features (TF signal, histone modification 
signal, sequence motifs) are enriched at rDHSs with REST binding and using these 
features, identify cREs that are likely to silence gene expression. In addition to 
identifying new classes of cREs, we hope to develop a more sophisticated 
classification scheme for cREs. We currently categorize cREs in generalized 
groups, which make interpretation easy but may miss finer biological features. For 
example, we currently classify all proximal cREs with high H3K4me3 signal as 
PLS. However, we have observed that PLS cRE that directly overlap TSS have 
different features than those that do not. Therefore, we might be able to split these 
cREs into two distinctive classes. In cell types such as GM12878, K562 and H1-
hESCs, we hope to integrate TF data and cluster cREs based on TF binding to 
observe if there are any natural classes of elements. These analyses may reveal 
sub-types of regulatory elements. 
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Evaluating Methods Prediction Enhancer-Gene Links 
In order to accurately evaluate enhancer-gene linking methods we 
developed a benchmark of ELS-gene pairs base on chromatin and genetic 
interaction data. We used this benchmark to test correlation base methods and 
found they had low overall performance. While these methods can identify ELS-
gene pairs, they have extremely high false negative and positive rates. These 
results suggest that previous work by ENCODE labs may not identify the correct 
target gene and should be used with caution. We then developed Random Forest 
models which had remarkable improvement over unsupervised approaches and 
can be applied across cell types. Finally, we demonstrated the practical 
applications of target gene predictions by identifying a novel GWAS gene 
associated with multiple sclerosis. 
We felt that it was important to included different types of genomic 
interaction data in our benchmark because each experiment assays a different 
type of interaction. For example, POLII ChIA-PET links tend to be close together 
and occur within the larger domain of CTCF ChIA-PET links67. Eventually, we hope 
to train models that will be able to identify specific links; for example, using 
Shannon Entropy, we can predict whether an ELS cRE is more likely to be an a 
CTCF loop (ubiquitous activity) or POLII loop (cell type specific activity). In the 
future, we also hope to expand our benchmark. During phase IV of the ENCODE 
project, the Ruan and Aiden labs plan on generating new ChIA-PET and Hi-C 
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datasets for cell types covered by the Registry of cREs. Therefore, we will 
incorporate these new links into our benchmark. Additionally, we plan on adding 
confidence levels to our benchmark. With our proposed classification scheme, 
most of our ELS-gene pairs would be considered a "bronze" standard (i.e. they are 
supported by one type of link). A subset of the pairs would be considered a "silver" 
standard if they are supported by both physical and genetic interactions (i.e. Hi-
C/ChIA-PET and eQTLs). Finally, if some of these predictions are experimentally 
validated using genome editing techniques, we will label them as a "gold" standard. 
Expanding this benchmark will enable us to further refine our methods as well as 
continue to annotate the registry of cREs. 
One interesting result from our analysis was the importantance of distance 
for predicting ELS-gene links. Simply ranking genes by distance has a higher 
AUPR than even the best performing correlation method and distance was 
consistently the most important feature in our Random Forest models. This heavy 
reliance on distance is partially due to how ELS-gene links are distributed. Some 
methods such as TargetFinder, use a distance matched negative set, but we feel 
this method is impractical. In practice, to predict the enhancer of a target gene one 
would test all genes within a specific distance boundary (e.g. 200 kb) not genes of 
matched distances. Therefore, while distance may dominate our models, it is a 
biologically relevant feature that should not be ignored. Additionally, this 
dependence on distance suggests that while some enhancers target genes at very 
far distances, the majority of interactions occur nearby. 
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 Moving forward we plan on refining our Random Forest models, by including 
additional biological features such as CTCF binding sites, and patterns of gene 
expression. We also plan on comparing our models with the published models 
PReSTIGE, IM-PET, PETmodule, and TargetFinder. Of particular interest will be 
how each program performs on individual datasets. For example, TargetFinder, 
which is trained on Hi-C loops, claims to be able to better identify long range 
interactions than close range interactions. Therefore, TargetFinder may 
outperform the other algorithms for identifying Aiden Hi-C pairs but may have lower 
performance for POLII ChIA-PET pairs.  
 Ultimately, we hope to apply the best performing model to predict ELS-gene 
pairs across all cell types in the registry. Then we can identify differences in links 
between cell types and how these links change over embryonic development. 
 
Annotating Genetic Variants Associated with Psychiatric Disorders 
In chapter IV we demonstrated how we can use the Registry of cREs to 
annotated noncoding variants associated with schizophrenia (SCZ), bipolar 
disorder (BPD) and major depressive disorder (MDD). By analyzing cRE activity 
and gene expression, we determined that SCZ SNPs and CD SNPs were enriched 
for cREs and target genes active in brain tissue and neural development pathways. 
Interestingly, we also observed enrichments in immune related features such as 
cRE activity in blood cells and TFs involved in the immune system. These findings 
are also supported by the previous enrichment in B cell specific H3K27ac peaks 
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reported by the PGC105. 
We developed several hypotheses for this observed enrichment. The first 
being that the immune system is interacting directly with the central nervous 
system and its dysregulation results in CNS changes. Second, these immune 
related TFs are active in glial cells that are not surveyed by ENCODE. The brain 
sub-regions contain a mixture of cell types and therefore the enrichments we 
observe could be due to these non-neuron cells. Third, these factors may have 
dual roles in the CNS and immune system. This hypothesis is not completely 
independent from our second hypothesis but suggests that TFs involved in the 
immune system also have roles in brain development. We plan on testing these 
hypotheses first by analyzing cRE activity and gene expression. For example, we 
can analyzed whether psych cREs  are active in both brain and immune tissues or 
if they tissue specific. We also plan on integrating data from the psychENCODE 
consortium who have generated cell type specific (neuron +, neuron -) histone 
modification data from brain samples. Finally, we also plan to systematically 
analyzing TF expression between human and mouse datasets to determine 
whether there is a general enrichment for TF activity in the brain and immune 
system. 
Overall our analysis demonstrated that psych SNPs across different 
disorders share common enrichments for cRE activity, gene expression, and TF 
motifs. The most strikely was that both SCZ and CD SNPs were enriched for TF 
SP4 motif sites. As we detailed in Chapter IV, SP4 has previously been linked with 
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psychiatric disorders and has been shown to prune dendrites during brain 
development147. Moving forward, we plan to further characterize SP4 binding sites 
using the Registry of cREs and identify potential target genes to determine 
regulatory networks that may be disrupted by the dysregulation of SP4. We also 
plan on further characterizing SP4 expression to determine if it would be a viable 
therapeutic target. For example, if SP4 only targets psych risk genes during brain 
development, it would not be a reasonable target. 
While we observed many similarities between enrichments across the four 
studies, we currently are unable to analyze differences between the disorders. For 
example, we have far more variants associated with SCZ than BPD. The lack of 
enrichment for BPD SNPs in brain regions does not mean that BPD risk factors 
are not active in the brain – just that the BPD GWAS did not report significant hits 
in these regions. This could be due to a number of factors most notably the size of 
the cohort. Therefore, in the future, we hope to develop a method for combining 
multiple GWAS for the same phenotype to increase statistical power. We cannot 
simply just concatenate results from multiple studies due differences in 
methodologies, but we could develop an ensemble voting scheme that would 
weight enrichments observed in different studies. Additionally, the NHGRI-EBI 
GWAS catalog continues to release summary statistics from GWAS. We could use 
these to further prioritize regions of interest that may not reach genome wide 
significance. Both of these approaches would allow us to substantially increase the 
number of variants we could analyze and possible reveal even more about the 
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genetic risk factors of psychiatric disorders. 
Additionally, we showcased two examples of cREs with distinct enhancer 
activity patterns across mouse embryonic development. We are currently 
collaborating with the Pinnacchio and Visel labs to experimentally validate these 
regions and investigate allele specific activity changes. These ELS cREs have 
important yet different biological implications. CACNA1C, is expressed in many 
different tissues, such as the heart, muscle, and brain. EH37E0250841, which 
overlaps a CD SNP, is a brain specific cRE that we predict regulates CACNA1C. 
Because of this brain tissue specificity, the SNP would presumably only effect the 
expression of CACNA1C in the brain, not the heart or muscle.  
Unlike EH37E0250841, EH37E1112284, which overlaps a SCZ SNP, is 
only active during early stages of brain development. ASCL1, EH37E1112284's 
target gene, is involved in neuronal commitment and is highly expressed in brain 
at early embryonic time points. Interestingly, while psychiatric disorders manifest 
during early adulthood, we did not observe enrichment for SNPs in cREs active at 
later time points. Therefore, we hypothesize that these common genetic variants 
result in changes in brain structure and composition that increase an individual's 
risk for developing a psychiatric disorder. 
These two examples also demonstrate the advantage of using orthologous 
mouse cREs to study cRE activity patterns across embryonic development. 
Without the mouse embryonic data, we would not be able to cleanly define 
temporal patterns of brain cRE activity. While we did have fetal brain DNase data 
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for a number of fetal stages, these samples were not surveyed at uniform time 
points and were subject to a number of uncontrollable biases (i.e. genetic 
background, gestational conditions, gender, collection methods). The brain 
samples collected from the embryonic mice, however, were collected from mice 
with the same genetic background and similar gestational conditions using uniform 
protocols. In the future, we plan on extending our analysis to study SNPs 
associated with other human disease. By analyzing enrichments in temporal 
patterns, we can classify diseases based on when their genetic risk factors are 
active (i.e. development, adulthood) which will also give us more information about 
possible therapeutic targets. 
We also plan on generalizing our analysis by annotating cREs allele specific 
binding of TFs and chromatin accessibility. We plan to apply our in silico 
genotyping method described in Chapter IV to genotype SNPs overlapping cREs 
across all 600 cell and tissue types covered by the Registry. For each cell type, we 
can test at heterozygous loci whether DNase, histone modification, or TF ChIP-
seq reads favor one allele. This will be a valuable resource for interpreting genetic 
variants reported by GWAS and whole genome sequencing but also may explain 
underlying mechanisms of gene regulation. For example, one anecdotal 
observation from characterizing allelic imbalance at psych SNPs was that the 
direction of allelic imbalance changed depending on the cell type. We observed 
this for BPD SNP rs2861405 at ZNF490 and ZNF791. When we manually 
surveyed other SNPs that had allelic imbalance in both directions we observed 
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that the many of them located at bidirectional promoters. This anecdotal evidence 
suggests that different TFs bind at promoters depending on cell type context, thus 
resulting in differences in chromatin accessibility between alleles. While this is a 
very small sampling, we aim to test if this phenomenon is more global by 
characterizing AS binding at cREs. 
 
Final Comments 
 Overall our work has created a foundation for the future characterization 
and annotation of regulatory elements in the human genome. We developed a 
pipeline for curating and characterizing candidate regulatory regions in human and 
mouse which can be expanded as more epigenomic datasets are produced. We 
can functionally annotate these cREs by predicting the genes they regulate and 
our work demonstrated that several popular methods of linking enhancer and 
genes should not be used. Additionally, we can utilize these tools to interpret 
variants associated with disease. While we demonstrated the Registry's use for 
annotated common variants, these methods can be applied to annotate rare, 
personal, or cancerous mutations as well. This is especially pertinent to clinicians 
as researchers as whole genome sequencing become more widely used. 
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